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The objectives of this study were to characterise the primary genetic abnormalities, 
genomic copy number changes and mutational landscape of ALL in older adults. 
The primary chromosomal abnormalities from patients aged ≥60 years recruited into 
the UKALL14 (n=94) and UKALL60+ (N=116) trials were first evaluated. B-cell 
precursor (BCP) ALL patients lacking a primary chromosomal abnormality (B-other 
ALL) were screened for ABL-class fusions, JAK-STAT abnormalities and other 
rearrangements using fluorescence in situ hybridisation (FISH). CRLF2 and ZNF384 
rearrangements were detected in 17% and 7% of tested patients respectively. ABL-
class fusions were notably absent. 
Next, single nucleotide polymorphism (SNP) arrays were performed to identify copy 
number abnormalities in patients with suitable material (n=83). Deletions were 
detected in IKZF1 (52%), CDKN2A/B (45%) and PAX5 (39%), as well as arm level 
events including del(9p) (21%), monosomy 7 (10%) and gain 1q (10%). Selected novel 
abnormalities were then validated using a customised sequencing approach. 
Recurrent novel deletions were confirmed in LEMD3, KDM6A and CXCR4, potentially 
contributing to leukaemogenesis. 
Separately, SNP arrays were performed on DNA from patients with low hypodiploidy 
or high hyperdiploidy (n=88) and machine-learning techniques were used to cluster 
cases based on log2 ratio data. Discrepancies between the cytogenetic-derived and 
SNP array-derived genetic subgroup were identified. A diagnostic classifier based on 
chromosomal log2 ratios was then designed using classification and regression tree 
analysis (CART). 
Finally, the mutational landscape of ALL in older adults was characterised in selected 
patients using exome sequencing (n=6) and a customised sequencing panel (n=30). 
Pathogenic variants were identified in TP53, NF1, JAK2 as well as members of the 
RAS signalling pathway, and were closely related to specific primary chromosomal 
abnormalities.  
This project has helped characterise the landscape of genetic prognostic biomarkers 
in older adults with ALL, and identified novel therapeutically actionable abnormalities 
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Chapter 1. Introduction 
 
1.1 Leukaemia 
Leukaemia represents a heterogenous group of malignant diseases of the 
haematopoietic system, predominantly initiating in the bone marrow. In common with 
other cancers, leukaemias are genetic diseases, whereby one or more key aberrations 
occur within the DNA of haematopoietic cells, hijacking their normal function and 
leading to increased proliferation and survival (Hanahan and Weinberg, 2011).  
Acute leukaemias are characterised by differentiation arrest and abnormal proliferation 
of a population of immature progenitors (blasts). This results in heavy bone marrow 
infiltration with a consequent failure of normal haematopoiesis (De Kouchkovsky and 
Abdul-Hay, 2016). Left untreated, patients rapidly succumb to the effects of profound 
immunosuppression and bone marrow failure. In comparison, chronic leukaemias 
usually present more indolently and are characterised by a much lower rate of 
proliferation and at least some retention of normal cellular function and differentiation 
capabilities (Jabbour and Kantarjian, 2020). 
The two principal subtypes of acute leukaemia are acute myeloid leukaemia (AML) and 
acute lymphoblastic leukaemia (ALL). In AML, the blasts express myeloid antigens and 
may progress from pre-leukaemic myeloid neoplasms such as myelodysplastic 
syndrome (MDS) or myeloproliferative neoplasms (MPNs) (Arber et al., 2016). The 
incidence of AML follows the patterns of most cancers and rises with age, most likely 
due to the accrual of DNA damage over many years (Jan et al., 2012). In comparison 
ALL almost always arises de novo, with only rare cases of secondary ALL described 
(Rosenberg et al., 2017). Moreover, the disease incidence has a very different age-
profile with a high peak in early childhood (Inaba et al., 2013), implying a distinct 
pathophysiology from most other malignancies.  
 2 
1.2 Acute lymphoblastic leukaemia overview 
ALL is a subtype of acute leukaemia affecting precursor B or T cells in the bone 
marrow. Clinically, the disease progresses rapidly, with leukaemic blasts usually 
detected in the peripheral blood and often accompanied by life-threatening anaemia, 
thrombocytopenia and infection. Fortunately, the management of ALL in children has 
been a paradigm for the success of translational medical research in improving patient 
outcomes. Successive large clinical trials have improved the 5-year overall survival 
from 30% in the 1960s to 90% in the modern era, through the adoption of better 
supportive care, risk stratification and intensified treatment (Inaba et al., 2013). In 
comparison, adult ALL has not yet seen the same degree of research or improvement 
in prognosis, and fewer than 50% of affected patients are currently cured of their 
disease (Rowe et al., 2005, Marks et al., 2019). 
 
1.3 Epidemiology 
In the UK, approximately 700-800 patients are diagnosed with ALL each year (Cancer 
Research UK, 2016). Three quarters of adults and 85% of children present with B-cell 
precursor ALL (BCP-ALL). T-cell ALL (T-ALL) is rarer and accounts for the remaining 
25% and 15% of adult and paediatric patients respectively (Chiaretti and Foà, 2009).  
The overall UK incidence of ALL is stable at 1.2 cases per 100,000 population per year 
and males are slightly more commonly affected than females with a male to female 
ratio of 1.4:1 (Cancer Research UK, 2016). The peak incidence is seen in early 
childhood with an average of 250 new cases per year in UK children aged 0-4 years. 
The disease is rarer in adults and becomes eclipsed by the more common AML. 
However, the incidence of ALL has a bimodal distribution, which increases again after 
the age of 60 years (figure 1.1) (Moorman et al., 2010), with approximately 120-150 
new cases per year in UK adults aged over 60 years. Indeed the age-specific annual 
incidence in those aged 60 years and over is 0.9–1.6 per 100,000, compared to 0.4–




Figure 1.1. Age-specific incidence of ALL. Average number of new cases per year and age-
specific incidence rates per 100,000 population split by gender, UK, 2014-2016 (taken from 
Cancer Research UK, cruk.org/cancerstats) 
 
The care of older adults with ALL is an area of unmet clinical need. Although older 
adults comprise 20-25% of new diagnoses each year, around 60% of disease-related 
deaths are seen in this age group, and they are the only ALL patients not to have 
benefitted from the stepwise improvements in prognosis driven through successive 
clinical trials in children and younger adults (Dinmohamed et al., 2016).  
 
1.4 Pathophysiology 
ALL arises through sequential genetic lesions in precursor B or T cells. The 
mechanisms by which these aberrations arise has not been fully elucidated and is likely 
to differ between adults and children.  
To date, the most robust evidence of an early initiating event resulting in a 
preleukaemic clone has been provided by the discovery that ETV6-RUNX1 transcripts 
can be retrospectively detected in newborn Guthrie cards of patients presenting with 
ALL with t(12;21)(p13;q22)/ETV6-RUNX1 in later childhood (Mori et al., 2002). 
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Moreover, both the several year latency and the observation that such transcripts can 
be found in up to 1% of Guthrie cards (more than 100 times the incidence of ETV6-
RUNX1+ ALL) confirms that additional co-operating secondary mutations are required 
for leukaemogenesis. Additionally, a high rate of concordance of specific cytogenetic 
ALL subtypes has been observed in monozygotic twins (Greaves et al., 2003, Ford et 
al., 1998). Interestingly, in monozygotic twins concordant for ALL, the same fusion 
gene with identical breakpoints can be found in both affected twins, unequivocally 
proving that preleukaemic or leukaemic cells metastasise through a shared placental 
circulation, rather than the concordance being related to a particularly strong germline 
predisposition and occurring independently in each twin. 
Aside from genetic leukaemia predisposition syndromes, such as Down’s syndrome or 
Ataxia Telangectasia, inherited susceptibility to ALL is likely to play at most a very 
modest role in its pathogenesis (Inaba et al., 2013). Genome-wide association studies 
have identified germline single nucleotide polymorphisms (SNPs) conferring only a 
small increased risk of ALL (Papaemmanuil et al., 2009). Common low penetrance 
variants in IKZF1, ARID5B and CEPBE were associated with odds ratios for childhood 
ALL of 1.69, 1.65 and 1.34 respectively. 
An initiating somatic lesion or germline predisposition alone is insufficient to cause 
overt disease. A number of co-operating secondary events are required, often affecting 
genes in cell cycle regulation, B-cell development, or kinase signalling among others 
(Iacobucci and Mullighan, 2017). The mechanism of these events is also subject to 
debate. Plausibly, as with many cancers, environmental exposures are likely to play a 
part. Exposure to ionising radiation has been proven to have a causative role as 
evidenced by the increased rate of childhood ALL cases seen following the 1945 
atomic bombing of Hiroshima and Nagasaki, Japan (Preston et al., 1994). Such 
radiation exposures are unlikely to be relevant currently, and the impact of non-ionising 
electromagnetic radiation in leukaemogenesis has been contentious (Inaba et al., 
2013). Rather, the role of infectious exposures has proven a more plausible hypothesis 
for the conversion of a preleukaemic clone to overt ALL. This has been supported by 
observations that children exposed to common infections during infancy have a lower 
risk of ALL in early childhood years than those sheltered from such exposures, through 
a variety of common societal practices (e.g. childcare in home environment, often 
linked to higher socio-economic status) (Greaves et al., 1985). It is hypothesised that 
a subsequent delayed exposure to common infections during early childhood produces 
 5 
an abnormal immune response resulting in the conversion of an existing and persistent 
preleukaemic clone to overt leukaemia (Greaves delayed infection hypothesis), 
although the specific mechanism is yet to be elucidated (Greaves, 2006).  
These comprehensive aetiological studies have focussed on childhood ALL and 
currently very little evidence has been produced for the pathophysiology of ALL in 
adults and specifically older adults. In utero initiation of preleukaemic clones, germline 
predispositions and early childhood infections seem unlikely to be responsible for ALL 
occurring in later life. 
 
1.5 Treatment and prognosis 
The advances in the successful treatment of ALL in children since the 1960s has been 
one of the great achievements of translational and clinical research. Successive 
national and international collaborative clinical trials have seen the 5-year overall 
survival of childhood ALL increase from 35% in the first UK-wide ALL trial (UKALL1 
(Medical Research Council, 1973)) to >90% in the most recently reported UKALL 2003 
trial (Vora et al., 2013). Treatment of childhood ALL is now based on dose-intensive 
multi-agent chemotherapy accompanied by prolonged asparagine depletion and 
prophylactic CNS directed therapy throughout treatment. Treatment delays to allow 
bone marrow recovery are kept to a minimum between courses, and multiple 
prognostic factors are incorporated in protocols to inform either intensification or 
reduction of therapy at defined time points. Such is the success of multi-agent 
chemotherapy that allogeneic stem cell transplantation is rarely required in childhood 
ALL and is reserved for the relapse setting. 
In recent years, younger adults with ALL have benefitted from the adoption of similar 
‘paediatric-inspired’ protocols (Stock et al., 2008), although the success of these 
strategies has been less pronounced, and the use of stem cell transplantation in first 
remission with the aim of achieving long-term disease-free survival remains common.  
In comparison, very little consistency exists in the treatment of older adults with ALL. 
Adults aged ≥60 years have frequently been excluded from clinical trials and are often 
not referred to specialist treatment centres (Gokbuget, 2017). Existing co-morbidities 
and frailty frequently preclude the use of intensive chemotherapy and/or stem cell 
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transplant and the use of anthracyclines and asparaginase is often associated with 
unacceptable morbidity and mortality. The 5-year overall survival of adults aged ≥60 
years at ALL diagnosis is currently approximately 20% (Guru Murthy et al., 2015, 
Moorman et al., 2010). Typical treatment schedules for children and frail older patients 
are outlined in figure 1.2.  
 
Figure 1.2. Example overview treatment schedules for paediatric patients (regimen B of 
UKALL2011 protocol) (A) and frail older adults (UKALL60+ trial protocol) (B). Treatment cycles 
are shorter in older adults and doses of anthracyclines and steroids are much lower. A number 
of chemotherapeutic agents are avoided due to toxicity (cyclophosphamide, cytarabine, 
asparaginase) and treatment is not minimal residual disease (MRD)-adapted. 
 
1.6 Risk stratification 
The vital importance of accurately identifying subgroups of ALL patients with different 
prognosis has been apparent for several decades and has led to intensified treatment 
for those with high risk features and more recently, treatment reduction for those with 
the best prognosis (Vora et al., 2013). A number of clinical and biological risk factors 




Historically, male sex has been associated with reduced event free survival (EFS) (Pui 
et al., 1999, Shuster et al., 1998). The reasons for this difference are poorly explained. 
Less intensive protocols from 1960s and 1970s were associated with a high risk of 
testicular relapse (up to 9%), although this has been <1% since the mid-1980s (Pui et 
al., 1999). Subsequently, persisting sex related differences in prognosis were 
explained by an increased rate of T cell disease in males and possible lower frequency 
of favourable cytogenetics (Pui et al., 1999), although modern protocols appear to have 
also largely abolished this residual disparity in prognosis (Pui et al., 2008, Pui et al., 
2004, Vora et al., 2013). Some modern protocols still use a longer maintenance period 
for male patients, although this practice is not uniform. In comparison, modern 
protocols for adults and older adults make no distinction in the treatment of male and 
female patients, and a large study of more than 1500 did not show sex to be an 
independent predictor for overall or disease-free survival in adult ALL (Rowe et al., 
2005).  
 
1.6.2 Age and white cell count at diagnosis 
In both adult and paediatric ALL population, age at diagnosis is consistently related to 
prognosis. Children aged ≥1 and <10 years at diagnosis have a better prognosis than 
those aged ≥10 years or <1 year (Chessells et al., 1998, Pui et al., 2008). Similarly, 
adults, aged >35-40 years have a worse prognosis than their younger counterparts 
(Chessells et al., 1998, Thomas et al., 2004b, Pui et al., 2008).  
Along with age, white cell count (WCC) has been one of the earliest features found to 
be associated with prognosis, with high white cell counts at diagnosis of ALL 
associated with poorer outcome (Chessells et al., 1995). WCC has retained its 
independent prognostic value, even in the era of multiple, often co-operating and inter-
linked risk features (Vaitkevičienė et al., 2011). In modern paediatric protocols, age 
and WCC are usually combined as an NCI risk stratification, where patients aged ≥1 
and <10 years with presenting WCC <50 x109/L are designated NCI standard risk and 
all others NCI high risk. The basis for this can be seen from the results of the UKALLXI 
trial for paediatric ALL, where patients aged <10 years with a presenting WCC <50 
x109/L fared significantly better than other groups (figure 1.3).  
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Figure 1.3. Event free survival (EFS) by age and white cell count (WCC) in UKALLXI trial. Patients 
aged <10 years and with WCC <50x109/L had significantly higher EFS compared with other 
groups. Taken from Hann et al (Hann et al., 2001).  
 
From 1997 onwards (ALL97/99 trial), all UK clinical trials for paediatric ALL patients 
have incorporated NCI risk as the first separator of treatment arms with differing 
intensity.  
Similarly, in adults, age >35-40 years and/or WCC >30x109/L for BCP-ALL or 
>100x109/L for T-ALL have been associated with high risk disease, and affected 
patients considered for allogeneic stem cell transplantation in first remission (Thomas 
et al., 2004b, Goldstone et al., 2008, Rowe et al., 2005). The large 
UKALLXII/ECOG2993 study identified age above vs below 35 years and WCC above 
or below 30x109/L and 100x109/L for BCP and T-cell disease respectively to be two of 
the strongest independent predictors of survival. This persisted in a multivariate 
analysis where these were analysed as continuous variables, predictably 
demonstrating that the poor outcome continues to worsen with advancing age beyond 
35 years (Rowe et al., 2005). 
However, the relationship between age and prognosis is complex and closely related 
to multiple other co-operating risk factors, particularly in older adults, which are both 
patient and therapy-related. For example, adults aged over 60 years at diagnosis often 
have both high risk biological features and increased rates of treatment related 
morbidity and mortality (Pui et al., 2008). Most patients aged under 60 years old at 
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diagnosis will be deemed fit for intensive therapy with curative intent. However, the 
situation is more complex in older adults, and historically, many such patients have 
been managed much more palliatively, with low expectations of durable remissions 
(Taylor et al., 1992, Gökbuget, 2013). 
 
1.6.3 Cytogenetics 
The study of chromosomal abnormalities in leukaemic cells has been a key feature of 
both diagnosis and prognosis since the discovery that the Philadelphia chromosome 
in chronic myeloid leukaemia (CML) arises as a result of a balanced chromosomal 
translocation (Rowley, 1973). Detailed karyotyping of leukaemia samples has since 
permitted the identification of a number of non-random chromosomal aberrations in 
ALL and this has led to a clear association between specific cytogenetic lesions and 
prognosis. Specifically, hyperdiploidy of ALL cells was first noted to be associated with 
a better outcome than diploid or other ploidy shifts (Secker-Walker et al., 1978). To 
date, the WHO recognises 9 specific recurrent genetic entities in ALL (table 1.1) 
(Terwilliger and Abdul-Hay, 2017, Arber et al., 2016), although others have since been 
described.  
B-lymphoblastic leukaemia/lymphoma  
 B-lymphoblastic leukaemia/lymphoma, NOS  
 B-lymphoblastic leukaemia/lymphoma with recurrent genetic abnormalities  
 B-lymphoblastic leukaemia/lymphoma with t(9;22)(q34.1;q11.2);BCR-ABL1  
 B-lymphoblastic leukaemia/lymphoma with t(v;11q23.3);KMT2A rearranged  
 B-lymphoblastic leukaemia/lymphoma with t(12;21)(p13.2;q22.1);ETV6-RUNX1  
 B-lymphoblastic leukaemia/lymphoma with hyperdiploidy  
 B-lymphoblastic leukaemia/lymphoma with hypodiploidy  
 B-lymphoblastic leukaemia/lymphoma with t(5;14)(q31.1;q32.3);IL3-IGH  
 B-lymphoblastic leukaemia/lymphoma with t(1;19)(q23;p13.3);TCF3-PBX1  
 Provisional entity: B-lymphoblastic leukaemia/lymphoma, BCR-ABL1–like  
 Provisional entity: B-lymphoblastic leukaemia/lymphoma with iAMP21  
T-lymphoblastic leukaemia/lymphoma  
 Provisional entity: Early T-cell precursor lymphoblastic leukaemia  
 Provisional entity: Natural killer (NK) cell lymphoblastic leukaemia/lymphoma  
Table 1.1. 2016 revision WHO classification of lymphoblastic leukaemia/lymphoma. Adapted 
from Arber et al (Arber et al., 2016).  
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Despite the improvements in outcome achieved through treatment intensification and 
supportive care, cytogenetics continues to be one of the most important prognostic 
factors and plays a key role in treatment decisions (Moorman et al., 2007, Pullarkat et 
al., 2008). Cytogenetics is also closely related to age, and the frequency of poor risk 
abnormalities increases with age at diagnosis, with the notable exception of infant ALL 
which is characterised by a 70-80% frequency of the high risk 
t(4;11)(q21;q23)/KMT2A-AFF1 fusion (Hilden et al., 2006).  
 
1.6.4 Response to treatment – early marrow response and minimal 
residual disease assessment 
The single most important recent development in the risk stratification of ALL patients 
has been the incorporation of response to treatment assessments in therapeutic 
decisions.  
Early morphological assessment after 1-2 weeks of induction chemotherapy has been 
used to identify rapid early responders, who have a better prognosis than slow early 
responders (Gaynon et al., 1997). However, early morphological assessment, before 
haematological recovery has occurred, is challenging and error prone. Bone marrow 
smears are often difficult to interpret during early treatment and regenerating 
haematogones and lymphocytes can be mistaken for ALL blast cells and vice versa 
(Gupta et al., 2018). Even in optimal samples, morphological assessment is only 
sensitive to a blast percentage ≥5%. Although more reproducible, morphological 
assessments at later time points and following haematological recovery (e.g. following 
4 weeks of induction treatment), are less valuable as the vast majority of patients are 
in morphological remission, and only patients with a dismal outcome (‘induction failure’) 
will be positively identified (Schrappe et al., 2012).  
The development of techniques for detecting minimal residual disease (MRD) has 
permitted the detection of much smaller numbers of leukaemic cells, generating one of 
the most valuable biomarkers for risk stratification and treatment allocation (Cavé et 
al., 1998, Brüggemann et al., 2006). The most extensively validated and frequently 
used technique involves tracking leukaemia specific immunoglobulin and/or T-cell 
receptor rearrangements (Ig/TCR). Like all B-cells, BCP-ALL blasts undergo 
rearrangement of the V, D and J segments of their immunoglobulin gene through 
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random deletions and insertions of nucleotides at the junctional sites. T-ALL blasts 
undergo a similar process with their TCR. This creates a unique molecular signature 
which is inherited by all daughter cells produced during clonal expansion, and will 
therefore be specific to all leukaemic cells within a particular patient (Campana, 2010). 
At diagnosis, the junctional regions of the immunoglobulin or TCR gene in a bone 
marrow sample are sequenced to identify the patient leukaemia-specific MRD 
marker(s). Allele specific oligonucleotides (ASOs) can then be designed and used in a 
real time quantitative polymerase chain reaction (RQ-PCR) to measure residual 
leukaemia in follow up samples (Campana, 2010, van der Velden et al., 2007). This 
technique can typically detect residual ALL blasts down to a concentration of 1 in 
10,000-100,000.  
In patients presenting with leukaemia-specific gene fusions (such as ETV6-RUNX1, 
BCR-ABL1, TCF3-PBX1), the aberrant mRNA transcript can be used as an MRD 
marker (van Dongen et al., 1999). As the breakpoints cluster within well-defined 
genomic regions, universal primers can be used in an RQ-PCR assay without the need 
for time-consuming sequencing on a diagnostic sample followed by design and 
validation of patient specific ASOs. This MRD technique is well validated and 
extensively used for BCR-ABL1+ ALL. Interestingly, although the correlation with 
Ig/TCR-based MRD is usually good, significant discrepancies are seen owing to the 
observation that the BCR-ABL1 translocation may also be present in non-lymphoid 
cells (Hovorkova et al., 2017). Thus, MRD results are always viewed in the context and 
sensitivity of the method used.  
More recently, multiparametric flow cytometry (MFC)-based MRD techniques have 
been developed, and make use of the observation that leukaemic cells often express 
aberrant cell surface markers, creating a leukaemia-associated immunophenotype, 
(LAIP) (Brüggemann and Kotrova, 2017). In post-remission samples, cells bearing the 
LAIP can therefore be detected using MFC and quantified to generate an MRD 
measurement.  
As with other biological and clinical features, MRD kinetics are influenced by other 
prognostic factors. Genetic abnormalities associated with a favourable prognosis are 
also associated with a more rapid clearance of MRD and vice versa for high risk genetic 
lesions (O’Connor et al., 2018). Moreover, treatment intensity is also likely to influence 
the persistence of MRD, which is encountered more frequently in adult than childhood 
ALL (Gökbuget et al., 2018). In adults treated intensively, typically using paediatric 
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inspired protocols, a number of trials in BCR-ABL1 negative patients have 
demonstrated that the attainment of MRD negativity is the most important prognostic 
factor and abrogates any survival benefit from allogeneic stem cell transplantation in 
first remission (Dhédin et al., 2015, Ribera et al., 2014, Bassan et al., 2020). Data, 
however, are currently lacking in older adults who receive the lowest intensity therapy. 
Interestingly, immunotherapies (such as blinatumomab) and targeted treatments (such 
as tyrosine kinase inhibitors for BCR-ABL1+ ALL) are both well tolerated and are able 
to produce high rates of MRD negativity (Gökbuget et al., 2018, Rousselot et al., 2016, 
Topp et al., 2012), even when combined with little or no chemotherapy so are 
particularly attractive treatment options in older and frailer patients. Indeed, one study 
combined the third generation TKI ponatinib with steroids alone in elderly and unfit 
patients with Ph+ ALL, and reported a complete molecular response in 45% of 
evaluable patients (Martinelli et al., 2017). Additionally, the recent D-ALBA phase 2 
study used a potent chemotherapy-free combination of the bispecific T-cell engaging 
antibody blinatumomab and the TKI dasatinib in Philadelphia positive patients and 
reported a molecular response in up to 81% of patients, with an impressive overall 
survival of 95% at a median follow up of 18 months (Foà et al., 2020).  
 
1.7 ALL in older adults 
Approximately 130 adults over the age of 60 years are diagnosed with ALL every year 
in the UK (Cancer Research UK, 2016). Prior to the UKALL60+ clinical trial, there were 
no dedicated UK studies focused on improving outcomes through the acquisition of 
biological, clinical and outcome data for these patients. The UKALL XII clinical trial 
included 100 patients over the age of 55 years (range 55-65 years) deemed fit for 
intensive chemotherapy-based treatment (Sive et al., 2012).  A subgroup analysis 
focused on the biological and clinical features of these older adults identified a 
significantly lower frequency of lymph node enlargement, hepatomegaly and 
splenomegaly compared with patients aged under 55 years old. The rate of complete 
remission after induction chemotherapy was 73% in older patients compared to 93% 
in the younger group. Treatment toxicities were much higher in older patients and the 
rate of death in induction was 18% compared to 4% in younger adults. Furthermore, 
46% of older patients required drug dose reductions, omissions or delays in induction, 
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suggesting these treatments are too intensive for a significant proportion of older 
adults, even those deemed biologically fit. To date, the GMALL group have performed 
one of the largest trials of ALL therapy in older adults (Goekbuget et al., 2012). The 
study included 268 patients with a median age of 67 years (range 55-85). Patients 
were treated with a moderately intensive regime of reduced dose multi-agent 
chemotherapy and CNS prophylaxis. Overall, 76% of patients achieved complete 
remission following induction and 14% had an early death. The study confirmed that 
early death was associated with the ECOG status and Charlson comorbidity score 
before onset of ALL, highlighting the importance of a comprehensive functional 
assessment to determine fitness for and timing of chemotherapy.  
Although the UKALL XII comparison between patients aged over and under 55 years 
at diagnosis did not identify significant differences in presenting white cell counts or B 
versus T cell disease, the population studied was aged 55-65 years so was not 
representative of all older ALL patients (Sive et al., 2012).  
A French study also identified biological differences between ALL in older adults and 
other age groups (Thomas et al., 2001). The male: female ratio declined from 1.75 in 
younger adults to 0.97 in older adults. A moderately lower presenting WCC was also 
observed which in combination with lower rates of lymphadenopathy and 
organomegaly may suggest age-related differences in disease behaviour. B cell 
disease also accounts for a significantly larger proportion of ALL diagnoses in older 
adults (75-89%) compared with younger patients (59-66%) (Gökbuget, 2013). 
 
1.7.1 Treatment of ALL in older patients 
The clinical management of ALL in older adults requires a careful balance between 
optimising response whilst minimising the risk of treatment-related morbidity and 
mortality. The principles of treatment are similar to those adopted in younger patients, 
namely remission induction, followed by consolidation and maintenance, with 
concomitant CNS directed therapy. However, unlike younger patients, most older 
adults (particularly aged over 70 years) will not be suitable for allogeneic stem cell 
transplantation, and certain chemotherapeutic agents need to be used with greater 
caution due to higher toxicities, specifically anthracyclines and asparaginase. 
Fortunately, well tolerated targeted treatment such as tyrosine kinase inhibitors (TKIs) 
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are particularly beneficial in older patients presenting with BCR-ABL1 positive disease. 
Indeed, such approaches have permitted significant reductions in the cytotoxic agents 
used, without inferior outcomes (Chalandon et al., 2015). However, similar approaches 
are not yet routinely available for BCR-ABL1 negative patients, and there is little scope 
to intensify treatments based on the presence of high-risk disease or MRD positivity. 
 
1.8 Cytogenetics in ALL 
The hallmark of ALL is the acquisition of chromosomal abnormalities in the leukaemic 
blasts (Terwilliger and Abdul-Hay, 2017). To date, a spectrum of karyotypic 
abnormalities, some bearing a clear effect on prognosis, have been identified 
(Bloomfield et al., 1986, Harrison et al., 2010).  
Good risk chromosomal abnormalities, such as high hyperdiploidy, deleted 9p, and 
t(12;21)/ETV6-RUNX1, have been associated with a 5-year overall survival around 
60% in adults (Moorman et al., 2007). However, in comparison with childhood ALL, 
adult ALL has a different cytogenetic profile with increasing frequency of the poor risk 
chromosomal abnormalities t(9;22)(q34;q11)/BCR-ABL1, t(4;11)(q21;q23)/MLL-AF4, 
low hypodiploidy/near triploidy, and complex karyotype (Moorman et al., 2007). The 
frequency of these poor risk features increases with age (figure 1.4). Combining this 
with a poorer tolerance to intensive therapy, particularly in older adults, significantly 
impacts on survival.  
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Figure 1.4. BCP-ALL cytogenetic subtypes in children, adolescents and adults aged 25-59. 
Red/orange regions indicate poor risk subgroups, green regions indicate good risk subgroups 
and blue regions indicate intermediate risk subgroups. Proportion of poor risk genetic 
abnormalities increases after infancy with corresponding decrease in good risk subgroups. 
Adapted from Moorman (Moorman, 2012).  
iAMP21: intrachromosomal amplification of chromosome 21; KMT2A: KMT2A fusion; B-
other/IGH: IGH@ rearrangement; B-other/ABL-class: ABL-class fusion including ABL1, ABL2, 
PDGFRB or CSF1R; B-other/CRLF2: CRLF2 rearrangement; B-other/ERG: focal ERG deletion. 
 
Recurrent chromosomal abnormalities include large scale gains or losses to the normal 
diploid complement or translocations resulting in characteristic chimeric fusion genes. 
 
1.8.1 Large scale ploidy shifts 
1.8.1.1 High hyperdiploidy 
High hyperdiploidy (HeH) is the most prevalent abnormality in childhood ALL and is 
associated with duplication of entire chromosomes (Moorman, 2016). By definition the 
total number of chromosomes within ALL blasts is between 51-67 and the pattern of 
chromosomal gains is non-random with eight chromosomes accounting for most gains 
(X, 4, 6, 10, 14, 17, 18, 21) (Chilton et al., 2013). Trisomies involving chromosomes 5 
and 20 are also seen and have been associated with poorer risk disease. HeH is much 
rarer in adult ALL (figure 1.4). The UKALLXII/ECOG2993 clinical trial enrolled 1,522 
adults aged 15-65 and HeH was identified as the primary cytogenetic abnormality in 
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around 7% of patients with successful cytogenetic analyses (Moorman et al., 2007). 
ALL with HeH is usually associated with a favourable prognosis (Moorman, 2016). 
 
1.8.1.2 Low hypodiploidy 
Low hypodiploid/near triploid ALL (HoTr) is rare in childhood (<2% of cases) and 
becomes more common with age (figure 1.4). Like HeH, the primary abnormality is 
characterised by gross chromosomal aneuploidy, in this case a hypodiploid clone 
consisting of 30-39 chromosomes. A duplication of the remaining chromosomes can 
also occur, resulting in a clone of cells with a near triploid karyotype (60-78 
chromosomes), which can make the abnormality difficult to differentiate from HeH if 
only near triploid metaphases are seen on karyotypic analysis (Charrin et al., 2004). 
Chromosomal losses are also non-random with chromosomes 3, 7, 15, 16, 17 being 
preferentially deleted. Both copies of chromosome 21 appear to be consistently 
retained (Harrison et al., 2004). HoTr ALL is associated with a very high frequency of 
TP53 mutations (over 90%), which are usually germline in paediatric cases and 
somatic in adults (Holmfeldt et al., 2013, Mühlbacher et al., 2014). Indeed, patients 
with the Li Fraumeni syndrome have a particularly high risk of developing this ALL 
subtype (Powell et al., 2013).  
 
1.8.1.3 Near haploidy 
Near haploid ALL (NH) is a very rare high-risk subgroup, characterised by large scale 
chromosomal loss in the leukaemic cells. The NH clone contains 23-29 chromosomes 
and like HoTr, can undergo chromosomal endoreduplication without subsequent 
cytokinesis, creating a “doubled-up”, low hyperdiploid clone with 46 to 58 
chromosomes (Ma et al., 1998, Stark et al., 2001). This, in particular, can present a 
diagnostic challenge in differentiating this subgroup from HeH. However, the doubled 
clone will present with numerous tetrasomies, and will usually lack the characteristic 
trisomies seen in HeH ALL. As with other genetic subtypes, chromosome 21 is always 
retained in a NH clone and becomes tetrasomic in a “doubled-up” clone (Harrison et 
al., 2004). NH-ALL occurs almost exclusively in childhood, where it accounts for 0.5% 
of new diagnoses and is almost unreported in adult ALL (Harrison et al., 2001, Harrison 
et al., 2004).  
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1.8.2 Gene fusions 
Chromosomal rearrangements resulting in the fusion of two normally distant genes are 
a common feature of leukaemogenesis. If expressed, the resulting fusion gene 
produces a chimeric protein with altered functionality and transformative capabilities.  
 
1.8.2.1 ETV6-RUNX1 fusion 
The t(12;21)/ETV6-RUNX1 translocation accounts for over a quarter of childhood BCP-
ALL cases but is very rare in adults (Moorman, 2016). ETV6 contains protein 
dimerisation domains which are fused to the DNA binding and activating regions of 
RUNX1 (Torrano et al., 2011, Golub et al., 1995). RUNX1 forms part of the core binding 
factor complex which is essential for the regulation of normal haematopoiesis. 
Interestingly, the fusion gene usually arises antenatally and additional postnatal 
abnormalities (including gene deletions) are required for the development of overt 
disease (section 1.4) (Ford et al., 1998). In rare adult ALL patients with ETV6-RUNX1 
fusion, the disease has been associated with a low white cell count at diagnosis and 
comparatively favourable prognosis (Burmeister et al., 2010). 
 
1.8.2.2 KMT2A fusions 
The KMT2A (formerly MLL) gene on chromosome 11q23 is implicated in both myeloid 
and lymphoid leukaemias (Meyer et al., 2018). Translocations with a variety of partner 
genes destroy the normal histone methyltransferase function of KMT2A resulting in 
transcription activation (Slany, 2009). KMT2A translocations occur in approximately 
70-80% of infant ALL and prognosis is universally poor (Brown, 2013). These 
abnormalities are rare in childhood ALL (1-2%) but become more common again in 
adults. In UKALLXII/ECOG2993, 9% of Philadelphia-negative patients (6.6% of all 
patients with a cytogenetic result) had a KMT2A translocation (Moorman et al., 2007). 
The majority of these (78%) had a t(4;11)(q21;q23)/KMT2A-AFF1 rearrangement. 
Within this study, patients with a KMT2A translocation had a higher presenting white 




1.8.2.3 BCR-ABL1 fusion (Philadelphia positive ALL) 
Philadelphia positive (Ph+) ALL is probably the most relevant genetic subtype of adult 
ALL due to its high prevalence and individualised treatment. The well described 
t(9;22)(q34;q11.2) creates a chimeric fusion gene juxtaposing BCR on chromosome 
22q11.2 to ABL1 on chromosome 9q34. The resultant BCR-ABL1 fusion gene exhibits 
constitutively active tyrosine kinase activity (Salesse and Verfaillie, 2002), which alone 
is sufficient to induce chronic myeloid leukaemia (CML). However, the development of 
Ph+ ALL also requires the activation of Src kinases by the bcr-abl oncoprotein (Hu et 
al., 2004) and has been associated with the acquisition of additional gene deletions 
compared with CML (Mullighan and Downing, 2009). Ph+ ALL accounts for less than 
5% of childhood ALL but its prevalence rises to approximately 25% of ALL in adults 
diagnosed in the fourth decade of life. Some studies have shown a further rise with 
advancing age (Byun et al., 2017). However, this was not seen in a large cohort of Ph+ 
patients from multiple GMALL (German Multicenter ALL) trials (Burmeister et al., 2008) 
or in a population study of 349 adult ALL patients treated over 19 years in a single 
institution in the North East of England (Moorman et al., 2010). Historically, Ph+ ALL 
has consistently been associated with high risk disease and a poor prognosis. 
However, the advent of imatinib and the subsequent second and third generation 
tyrosine kinase inhibitors (TKIs), has significantly improved the outcome of Ph+ ALL. 
Large prospective trials have confirmed the safety and efficacy of incorporating TKIs 
with frontline chemotherapy with improvements in morphologic and molecular 
remission rates and overall survival (Wassmann et al., 2006, Thomas et al., 2004a). In 
the era of routine use of TKIs in the treatment of Ph+ ALL, remission rates and overall 
survival at 4 years have significantly improved from 82% to 92% and 22% to 38% 
respectively with the addition of imatinib in the UKALLXII/ECOG2993 trial (Fielding et 
al., 2014). More recently, incorporation of the third generation TKI ponatinib into a 
multi-agent chemotherapy backbone resulted in a 3 year overall survival of 76% with 
a high rate of complete molecular response in a phase 2 study (Jabbour et al., 2018). 
Additionally, a phase 3 randomised controlled trial confirmed that the incorporation of 
frontline TKI in Ph+ patients has permitted a reduction in the intensity of the 
chemotherapy backbone with no reduction in event-free or overall survival (Chalandon 
et al., 2015). The addition of TKIs to induction chemotherapy has also permitted more 
patients to undergo allogeneic stem cell transplantation due to the attainment of 
complete remission, which is often considered a pre-requisite for consolidation with an 
allogeneic transplant (Wassmann et al., 2006). Separately, one of the groups to benefit 
 19 
most from this well-tolerated targeted therapy has been older adults with Ph+ ALL. A 
number of studies have demonstrated that TKIs administered either with steroids or 
low dose chemotherapy produce superior remission rates with much lower toxicity 
compared with standard chemotherapy schedules (Ottmann et al., 2007, Vignetti et al., 
2007, Rousselot et al., 2016).  
 
1.8.2.4 TCF3-PBX1 fusion 
A specific translocation between chromosomes 1 and 19 – t(1;19)(q23;p13) –  creates 
a TCF3-PBX1 fusion gene. The TCF3 gene encodes two transcription factors (E12 and 
E47) that play critical roles in B-cell maturation. PBX1 is a homeobox gene and is not 
usually expressed in B and T cells. TCF3-PBX1 fusion results in unphysiological 
expression of this homeobox gene in lymphoid cells, leading to malignant 
transformation (Burmeister et al., 2010). The abnormality is seen in ALL patients of all 
ages, at a frequency of approximately 3-6%, and is usually associated with an 
intermediate prognosis, although some studies have also reported an increased risk of 
CNS relapse and a very poor outcome in patients who relapse (Moorman, 2016). 
 
The majority of these abnormalities are detected using conventional karyotyping 
allowing enumeration of individual chromosomes and detection of structural 
abnormalities with a sensitivity of around 5 megabases (Mb) (Martin and Warburton, 
2015). However, certain chromosomal translocation such as t(12;21)/ETV6-RUNX1 
are cytogenetically cryptic and are best detected through fluorescence in situ 
hybridisation (FISH) or RT-PCR (reverse transcription polymerase chain reaction).  
 
1.8.3 B-other ALL 
Around a quarter of adults and children with BCP-ALL lack a known primary recurrent 
chromosomal abnormality and are termed ‘B-other ALL’ (Moorman, 2016). Many 
studies have used gene expression profiling to define a group of these patients with a 
gene expression signature similar to BCR-ABL1+ ALL, now termed BCR-ABL-like (Den 
Boer et al., 2009) or Philadelphia-like (Ph-like) (Mullighan et al., 2009b) ALL 
(depending on studies and specific gene set). Around half of B-other ALL patients have 
been found to harbour a Ph-like signature, which is driven by ABL-class fusions or 
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JAK-STAT pathway activating lesions in over 80% of cases (Roberts et al., 2017). A 
range of kinase activating abnormalities have been identified, specifically ABL-class 
fusions caused by gene rearrangements affecting ABL1, ABL2, PDGFRB and CSF1R, 
or JAK-STAT pathway activating abnormalities caused by JAK2, CRLF2 or rarer EPOR 
rearrangements (Roberts et al., 2014).  
However, older adults have been underrepresented in many of these cohorts, and the 
frequency of these kinase activating lesions in older B-other ALL patients remains 
unclear. Interestingly, a study performed gene expression profiling across a cohort of 
BCP-ALL patients with older adults reasonably well represented (67 patients aged 56 
to 84 years of age) (Herold et al., 2014). The authors identified a peak in the BCR-
ABL-like signature in adolescents and young adults and a marked reduction in 
incidence in the older age group. This was matched with an ongoing rise in the 
incidence of Philadelphia-positive ALL, which peaked over 50% in the older cohort of 
patients.  
As a group, the disease-defining gene rearrangements in B-other ALL are 
cytogenetically cryptic and require the use of fluorescence in situ hybridisation (FISH) 
or genomic techniques to be detected. Most abnormalities involve a specific tyrosine 
kinase or cytokine receptor, constitutively activated through fusion to a range of 
different partner genes (figure 1.5). 
 
 
Figure 1.5. Ph-like/BCR-ABL-like gene rearrangements with reported partner genes. ABL1, ABL2, 
CSF1R and PDGFRB rearrangements represent ABL-class fusions. JAK2, CRLF2 and EPOR 




1.8.3.1 ABL-class fusions 
Rearrangements of ABL1, ABL2, PDGFRB or CSF1R result from balanced 
translocations, interstitial deletions or inversions and the resultant chimeric genes fuse 
the carboxyl terminal of the tyrosine kinase protein to the amino terminal portion of the 
partner gene resulting in a constitutively active tyrosine kinase (Roberts et al., 2014). 
Fusions with a number of different partner genes have been identified, with no 
evidence that specific partners impact on outcome or disease phenotype. Patients with 
ABL-class fusions, of which PDGFRB rearrangements are the commonest, often 
respond suboptimally to standard induction chemotherapy and are enriched in the <5% 
of patients with refractory disease post induction (O’Connor et al., 2017, Schwab et al., 
2016). Importantly, as a result of their tyrosine kinase activity, ABL-class fusions are 
sensitive to imatinib and other TKIs, and early use of TKIs has been associated with 
an improved outcome (Tanasi et al., 2019, Moorman et al., 2020).  
 
1.8.3.2 CRLF2 rearrangements 
CRLF2 pairs with the IL7R-alpha subunit to form a thymic stromal lymphopoietin 
receptor (TSLPR), which is implicated in early B-cell development. Between 15-50% 
of Ph/BCR-ABL-like patients (depending on the gene set used to define the gene 
expression signature) have a CRLF2 gene rearrangement (Russell et al., 2017). The 
rearrangement either occurs as part of an IGH-CRLF2 translocation or an interstitial 
deletion on the pseudoautosomal region (PAR) of Xp22/Yp11, juxtaposing CRLF2 to 
the first non-coding exon of P2RY8 and resulting in the expression of P2RY8-CRLF2 
fusion transcripts. These rearrangements lead to CRLF2 overexpression. In addition, 
mutations activating of JAK2 (or rarely JAK1) are found in approximately 50% of 
CRLF2 rearranged cases (Harvey et al., 2010). The combination of CRLF2 
rearrangements and JAK1/2 mutations result in activation of JAK-STAT signalling. 
CRLF2 rearrangements are seen in greater than 50% of paediatric ALL patients with 
Down’s syndrome and are also more common in Hispanic patients (Mullighan et al., 
2009a, Harvey et al., 2010). P2RY8 is the more common CRLF2 rearrangement 
partner in children with CRLF2 deregulated ALL, whereas IGH-CRLF2 is seen more 
commonly in adults (Russell et al., 2017). CRLF2 abnormalities have been associated 
with high rates of MRD persistence and poor overall outcome (Herold et al., 2017, 
Yoda et al., 2010). Unlike ABL-class fusions, no effective targeted treatment are 
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available, although the JAK1/JAK2 inhibitor ruxolitinib has provided a plausible 
therapeutic option (Tasian et al., 2012) and clinical trials are underway.  
 
1.8.3.3 JAK2 fusions 
The amino terminus of a partner gene is fused to the carboxyl terminal portion of JAK2 
resulting in activation of STAT5 and constitutive activation of JAK-STAT signalling 
(Schinnerl et al., 2015). These translocations or interstitial deletions are seen in 
approximately 5% of paediatric ALL patients and more commonly in young adults 
(Roberts et al., 2014). As with other JAK-STAT pathway abnormalities, JAK2 
rearranged cases have been associated with high risk disease and pre-clinical studies 
with ruxolitinib have produced mixed findings, both with evidence for mutations in 
alternative survival pathways promoting drug resistance and ruxolitinib-induced 
accumulation of phosphorylated JAK2 producing a sharp increase in JAK-STAT 
signalling on drug withdrawal (Boer et al., 2017).  
 
1.8.3.4 EPOR (erythropoietin receptor) rearrangements 
These are rare events, occurring in approximately 1% of BCP-ALL cases. They are 
usually due to truncating mutations in the EPOR gene arising through rearrangements 
with a variety of partners including the IGH@ locus (Iacobucci et al., 2016). This results 
in deregulated EPOR expression of a truncated protein, with loss of the distal tyrosine 
residues, which are required for negative regulation of receptor signalling. As such, the 
truncated protein shows hypersensitivity to erythropoietin and increased JAK-STAT 
activation. The most common gene rearrangement involves insertion of a truncated 
EPOR gene, with loss of the terminal portion of exon 8, to a region distal to the IGH@ 
locus. This rearrangement is cryptic by both cytogenetics and FISH, and can only be 
detected through sequencing or a dedicated quantitative real-time PCR assay 
(Iacobucci et al., 2016).  
 
1.8.3.5 ZNF384 translocations 
Rearrangements of ZNF384 produce a distinct subtype of ALL with a distinct 
immunophenotype including weak CD10 expression and aberrant expression of 
myeloid antigens CD13 and CD33 (Hirabayashi et al., 2017). ZNF384 encodes a 
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transcription factor known to regulate promoters of the extracellular matrix genes and 
is rearranged with a number of different partner genes including the TET family genes 
(EWSR1, TAF15 and TCF3) and EP300 among others (Schwab and Harrison, 2018, 
Hirabayashi et al., 2017). These translocations have been identified in around 4% of 
childhood ALL patients, and these patients cluster together and separately from other 
genetic subtypes on gene expression analysis. The incidence of ZNF384 
translocations in adults has not yet been clearly defined but also appears to be <10% 
(Moorman et al., 2019, Liu et al., 2016).  
 
1.8.3.6 MEF2D rearrangements 
MEF2D belongs to a family of 4 myocyte enhancer factor (MEF) transcription factors 
and plays an important role in neuronal differentiation. MEF2D rearrangements with a 
variety of partner genes enhance its transcriptional activity resulting in activation of 
HDAC9 expression and subsequent lymphoid transformation (Gu et al., 2016a). These 
events are reported in ~2% of childhood BCP-ALL and have been associated with an 
older age at diagnosis, higher white count and inferior survival (Ohki et al., 2019). The 
most frequent rearrangement involves a BCL9-MEF2D fusion. Both genes are located 
on 1q21.2-22 and a small cytogenetically cryptic interstitial insertion is required to 
produce this fusion gene. However, the mechanisms of rearrangement can be 
significantly more complex including insertion of the fusion into a different chromosome 
and can involve complex karyotypic abnormalities, making their detection more 
challenging (Gu et al., 2016a). MEF2D rearrangements result in activation of HDAC9, 
which has been shown to induce cell proliferation and has been implicated in the 
pathogenesis of B-cell lymphomas (Gil et al., 2016).  
 
1.8.3.7 IGH@ translocations 
Translocations involving the immunoglobulin heavy chain (IGH@) locus are common 
primary events in mature B-cell malignancies. Typically, following a reciprocal 
translocation, an oncogene becomes overexpressed through close proximity to the 
IGH enhancer region. Such events are the hallmarks of Burkitt’s lymphoma 
(t(8;14)(q24;q32)/MYC-IGH translocation) and follicular lymphoma 
(t(14;18)(q32;q21)/IGH-BCL2 translocation) among others (Küppers, 2005). Although 
well described, IGH@ translocations are rarer in ALL and are associated with different 
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partner genes to those described in mature B-cell malignancies (Russell et al., 2014). 
The consequences are similar, resulting in overexpression of a gene with anti-
apoptotic or transformative properties, and contributing to leukaemogenesis. Such 
cases have been identified in 5% of ALL patients with a peak incidence in adolescents 
and young adults (Russell et al., 2014). The most frequent partner gene is CRLF2, 
which is implicated in 22% of IGH@ translocated cases, followed by members of the 
CCAAT/enhancer binding protein (CEBP) family and ID4 in 11% and 7% respectively 
(Russell et al., 2014).  
More recently, DUX4 has been identified as another IGH@ partner gene and IGH-
DUX4 rearrangements are recurrent events, seen in ~7% of childhood BCP-ALL. 
DUX4 is a small intronless gene with transcription factor activity, located within the 
D4Z4 repeat regions on the subtelomeric regions of 4q35 and 10q26. The abnormality 
is characterised by insertion of variable numbers of DUX4 repeats within the vicinity of 
the IGH@ enhancer, resulting in transcriptional activation (Tian et al., 2019). IGH-
DUX4 rearrangements are cytogenetically cryptic and challenging to detect by 
conventional techniques due to the small and highly repetitive nature of the inserted 
region, and transcriptome analysis has proven the most reliable method to date 
(Schwab and Harrison, 2018). However, a clear association has been identified 
between IGH-DUX4 and intragenic deletions of the ETS transcription factor ERG 
(ERG) gene at 21q22.2, which are thought be exclusive to this subgroup, and occur in 
50-60% of cases (Schwab and Harrison, 2018, Lilljebjörn et al., 2016). As a possible 
surrogate for IGH-DUX4, ERG deletions are easier to detect by conventional methods 
and have been associated with excellent prognosis in paediatric cohorts (Clappier et 
al., 2014).  
 
1.9 T-cell ALL 
The incidence of T-ALL peaks in adolescents and young adults, and is rare in older 
age groups (Guru Murthy et al., 2019). Recurrent chromosomal rearrangements are 
well established but do not impact on prognosis or risk stratification (table 1.2). The 
translocations are more structurally diverse than those report in B-cell disease and 
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usually serve to upregulate a relevant transcription factor oncogene, although rarer 
chimeric gene fusions are also described (Girardi et al., 2017).  
Oncogene Partner gene Consequence 
TAL1 STIL, TCRA, TCRD TAL1 upregulation 
TLX1 TCRA, TCRB, TCRD TLX1 upregulation 
TLX3 TCRD, BCL11B TLX3 overexpression 
HOXA9/HOXA10 TCRB HOXA gene overexpression 
PICALM MLLT10 PICALM-MLLT10 fusion 
SET NUP214 SET-NUP214 fusion 
NKX2-1 TCRA NKX2-1 overexpression 
NKX2-2 TCRD NKX2-2 overexpression 
LMO1 TCRA, TCRD LMO1 overexpression 
MEF2C - Deletion causing MEF2C overexpression 
LYL1 TCRB LYL1 overexpression 
SPI1 BCL11B SPI1 overexpression 
Table 1.2. Recurrent gene rearrangements reported in T-ALL. Reported rearrangements 
predominantly result in overexpression of an oncogene rather than formation of chimeric fusion 
genes. Adapted from Girardi et al, (Girardi et al., 2017) 
 
1.10 Copy number abnormalities in ALL 
Cancer genomes harbour a range of copy number abnormalities (CNAs), 
characterised by losses or gains of regions of the genome. These may be random and 
part of the generalised genomic instability associated with malignancy (passenger 
lesions) or play a specific part in the cancer process, conferring transformative 
capabilities and survival advantage (driver lesions). Within a cohort of comparable 
tumour samples, driver lesions will occur at a higher frequency than passenger 
abnormalities, and will often be targeted to a focal gene or locus, which confers the 
oncogenic properties (Mermel et al., 2011). 
Conversely, copy number changes also form a very common part of normal genomic 
variation between individuals (Mills et al., 2011). Indeed, analysis of the HapMap 
collection of 270 healthy individuals has identified that up to 12% of the human genome 
is subject to germline copy number variation (CNVs) when compared to a reference 
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genome, covering more genomic loci than single nucleotide polymorphisms (SNPs) 
(Redon et al., 2006).  
Initiating primary chromosomal abnormalities alone are usually insufficient to cause 
ALL (Mullighan et al., 2007). A spectrum of secondary co-operating abnormalities, 
often characterised by deletions or gains of smaller genomic regions, contribute to 
leukaemogenesis and also impact on prognosis. Recurrent deletions affecting specific 
genes or loci are twice as common as gains (Strefford et al., 2007), and particularly 
affect genes encoding B-cell development and differentiation, cell cycle regulation 
(tumour suppressor genes) and haematopoietic control (table 1.3).  
Gene/locus Locus ALL Subtype Function 
IKZF2 2q34 BCP* B cell differentiation 
CD200/BTLA 3q13.2 BCP Lymphoid signalling 
LEF1 4q25 T-cell Haematopoietic control 
EBF1 5q33.3 BCP B cell differentiation 
IKZF1 7p12.2 BCP Lymphoid development 
CDKN2A/B 9p21.3 BCP and T-cell Cell cycle regulation 
PAX5 9p13.2 BCP B cell differentiation 
PTEN 10q23.31 T-cell Cell cycle regulation 
RAG1/2 11p12 BCP V(D)J-recombination 
ETV6 12p13.2 BCP and T-cell Haematopoietic control 
BTG1 12q21.33 BCP Apoptosis regulation 
RB1 13q14.2 BCP and T-cell Cell cycle regulation 
IKZF3 17q12 BCP* B cell differentiation 
NF1 17q12.2 T-cell Cell cycle regulation 
TCF3 19p13.3 BCP B cell differentiation 
ERG 21q22 BCP Haematopoietic control 
PAR1‡ Xp22.3/Yp11.2 BCP JAK/STAT activation 
Table 1.3.: Recurrently deleted genes/loci in ALL identified from SNP array (Mullighan et al., 
2009b, Ribera et al., 2017, Mullighan et al., 2007, Paulsson et al., 2008) and MLPA (Schwab et al., 
2013) studies.  
*IKZF2 and IKZF3 deletions are specifically associated with low hypodiploid and near haploid 
ALL respectively.  
‡Specific deletion on pseudoautosomal region 1 on Xp22.3/Yp11.2 (PAR1) results in P2RY8-
CRLF2 fusion and CRLF2 overexpression. 
 
In childhood ALL, specific combinations of gene deletions have a clear impact on 
prognosis. Paediatric ALL patients presenting with an IKZF1 deletion co-occurring with 
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deletions in one or more of CDKN2A, CDKN2B, PAX5 or PAR1 in the absence of ERG 
deletion (IKZF1plus profile) have been found to have an event free survival of 53% 
compared with patients with isolated IKZF1 deletion or intact IKZF1, who had an EFS 
of 79% and 87% respectively (Stanulla et al., 2018). In comparison, paediatric patients 
harbouring focal ERG deletions have an excellent prognosis, with an 8 year overall 
survival >95% (Clappier et al., 2014). These patients lack conventional chromosomal 
abnormalities and form part of the B-other subgroup. Interestingly over a third of 
affected patients had an IKZF1 deletion, which did not impact on their prognosis, 
highlighting the importance of considering the interaction of CNAs rather than 
individual lesions in isolation. Furthermore, combining baseline cytogenetic risk groups 
with copy number profiles can provide a powerful prognostic biomarker in paediatric 
ALL populations. In one study, subsequently validated with a large international 
external cohort (Moorman et al., 2014, Hamadeh et al., 2019), patients could be divided 
into genetic good risk and genetic poor risk categories based on the combination of 
primary chromosomal abnormalities and copy number profiles (UKALL-CNA). This 
proved particularly relevant for patients with intermediate risk cytogenetics (TCF3-
PBX1 or B-other ALL), whereby a good risk UKALL-CNA profile (table 1.4) was 
associated with an EFS of 88% (genetic good risk), whereas those with poor risk 
UKALL-CNA profile had an EFS of 69% (genetic poor risk). 
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Classification Risk category Features 
Cytogenetics 
Good risk HeH ETV6-RUNX1 








No deletions  
Isolated deletion of ETV6, PAX5 or BTG1 
ETV6 + single deletion of BTG1, CDKN2A/B or 
BTG1 
Intermediate risk All other CNA profiles 
Poor risk Isolated IKZF1, PAR1 or RB1 deletion Deletion of IKZF1/PAX5/CDKN2A/B 
Table 1.4. Cytogenetic and CNA risk categories based on international study of 3239 cases of 
childhood BCP-ALL. Table adapted from Hamadeh et al (Hamadeh et al., 2019). Cytogenetic risk 
group and UKALL-CNA risk group are combined to form an overall genetic risk group. Genetic 
good risk consists of patients with cytogenetics good risk with any UKALL-CNA risk or 
cytogenetic intermediate risk with UKALL-CNA good risk. Genetic poor risk consists of patients 
with cytogenetic poor risk with any UKALL-CNA risk or cytogenetic intermediate risk with 
UKALL-CNA intermediate or poor risk.  
HeH: high hyperdiploidy; B-other: BCP-ALL with no primary chromosomal abnormality 
identified; HoTr: low hypodiploidy/near triploidy; CNA: copy number abnormality; PAR1: 
pseudoautosomal region at Xp22.3/Yp11.2. 
 
In adults, limited studies have shown specific CNAs to have an adverse effect on 
prognosis (e.g. deletion of EBF1, IKZF1, and CDKN2A/B) (Jordi et al., 2015). However, 
these have failed to be validated (Moorman et al., 2019) and detailed copy number 
analyses have not yet been performed in older patients.  
 
1.11 Mutational landscape of ALL and relevance to 
relapse 
Together with primary chromosomal aberrations and co-operating CNAs, ALL 
genomes harbour a range of smaller abnormalities including single nucleotide variants 
(SNVs) and small insertions and deletions (indels) that can only be detected through 
next generation sequencing (NGS) techniques. As with most genetic and genomic 
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profiling of ALL, studies have focussed on children and younger adults. Such studies 
have identified a low mutational burden with <10-20 non-silent mutations per case, 
although occasional relapse samples show a hypermutated phenotype (Mullighan, 
2014). Despite the low total number of coding variants, recurrent mutations in key 
pathways are well described in both T and B-cell disease (tables 1.5 and 1.6).  
Cellular process Genes 
Signaling KRAS, NRAS, NF1, PTPN11, FLT3, JAK1, JAK2, SH2B3, IL7R, STAT5B 
Epigenetic 
modification 
EZH2, CREBBP, SETD2, KMT2D, WHSC1, TRRAP, 
SETD1B, KMT2C, CTCF, KMT2A, ASXL1, ARID1B, 
NCOR2, CHD4, KDM6A, ARID1A, EP300, TET2, CHD8, 
ASXL2 
Transcription factors PAX5, IKZF1, ZEB2, ETV6, MGA, RUNX1, MYC 
Cell cycle regulation TP53, CDKN2A, MED12 
Others HERC1, SACS, USP9X, ASPM 
Table 1.5. Recurrent mutations identified through transcriptome sequencing of 1,223 BCP-ALL 
cases. Mutations data were obtained from whole exome sequencing of predominantly childhood 
BCP-ALL samples. Adapted from Li et al (Li et al., 2018). 
 
Cellular process Genes 
NOTCH1 signaling FBXW7, NOTCH1 
Transcription factors BCL11, ETV6, GATA3, HOXA, LEF1, MYB, RUNX1, WT1 
Signalling AKT, DNM2, FLT3, JAK1, JAK3, IL7R, KRAS, NRAS, PI3KCA, PTEN, PTPN2, STAT5B 
Epigenetic factors DNMT3A, EED, EZH2, KDM6A, PHF6, SUZ12 
Translation and RNA stability CNOT3, mTOR, RPL5, RPL10, RPL22 
Table 1.6. Recurrent mutations in T-ALL. Activating NOTCH1 mutations are the most common 
finding and epigenetic mutations are present in more than 50% of cases. Adapted from Girardi 
et al (Girardi et al., 2017). 
 
Moreover, patterns are increasingly recognised between the mutational landscape at 
diagnosis and relapse. As the presumed initiating events, primary chromosomal 
abnormalities are almost always retained between diagnosis and relapse. Studies into 
relapsed childhood ALL demonstrate a similar mutational landscape at diagnosis and 
relapse in the majority of cases (Waanders et al., 2020). However, genes associated 
with drug metabolism (e.g. NT5C2 for purine metabolism) are specifically acquired at 
relapse (Barz et al., 2020, Tzoneva et al., 2013). Such findings are consistent with 
positive selection of a clone which confers resistance to the purine analogues given 
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during maintenance chemotherapy, and illustrates the effects of a therapeutic selection 
pressure. Moreover, clear correlation has been seen between a minor subclone at 
diagnosis and relapse-founder clones (Ma et al., 2015, Waanders et al., 2020). 
Specifically, multiple mutations may be seen in RAS pathway genes at diagnosis, with 
a single minor subclone shown to drive disease relapse (Irving et al., 2014, Ryan et 
al., 2016).  
Importantly, given the highly intensive and successful treatment delivered to children 
with ALL, detecting and quantifying these subclonal populations during remission is 
challenging (Ma et al., 2015). However, research into older adults receiving much less 
intensive therapy could provide a clearer insight into the fluctuation of subclones on 
treatment. In these patients, periods of remission are likely to be related to disease 
control rather than eradication, and understanding these mechanisms could pave the 
way to modifying therapy to control and suppress the disease to subclinical levels, 
potentially improving both quantity and quality of life for older adults with ALL. In the 
GMALL 05/93 trial, minimal residual disease (MRD) of 10-4 cells or higher was 
detectable in 71% of intensively treated adults with ALL at day 29 (post induction 1) 
and in 42% after induction 2 (Brüggemann et al., 2006). A significant proportion of 
follow up samples on even less intensively treated older patients are therefore likely to 
contain ALL cells detectable by sensitive molecular techniques and there have been 
no studies examining the dynamics of leukaemic clones over a long period of time and 
in the context of a therapeutic selection pressure. The longitudinal study of such 
patients would therefore provide a valuable insight into the biology and clonal dynamics 
of ALL in older adults, and could provide a novel understanding of clonal fluctuations 
on treatment. Ultimately, such data could inform the development of additional targeted 
therapies or re-purpose those already in existence.  
 
1.11.1 Age-related clonal haematopoiesis 
In childhood, it is clear that certain genetic abnormalities (e.g. ETV6-RUNX1 fusion) 
may be present antenatally, and together with co-operating mutations acquired later in 
childhood, result in the development of ALL (Alpar et al., 2014). It is also well 
recognised that many of these primary lesions alone are insufficient to cause 
leukaemia. The prevalence of ETV6-RUNX1 fusion in neonatal Guthrie spots is 100x 
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greater than the prevalence of ALL (Mori et al., 2002), indicating that additional lesions 
such as CNAs are required to cause clinical disease (section 1.4). 
Much less is known about the pathogenesis of ALL in older adults, but it is reasonable 
to assume that it does not arise antenatally but rather via the sequential acquisition of 
somatic mutations during the lifetime of the patients; potentially over many years. In 
2014, three large population-based studies identified a number of acquired mutations 
in haematopoietic cells that become more prevalent with age (table 1.7) (Jaiswal et al., 
2014, Genovese et al., 2014, Xie et al., 2014). Affected individuals did not have clinical 
or biochemical evidence of haematological disorders and the mutations instead 
reflected a state whereby the pool of haematopoietic progenitors had become clonally 
restricted and was thus termed age-related clonal haematopoiesis. The most prevalent 
mutations were in the epigenetic regulators DNMT3A, TET2 and ASXL1. These 
incidental findings have been identified in 10% of people over 70, and their prevalence 
continues to rise with advancing age (Jaiswal et al., 2014, Natarajan et al., 2018).  
Gene Function of Gene Product 
DNMT3A De novo genome-wide methylation 
TET2 Conversion of methylcytosine to 5-hydroxymethylcytosine, including downstream DNA demethylation 
ASXL1 Chromatin-binding protein regulating transcription through nuclear hormone receptors 
TP53 Cell cycle regulation 
JAK2 Protein tyrosine kinase 
SF3B1 RNA splicing regulation 
GNB1 Transmembrane signal transduction and modulation 
CBL Proteosomal degradation 
SRSF2 Promotes RNA splicing 
GNAS Transmembrane signal transduction and modulation 
PPM1D Negatively regulates p38 MAPK 
BCORL1 Interacts with histone deacetylases to repress transcription 
Table 1.7. Genes with largest burden of somatic mutations in blood cells from population-based 
studies of individuals without haematological disease. Adapted from Natarajan et al (Natarajan 
et al., 2018) 
 
Although these mutations are associated with clonal expansion and survival advantage 
compared to wild type cells, they are typically present at a low variant allele frequency 
(VAF) (mean 0.09) and most individuals carrying these mutations have no evidence of 
haematological disease. However, clonal haematopoiesis is associated with increased 
risk of AML as well as cardiovascular disease (Natarajan et al., 2018, Jaiswal et al., 
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2014) and the state is now more commonly termed clonal haematopoiesis of 
indeterminate potential (CHIP).  
Interestingly, the discovery of clonal haematopoiesis has also helped to confirm the 
leukaemia cell of origin in AML. DNMT3A-mutated AML patients were found to harbour 
the same mutation in their T cells, albeit at a lower VAF. This indicated that DNMT3A 
mutation had occurred very early in the disease process, probably in an HSC. The 
mutations were shown to result in clonal expansion of a pre-leukaemic HSC pool, from 
which the leukaemia arose (Shlush et al., 2014), confirming this as a disease-initiating 
event.  
In clonal haematopoiesis, DNMT3A and TET2 mutations are reported across their 
coding sequences and cause a loss of function effect. In comparison, the ASXL1 
variants are truncating mutations which occur in hotspot regions in exons 11 and 12 
(Gelsi-Boyer et al., 2012) and are thought to result in gain of function (Natarajan et al., 
2018). Regarding lymphoid malignancies, DNMT3A mutations have already been 
identified in a high frequency of patient with early-T precursor ALL (ETP-ALL) 
(Neumann et al., 2013) and TET2 mutations are implicated in lymphomagenesis 
(Quivoron et al., 2011). However, to date, a link with ALL in older adults has not been 
investigated. 
 
1.12 Aims and objectives 
An ageing population together with high morbidity from the current treatment of older 
adults with ALL creates a disproportionate burden on healthcare resources. 
Conventional chemotherapeutic approaches are associated with a very high rate of 
complications in older patients, often leading to prolonged hospitalisations, which in 
turn necessitate the use of costly interventions (Sive et al., 2012, Sancho et al., 2007). 
Affected patients are further impacted by a decline in functional status contributing to 
a vicious cycle of increasing frailty and reduced fitness for treatment. Judicious use of 
more targeted therapy based on a comprehensive genomic characterisation and 
regular in-depth re-assessment of the disease’s genomic profile could prolong both 
quality and quantity of life for these patients. The overarching aim of this research was 
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therefore to characterise the genetic and genomic landscape of ALL in older adults, 
and assess its evolution on treatment, ultimately paving the way for novel therapies. 
Using cytogenetic and molecular techniques, the project was divided into the following 
objectives. 
 
1. Identify primary chromosomal abnormalities in a large cohort of older adults 
enrolled in the UKALL14 and UKALL60+ clinical trials. Where standard 
diagnostic analyses had not identified a primary abnormality, extended FISH 
experiments were planned to characterise these B-other patients. 
2. Detect and classify the secondary CNAs that drive leukaemogenesis in older 
adults. Using high density SNP arrays, a comprehensive profile of the genomic 
deletions and gains needed to be generated from older adults in the UKALL14 
and UKALL60+ clinical trial cohort. 
3. Optimise the use of SNP arrays to accurately classify patients with primary 
ploidy shift and identify discrepancies with cytogenetic analyses. 
4. Identify mutations and perform serial monitoring of the clonal architecture 
through treatment. A small cohort of prospectively recruited older adults with 
ALL first needed to be defined. Sensitive NGS techniques could then be 
designed on diagnostic and follow up material to determine and quantify the 
fluctuation of leukaemia-associated mutations through treatment. The presence 




Chapter 2. Materials and Methods 
 
2.1 Ethical approval 
All experiments were performed on primary patient material. Patients were enrolled in 
the UKALL14 or UKALL60+ clinical trials and had existing REC approval in place 
(Study title: Genetic and functional characterisation of adult acute lymphoblastic 
leukaemia using patient specimens, REC reference: 16/LO/2055, IRAS project ID: 
179685)  
Separately, patients were recruited within the Newcastle-upon-Tyne Hospitals NHS 
Foundation Trust for sample biobanking at the Newcastle Biobank (Study title: 
Collection of samples to support the Newcastle Academic Health Partners 
Bioresource, REC reference: 12/NE/0395).  
Informed consent was given by all patients in accordance with the Declaration of 





Goods and services throughout the project were obtained from all the manufacturers 
listed in table 2.1. Standard laboratory equipment such as microsyringe tubes, pipettes 
and pipette tips are not included. 
Manufacturer  Location  
Abbott Molecular  Chicago, IL, USA  
Affymetrix  Santa Clara, CA, USA  
Agilent Technologies  Santa Clara, CA, USA  
Applied Biosystems Waltham, MA, USA  
Beckman Coulter  Brea, CA, USA  
BGM Labtech  Ortenberg, Germany  
Cytocell  Cambridge, UK  
Diagenode Liège, Belgium 
Eppendorf  Hamburg, Germany  
Fisher Scientific Loughborough, UK 
IKA Oxford, UK 
Illumina San Diego, CA, USA 
Isohelix Harrietsham, UK 
Kreatech Diagnostics Amsterdam, Netherlands  
Labnet International Edison, NJ, USA 
Leica Biosystems  Nussloch, Germany  
MRC Holland  Amsterdam, Netherlands  
New England Biolabs Ipswich MA, USA 
Qiagen  Venlo, Netherlands  
Santa Cruz Biotechnologies  Dallas, TX, USA  
Sigma-Aldrich  St. Louis, MO, USA  
Stem Cell Technologies Vancouver, BC, CA 
Thermo Scientific Waltham, MA, USA  
ThermoFisher Scientific Waltham, MA, USA  
Twist Bioscience San Francisco, CA, USA 
VWR International Radnor, PA, USA 
Zeiss Oberkochen, Germany 
Table 2.1. List of suppliers 
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2.2.2 Laboratory equipment 
All equipment used to conduct the laboratory experiments throughout this project are 
listed in table 2.2.  
Equipment Manufacturer  
Axioskop microscope Zeiss 
Bioanalyzer 2100 Agilent Technologies  
Bioanalyzer chip priming station Agilent Technologies 
Bioruptor Pico Diagenode 
Bioruptor Pico microtubes (0.65ml) Diagenode 
Coplin jars Thermo Scientific 
Cover glasses (rectangular 24x50mm) VWR International 
Cover glasses (round 13mm) VWR International 
DNA LoBind tubes Eppendorf  
Fluostar Omega BGM Labtech  
Microscope slides VWR International 
MS3 vortex mixer IKA 
Mr Frosty freezing container Thermo Scientific 
Nanodrop 1000 Thermo Scientific 
Nutator mixer  
SK-1S buccal swabs Isohelix 
Tapestation 4200 Agilent Technologies  
Thermal Cycler 2720 Applied Biosystems 
Thermobrite Leica Biosystems  
Vaccum Concentrator 5301 Eppendorf  
Vortex mixer Labnet International 




2.2.3 Analytical software 
Specialist computer software required for statistic, SNP array and bioinformatic 
analyses is detailed in table 2.3.  
Software Manufacturer 
Bioconductor packages (various) Bioconductor 
BlueFuse Multi Illumina 
Chromosome Analysis Suite Affymetrix 
Cytovision 7.1 Leica Biosystems 
GeneMarker V1.85 SoftGenetics 
GenomeStudio 2.0 Illumina 
Integrative Genomics Viewer Broad Institute 
Nexus copy number 10 Biodiscovery 
R version 4.0 R Foundation for Statistical Computing 




2.2.4 Chemicals and reagents 
All chemicals and reagents that were not part of standardised experimental kits are 
listed in table 2.4.  
Chemical/reagent Manufacturer 
20 x saline-sodium citrate (SSC) buffer Fisher Scientific 
4′,6-diamidino-2-phenylindole (DAPI) Cytocell 
Acetic acid (100%, glacial) Fisher Scientific 
Agencourt AMPure XP Beckman Coulter 
Distilled water Newcastle University 
Dimethyl sulfoxide (DMSO) Sigma Aldrich 
Dynabeads MyOne Streptavidin T1  Invitrogen 
Ethanol (100%) Fisher Scientific 
Fetal Bovine Serum Gibco 
Hybridisation solution Cytocell 
Igepal-CA-630 Sigma Aldrich 
Low TE buffer Sigma Aldrich 
Lymphoprep Stem Cell Technologies 
Methanol Fisher Scientific 
Nuclease free water Invitrogen 
Phosphate-buffered saline (PBS) Newcastle University 




2.2.5 Experimental kits 
Experimental kits containing reagents and protocols for specific laboratory techniques 
were used and are detailed in table 2.5.  
Experimental kit Manufacturer 
DNA 1000 kit Agilent 
DNA Isolation kit: DDK-50 / DDK-3 Isohelix 
DNeasy Blood and Tissue Kit Qiagen 
Genomic DNA screen tape analysis kit Agilent 
High sensitivity DNA kit Agilent 
Quant-iT dsDNA Assay Kit, broad range Invitrogen 
REPLI-g Mini Kit Qiagen 
SALSA MLPA P335-IKZF1 probemix MRC Holland 
SureSelect XT2 reagent kit Agilent 
Table 2.5. List of experimental kits used.  
 
2.2.6 Services 
Specific service providers were utilised for SNP array and next generation sequencing 
experiments, which are conducted in specialised facilities (table 2.6). 
Service Manufacturer Provider 
Cytoscan HD arrays Affymetrix Newcastle Hospitals 
CytoSNP 850k arrays Illumina Newcastle Hospitals 
MLPA fragment analysis MRC Holland DBS Genomics 
NextSeq 550 sequencing Illumina Newcastle University 
NovoSeq sequencing Illumina Newcastle University 
Twist Human Exome kit Twist Bioscience Newcastle University 
Table 2.6. Internal and external providers used for array and next generation sequencing.  
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2.3 Patients and samples 
Primary patient samples were obtained from two large UK clinical trials.  
UKALL14 was a phase 3 randomised controlled trial that recruited patients with newly 
diagnosed ALL between 30/12/2010 and 26/07/2018. Patients were aged between 25-
65 years (or 19-65 if Philadelphia positive) at diagnosis, and needed to be sufficiently 
fit to tolerate intensive multi-agent chemotherapy and potential allogeneic stem cell 
transplantation. 
UKALL60+ was a phase 2 trial that recruited patients with newly diagnosed ALL 
between 07/12/2012 and 21/12/2018. Inclusion criteria specified that patients were 
aged ≥60 years at diagnosis (or ≥55 years if deemed unfit for UKALL14 treatment). A 
number of treatment arms were available based on the treating physician’s 
assessment of patient fitness, ranging from intensive multi-agent high dose 
chemotherapy to largely outpatient based non-intensive treatment.  
All patients had given written informed consent for data collection and genetic studies 
as specified by the trials’ protocols. 
Separately, newly diagnosed ALL patients at the Newcastle-upon-Tyne Hospitals NHS 
Foundation Trust and aged ≥60 years were approached to donate samples to the 
Newcastle Biobank (REC 12/NE/0395) between August 2017 and August 2019. Bone 
marrow samples were obtained at diagnosis and during follow up in line with clinical 
standard of care for the relevant treatment protocol. Additionally, buccal samples for 
DNA extraction were obtained using SK-1S DNA swabs (Isohelix). All patients were 
treated on established standard of care protocols based on the UKALL14 or the 
UKALL60+ clinical trials and treatment varied from intensive multi-agent chemotherapy 
to non-intensive predominantly oral outpatient regimes. 
 
All genetic and genomic analyses performed on patient samples along with baseline 
demographic characteristics are outlined in supplementary table 1. 
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2.4 General molecular biology techniques 
2.4.1 Isolation of mononuclear cells from patient bone marrow 
samples 
Approximately 3-5 ml of liquid bone marrow in EDTA was obtained from the locally 
recruited patients at each time point of bone marrow sampling. Mononuclear cells were 
isolated from fresh bone marrow aspirate samples using a density gradient medium 
(Lymphoprep) in aseptic conditions under a laminar flow hood, sterilising all surfaces 
with 70% ethanol. 
One part bone marrow was first diluted in 3 parts PBS in a 30 ml universal container. 
Two 8ml aliquots of lymphoprep medium were then introduced into separate 30ml 
universal containers. Half of the diluted bone marrow was then very slowly placed on 
top of each volume of lymphoprep, with special care to avoid disrupting the interface 
between the lymphoprep and the bone marrow. The samples were then centrifuged at 
800 x g for 30 minutes with the centrifuge brake off. Following centrifugation, a thin 
buffy coat layer consisting of mononuclear cells was visible between the lymphoprep 
medium and the top layer of plasma. Red cells and granulocytes have a higher density 
than mononuclear cells and migrated through the lymphoprep medium to the bottom 
of the universal container during centrifugation. Using a 3ml disposable Pasteur 
pipette, the buffy coat layer was carefully aspirated and transferred to a fresh universal 
container. The mononuclear cells were re-suspended in 15ml with sterile PBS and 
centrifuged at 400 x g for 10 minutes. This caused the mononuclear cells to pellet at 
the bottom of the universal container and the supernatant was then discarded. The 
cells were re-suspended in 5 ml of sterile PBS and centrifuged for a further 5 minutes 
at 400 x g. The PBS was again discarded and the cells were then re-suspended in a 
solution of 10% DMSO in FBS for cryopreservation. The volume of freeze media was 
varied based on the pellet size, aiming for an approximate concentration of 1-5 x 106 
cells/ml. The final cell suspension was then split into 1 ml aliquots, placed in cryovials 
and cooled to -80⁰C in a Mr Frosty Freezing Container to achieve a rate of cooling of 




2.4.2 Extraction of DNA from viable cells 
The DNeasy kit for the purification of total DNA from animal blood or cells (spin-column 
protocol) was used to extract DNA from the mononuclear cells that had been isolated 
from patient bone marrow samples (section 2.4.1). Viable cells were allowed to thaw 
at room temperature and then centrifuged for 5 minutes at 300 x g to pellet the cells. 
The freeze media was removed and discarded, with care not to disturb the cell pellet. 
The cells were then re-suspended in 200 ul PBS and centrifuged again for 5 minutes 
at 300 x g to then remove and discard the supernatant containing any residual freeze 
media. The viable cells were re-suspended in fresh 200 ul PBS and 20 ul proteinase 
K was added, followed by 4 ul RNase. Next, 200 ul Buffer AL was thoroughly mixed 
into the sample by vortexing, before incubating at 56⁰C for 10 minutes. Following this, 
200 ul of 96-100% ethanol was added to the sample and mixed thoroughly by 
vortexing. The mixture was then carefully transferred to a DNeasy mini spin column 
placed in a 2 ml collection tube. The column was centrifuged at 6000 x g for 1 minute 
and the flow through in the collection tube was discarded. The column was placed in a 
fresh 2 ml collection tube and 500 ul of Buffer AW1 was added to the spin column. The 
mixture was then centrifuged at 6000 x g for 1 minute and the flow through discarded 
as previously. The spin column was placed in a fresh collection tube and 500 ul of 
Buffer AW2 was added, before centrifuging at 20,000 x g for 3 minutes to dry out the 
DNeasy membrane and discarding the flow through and collection tube. The spin 
column was then placed in a pre-labelled 1.5 ml Eppendorf tube. To elute the DNA, 30 
ul of nuclease free water was first placed directly onto the DNeasy membrane in the 
spin column and allowed to incubate at room temperature for at least 1 minute. The 
Eppendorf tube containing the spin column was then centrifuged at 6000 x g for 1 
minute. To maximise DNA yield a second elution was also performed by placing a 
further 30 ul nuclease free water onto the spin column in a fresh pre-labelled 1.5 ml 
Eppendorf tube and incubating the sample overnight at 4⁰C. The following day, the 




2.4.3 Extraction of DNA from buccal swabs 
Buccal DNA samples were obtained from the locally recruited patients in accordance 
with the manufacturer’s recommendations by rubbing the SK-1S swab against the 
inside of the patient’s cheek for 1 minute, before placing it in the sealed tube provided. 
Buccal DNA was extracted using the DDK-3/DDK-50 protocol. The swab was carefully 
removed from the sealed tube and placed in a fresh 1.5 ml centrifuge tube, ensuring 
the swab head was at the bottom of the tube. To stabilise the DNA, 500 ul of LS solution 
was added, followed by 20 ul of PK solution. The tube contents were mixed on a vortex 
mixer and at this point the DNA was stable at room temperature for at least 3.5 years. 
To isolate the sample DNA, the tube was first heated to 60⁰C on a heating block. To 
increase DNA yield before discarding the swab, any remaining liquid in the swab was 
then extracted by briefly centrifuging the swab in a separate 1.5 ml centrifuge tube and 
adding the supernatant to the rest of the sample. Following this, 500 ul of CT solution 
was added and the sample was mixed using a vortex mixer and then centrifuged at 
maximum speed for 7 minutes to pellet the DNA. The supernatant was then removed 
and discarded, with care not to disturb the DNA pellet. A further centrifugation was 
then performed at 12,000 x g for 1 minute and again any remaining supernatant was 
removed and discarded. The pelleted DNA was then re-hydrated by adding 30 ul of 
nuclease free water and allowing the DNA to elute into the water for 30 minutes. The 
contents were then mixed on a vortex mixer and centrifuged at maximum speed for 15 
minutes to pellet any undissolved debris. Following this, the supernatant, containing 
the extracted DNA, was transferred to a sterile 1.5 ml tube and the pellet of undissolved 
debris was discarded.  
 
2.4.4 Whole genome amplification (WGA) 
A minimum of 1 ug of sample DNA was required for the SureSelect XT2 library prep 
(section 2.7.2). Whole genome amplification (WGA) of relevant samples was therefore 
first required for sufficient input DNA. This was performed using the Qiagen REPLI-g 
mini kit and protocol. Denaturation and neutralisation buffers were prepared according 
to the manufacturer’s protocol. Briefly ~20ng of sample DNA in 5 ul was first denatured 
in a gentle alkaline denaturation step by adding 5 ul of buffer D1 (denaturation buffer) 
and incubating at room temperature for 3 minutes. The reaction was then stopped with 
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the addition of 5 ul of buffer N1 (neutralisation buffer) and a master mix containing a 
high-fidelity polymerase enzyme (Phi 29 polymerase) was then incubated with the 
sample for 10-16 hours to allow whole genome amplification. Following WGA, the 
concentration of double stranded DNA was measured using the Quant-iT PicoGreen 
dsDNA Assay Kit and the FLUOstar Omega microplate reader. 
 
2.4.5 Assessing DNA concentration and quality 
DNA samples for MLPA and/or SNP array were assessed by Nanodrop only. Samples 
for exome sequencing and SureSelect XT2 library prep were also assessed by Quant-
iT for accurate double stranded DNA (dsDNA) quantification and 4200 TapeStation 
System or 2100 Bioanalyzer for fragment sizing.  
 
2.4.5.1 Nanodrop spectrophotometer 
The Nanodrop 1000 spectrophotometer consists of two fibre optical cables which are 
located on the sample pedestal and on a mobile sampling arm. A sample is placed 
between the fibre optical cables and a light source and detector are used to measure 
absorbance at specific wavelengths (230, 260 and 280 nm), which can determine the 
purity and concentration of nucleic acids in the sample. 
Before use, the instrument was first cleaned and primed by loading a 1 ul water sample 
on the lower pedestal. A blank measurement was then made with 1 ul of the relevant 
DNA eluent (water or TE buffer). Next, 1ul of the DNA sample to be tested was carefully 
placed on the Nanodrop lower pedestal and the concentration and A260/A280 ratio 
measured.  
 
2.4.5.2 dsDNA concentration using Quant-iT Picogreen dsDNA reagent 
Quant-iT Picogreen dye emits a fluorescent signal upon binding to dsDNA, which does 
not occur in the presence of RNA a single stranded DNA. The strength of fluorescence 
rises linearly with dsDNA concentration over a broad range so can be used for accurate 
dsDNA quantification. Sufficient quantities of good quality dsDNA are particularly 
crucial for NGS-based assays.  
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All reagents of the Quant-iT dsDNA Assay Kit, broad range were allowed to equilibrate 
at room temperature for 30 minutes and a working solution was created by diluting 1 
ul Quant-iT Picogreen dsDNA reagent in 200 ul Quant-iT dsDNA BR buffer per sample 
to be tested. For each run, 8 standards with known DNA concentrations were included 
in duplicate. A flat-bottomed black 96 well plate was used and 200 ul of the diluted 
picogreen reagent was introduced into each well to be tested. Next, 10 ul of each 
standard was introduced into pre-specified wells and 1 ul of each sample DNA into 
other wells. The plate was sealed, mixed on a vortex mixer and briefly centrifuged to 
collect the liquid. The fluorescent signals emitted from each well were then measured 
on a FLUOstar Omega microplate reader, and a standard curve from the reference 
samples was constructed, which permitted quantification of dsDNA in all test samples.  
 
2.4.5.3 Assessing DNA fragment size using Agilent 4200 TapeStation System 
The Agilent 4200 TapeStation System allows automated electrophoresis for DNA 
fragment sizing and only requires 1 ul of sample DNA input. This was specifically used 
for quality control of DNA samples prior to exome sequencing. D1000 reagents were 
allowed to equilibrate at room temperature for 30 minutes. D1000 ScreenTape and 
loading tips were then introduced into the instrument. All reagents were mixed 
thoroughly on a vortex mixer and 3 ul of D1000 sample buffer was added into each 
position of a tube strip to be tested, followed by 1 ul of D1000 ladder in the A1 position 
of the tube strip and 1 ul of sample DNA in the other wells. The liquids were mixed at 
2000 rpm on an IKA vortex mixer for 1 minute and briefly centrifuged to collect the 
liquid at the bottom of the tube strip wells. The samples were then ready to be loaded 
and analysed by automated electrophoresis on the 4200 TapeStation. A DNA integrity 
number (DIN) was computed by the software based on the distribution of sizes of DNA 
fragments in the sample. Highly degraded DNA would produce a much lower DIN than 
samples with well-preserved DNA. For exome sequencing, a DIN>7 was required for 
successful library prep. 
 
2.4.5.4 Assessing DNA fragment size using Agilent 2100 Bioanalyzer 
The 2100 Bioanalyzer performs automated gel electrophoresis and was used for 
fragment sizing and quantification of SureSelect XT2 libraries. DNA 1000 or High 
Sensitivity chips and reagents were allowed to equilibrate at room temperature for 30 
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minutes and mixed on a vortex mixer. Gel dye mix was first prepared by adding 25 ul 
of dye concentrate to the DNA gel matrix. This was mixed by vortexing for 10 seconds 
and then transferred to the top receptacle of a spin filter. The gel dye mix was 
centrifuged at 2240 x g for 15 minutes and the filter could then be discarded. The chip 
priming station was set to the lower position and 9 ul of gel dye mix was loaded into 
the specified gel priming well. The chip priming syringe plunger was set to the 1 ml 
mark and closed by applying a constant and even pressure, and then held in position 
with the securing clip. After exactly 1 minute, the securing clip was released, allowing 
the plunger to rise gradually to the 0.3 ml position, before raising it back to the 1 ml 
mark over a further 5 seconds. Next, 9 ul of gel dye mix was placed in the specified 
wells, followed by 5 ul of DNA marker into the ladder and all sample wells. Lastly, 1 ul 
of sample DNA was added to testing wells and 1 ul of DNA ladder to the pre-specified 
ladder well. The contents of the DNA chip were then thoroughly mixed on an IKA MS3 
vortex mixer set to 2400 rpm for exactly 1 minute. The DNA chip was then loaded into 
the 2100 Bioanalyzer for DNA fragment analysis using the built-in software.  
 
2.5 Fluorescence in situ hybridisation (FISH) to detect 
gene rearrangements 
2.5.1 FISH introduction 
FISH is based on the principle that single stranded DNA can anneal to a 
complementary sequence. The method was developed in the late 1980s and has 
permitted the targeted detection of many specific genetic aberrations (Bishop, 2010). 
In contrast to karyotyping, which is limited by the need for actively dividing cells to 
create a metaphase spread, FISH can detect abnormalities in interphase nuclei, which 
are usually much more abundant in primary patient samples. Specific probes are 
designed with sequences complementary to the DNA regions of interest. The probes 
are either directly or indirectly labelled to permit visualisation using fluorescence 
microscopy. Direct probe labelling involves integration of a fluorophore, a compound 
which is able to re-emit light following light excitation (Speicher and Carter, 2005). In 
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comparison, indirect labelling relies on the inclusion of a hapten molecule, which in 
turn has affinity for a secondary detection reagent (Huber et al., 2018).  
FISH probes are usually created from Bacterial Artificial Chromosome (BAC) clones. 
These are cloned human DNA sequences, around 150-350 kb, that cover regions 
across the human genome, and can be amplified in bacteria (usually E. coli). A 
fluorochrome is integrated through nick translation. This involves creating a “nick” in 
the DNA sequence and extracting nucleotides through the action of polymerase I. 
These are then replaced with fluorescently tagged dNTPs, creating a fluorescent 
marker on the probe DNA sequence (Rigby et al., 1977). 
Hybridisation of probe to sample DNA requires denaturation of both the probe and 
target DNA. Although typically, a temperature of 95°C is required for DNA denaturation, 
the probe hybridisation solution contains formamide, an organic solvent that allows 
denaturation to take place at a lower temperature. Following hybridisation, unbound or 
weakly bound probe then needs to be removed with a series of washes. Wash 
solutions, which are slightly more stringent than the probe buffer solution, are used to 
achieve this. A counter stain such as 4’,6’-diamidino-2-phenylindole dihydrochloride 
(DAPI), which binds to all DNA, is then applied to facilitate visualisation of the signals 
in the context of individual nuclei. 
A FISH method can be used to identify rearrangements affecting ABL1, ABL2, 
PDGFRB, CSF1R, CRLF2 and JAK2, the most common abnormalities driving the 
Ph/BCR-ABL-like signature (Schwab et al., 2016). Dual colour break-apart probes 
consisting of red and green fluorochromes, which hybridise to genomic loci flanking 
the gene of interest, are used to detect such rearrangements. Two sets of adjacent red 
and green signals (2 fused signals) within an interphase nucleus indicate two normal 
copies of an undisrupted gene. In contrast, a single fused signal and separated red 
and green signals indicates a typical gene rearrangement pattern, often arising through 




Figure 2.1. Example fluorescence in situ hybridisation (FISH) image of a KMT2A gene 
rearrangement using KMT2A break apart probe. Both nuclei demonstrate a single fused signal 
representing the intact KMT2A allele and split red and green signals representing the rearranged 
allele (image courtesy of Claire Schwab). 
 
2.5.2 Patients and samples 
The Leukaemia Research Cytogenetics Group (LRCG) database was searched for all 
patients aged 60 years and over at ALL diagnosis who were enrolled in the UKALL14 
or UKALL60+ clinical trials. Patients lacking a known primary chromosomal 
abnormality were identified and those with available fixed cell samples were selected. 
 
2.5.3 FISH probes 
Commercially manufactured directly labelled dual colour break-apart probes were used 
to identify primary chromosomal rearrangements in patients hitherto lacking a recurrent 









MEF2D Cytocell  
1q22 147 Centromeric Red 
1q23.1 129 Telomeric Green 
ABL2 Cytocell  
1q25.2 318 Centromeric Red 
1q25.2 315 Telomeric Green 
PDGFRB/ 
CSF1R Cytocell 
5q33 107 Centromeric Red 
5q33 154 Telomeric Green 
JAK2 Kreatech 
9p24 550 Telomeric Red 
9p24 525 Centromeric Green 
ABL1 Cytocell  
9q34 283 Centromeric Red 
9q34 309 Telomeric Green 
ZNF384 Cytocell  
12p13.31 137 Centromeric Red 
12p13.31 104 Telomeric Green 
IGH@ Cytocell 
14q32.33 124 C-region Red 
14q32.33 617 V-segment Green 
CRLF2 Cytocell 
Xp22/Yp11 243 Centromeric Red 
Xp22/Yp11 71, 131 Telomeric Green 
Table 2.7. Details and manufacturers of FISH probes used for characterisation of B-other ALL 
patients. All probes were dual colour break apart probes, with normal signal pattern consisting 
of two fused signals in interphase nuclei.  
 
2.5.4 FISH method 
Samples consisted of frozen fixed cells suspended in fixative solution. These were 
retrieved and thawed at room temperature. The samples were then centrifuged at 
13,000 rpm on a bench-top centrifuge for 2 minutes to pellet the cells. The fixative 
solution was removed taking care not to disturb the cell pellet. Several drops of freshly 
prepared fixative solutions (table 2.8) were then added to each cell pellet to dilute this 
sufficiently to place a 3ul aliquot on a microscope slide ensuring nuclei could be readily 
seen without excessive overlap. The slides were air dried on a humid surface. The 
relevant FISH probe solution was then mixed briefly on a vortex mixer and 2ul aliquots 
were placed onto 13mm glass coverslips, which were subsequently applied to the fixed 
cell nuclei on each microscope slide. The coverslips were sealed in place with rubber 
solution and the slides were placed in a programmable Thermobrite probe 
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hybridisation system. This was heated to 75⁰C for 5 minutes to denature the probe and 
sample DNA, then rapidly cooled to 37⁰C and maintained at this temperature for a 
minimum of 16 hours (typically overnight) to allow probe hybridisation to their target 
sequences.  
 
2.5.5 Post hybridisation washes 
Following overnight hybridisation, the slides were removed from the Thermobrite 
system and the rubber solution was carefully peeled off. Each slide was then placed 
into 2xSSC solution (table 2.8) in a Coplin jar to loosen the coverslip, which was then 
gently removed. The slides were then soaked in Wash 1 solution heated to 72⁰C for 2 
minutes followed by Wash 2 solution at room temperature for a further 2 minutes (table 
2.8). Separately, 9ul aliquots of DAPI were placed onto 24x50mm coverslips and these 
were subsequently applied to each slide after the washing procedure was completed. 
Reagents Volume Composition Storage 
Fixative 40ml 30ml methanol 
10ml acetic acid 
RT 
2X SSC 1 litre 900ml distilled water 
100ml 20X SSC 
RT 
Wash 1 1 litre 980ml distilled water 
20ml 20X SSC 
3ml igepal-CA-630 
RT 
Wash 2 1 litre 900ml distilled water 
100ml 20X SSC 
1ml igepal-CA-630 
RT 
Table 2.8. Composition and storage of reagents used during FISH experiments.  
SSC: saline-sodium citrate buffer; RT: room temperature. 
 
2.5.6 FISH slide analysis 
FISH signal patterns were visualised on a Zeiss Axioskop fluorescence microscope 
and recorded for a minimum of 50 cells by two independent observers. In the context 
of break apart probes, a normal pattern was represented by two fused signals and a 
typical pattern for a gene rearrangement consisted of split red and green signals 
together with a single fused signal, although loss of a green or red signal could also 
indicate gene rearrangements within the context of specific probes (e.g. CRLF2, see 
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chapter 3, section 3.4.2.1). Previous in-house validation of the relevant probes had 
confirmed a 10% cut off of abnormal nuclei to confidently report a variant signal pattern. 
 
2.6 Detecting copy number abnormalities 
Copy number abnormalities (CNAs) involve deletions or gains of genomic material in 
cancer cells. These can be detected either through targeted assays, focussing solely 
on a predefined panel of genes, or genome-wide techniques. The general principle of 
the detection of copy number abnormalities involves the hybridisation of probes to 
target regions in the genome. The abundance of each target sequence can then be 
measured through signal intensity or PCR amplification-based methods. Within this 
project, two separate methods were used for copy number analysis, namely single 
nucleotide polymorphism (SNP) arrays and multiplex ligation-dependent probe 
amplification (MLPA). 
 
2.6.1 Single nucleotide polymorphism (SNP) arrays for the detection 
of CNAs 
SNPs represent genomic sites of inter-individual variation and account for around 0.1% 
of the entire human genome (Shen et al., 2013). As well as their role in genome wide 
association studies (GWAS), techniques interrogating SNP loci have also been used 
to characterise the copy number states of sites throughout the human genome (Shen 
et al., 2008, Redon et al., 2006). Using subtly different chemistries, Affymetrix and 
Illumina SNP array platforms can be used to identify genome-wide CNAs as well as 
loss of heterozygosity (LOH). SNP arrays detect the intensity of a fluorescent signal 
released when oligonucleotide probes hybridise to their complimentary sequences. 
The probes are bound to an array, and each position on the array relates to specific 
genomic co-ordinates. Following hybridisation, the signal intensity at each position on 
the array is therefore related to the number of copies of a specific sequence.  
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2.6.1.1 Polymorphic and non-polymorphic probes 
SNP array platforms consist of a variable number of non-polymorphic (copy number) 
probes and/or polymorphic (SNP) probes. Non-polymorphic probes cover regions of 
the genome with little inter-individual variation and hybridisation of target DNA 
fragments to probe DNA is therefore based predominantly on copy number status 
(Shen et al., 2008). In comparison, polymorphic probes target regions of single 
nucleotide polymorphisms. One of two possible alleles is present is these regions, 
denoted A or B. Based on the presence of a single maternal and single paternal 
chromosome in a normal diploid human genome, three possible allelic combinations 
can therefore arise at any SNP site (homozygous AA or BB or heterozygous AB 
alleles). As such, polymorphic SNP probes can both be used to determine the copy 
number state of these regions through loss of an allele (fewer target sequences binding 
to the array causing reduced signal intensity coupled with loss of heterozygous AB 
alleles), gain of an additional allele (more binding of target sequence resulting in 
increased signal intensity coupled with presence of AAA, AAB, ABB and BBB alleles) 
as well as identifying copy neutral loss of heterozygosity (CNN-LOH) (signal intensity 
similar to diploid background coupled with loss of heterozygous AB alleles) (figure 2.2).  
 
The Affymetrix Cytoscan HD array consists of 1.9 million non-polymorphic (copy 
number) probes and 750,000 polymorphic (SNP) probes. Probes are 25 nucleotides 
long (25-mer probes) which are entirely or almost entirely complimentary to individual 
SNPs covered by the array (LaFramboise, 2009). All SNPs bind to the probes, but the 
binding is more efficient if the entire sequence is complimentary and a stronger signal 
is released. This variation in signal strength can then be used to determine the 
presence of an A or B allele at the relevant position in the genome.  
In comparison, the Illumina CytoSNP 850k array consists exclusively of 850,000 
polymorphic (SNP) probes. The probes are composed of a 50-mer oligonucleotide 
sequence bound to a bead. Each probe sequence is complementary to a defined 
region in the genome adjacent to a SNP of interest. A single base extension labelled 
with either a red or green fluorophore (targeting the A or B allele) is then required to 
produce a signal. The red or green signal produced is therefore dependent on the A or 




2.6.1.2 Patients and samples 
All samples from patients aged ≥60 years enrolled in the UKALL14 or UKALL60+ trials 
with DNA extracted from the diagnostic bone marrow sample were identified. DNA 
concentrations were measured on the Nanodrop spectrophotometer (section 2.4.5.1). 
An aliquot of 500ng of DNA was then taken from the primary sample and diluted with 
nuclease free water to a total volume of 10ul for a final concentration of 50ng/ul, to be 
used for SNP array. 
 
2.6.1.3 SNP array protocol 
SNP arrays were performed on the Affymetrix Cytoscan HD or Illumina CytoSNP 850k 
arrays. The SNP arrays were performed by the Core Genomics Facility at the 
International Centre for Life, Newcastle-upon-Tyne Hospitals NHS Foundation Trust 
and all subsequent array analysis was performed using Nexus Copy Number 10. Probe 
density of the two SNP array platforms is shown in table 2.9. 
SNP array platform SNP probes Copy no. probes Total 
Affymetrix Cytoscan HD 750,000 1.9 million 2.67 million 
Illumina CytoSNP 850k 850,000 - 850,000 
Table 2.9. Details of Illumina and Affymetrix array probe characteristics. Affymetrix arrays 
contained both SNP and copy number probes whereas Illumina arrays consisted purely of SNP 
genotyping probes. 
 
2.6.1.4 Data format and pre-processing 
The raw signal intensities generated from a SNP array experiment can be influenced 
by many factors and normalising these values is therefore required before generating 
copy number and genotyping calls.  
The output from Affymetrix arrays is a .CEL file, which consists of probe-level signal 
intensities in a text-based format (Scionti et al., 2018).  
Log2 ratios are calculated using the formula: 
Log2 ratio = Log2(samplem / referencem) where m represents each marker. 
The reference log2 ratios are derived from a previously created reference model array 
file which includes 380 samples including 284 from the HapMap project (Scionti et al., 
2018). 
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The output of Illumina CytoSNP 850k arrays is in the form of IDAT files, which are raw 
image rather than text-based files. Copy number status is derived from a logR ratio 
(LRR), which is similar to the log2 ratio, but is based on data from polymorphic rather 
than copy-number probes and is calculated using the formula: 
LRR = Log2(sampleR/ referenceR) where R represents a combined intensity of the red 
and green signals.  
The reference values are derived from an in-silico dataset imported in the form of an 
array-specific cluster file.  
Signal intensities from the polymorphic SNP probes of both Affymetrix and Illumina 
arrays are used to determine the B-allele frequency. This complements information 
from the log2 ratio in identifying losses and gains, as well as characterising regions of 
copy number neutral loss of heterozygosity (CNN-LOH), which may arise when a 
genomic region is lost and then re-duplicated from the remaining homologue, 
potentially leading to the unmasking of recessive alleles (figure 2.2).  
 
Figure 2.2. Illustration of different allelic patterns arising in SNP arrays. Each circle denotes the 
signal from a single probe. A represents a normal diploid pattern with log2 ratio centred around 
0 (i.e. log2 of 2/2 copy ratio) and B-allele frequency demonstrating homozygous AA and BB 
alleles and heterozygous AB alleles. B represents a heterozygous deletion with log2 ratio 
reduced to -1 (i.e. log2 of ½ copy ratio) and B-allele frequency demonstrating loss of 
heterozygous AB alleles. C represents CNN-LOH with preserved log2 ratio of 0 but loss of 
heterozygous AB alleles. D represents single copy gain with log2 ratio increased to 0.58 (i.e. log2 
ratio of 3/2 copy ratio) and B-allele frequency demonstrating additional A or B allele. 
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2.6.1.5 Nexus Copy Number 10 
Nexus is a desktop software package specifically designed for the analysis of copy 
number data. The programme is platform and manufacturer agnostic and can therefore 
load data from numerous different primary array and NGS platforms from which the 
raw copy number data has been derived. SNP array segmentation can then be 
performed either based on pre-defined standard platform-specific settings or 
customised settings to account for sample quality, background noise and the required 
balance between maximising detection of abnormalities and minimising false positive 
calls. 
Raw array data from Affymetrix arrays can be loaded directly to Nexus in the form of 
.CEL files. In comparison, Illumina-generated IDAT files first needed to be converted 
into a text-based format before being loaded to Nexus. To achieve this, an Illumina-
specific SNP array software package (GenomeStudio 2.0) was used, in accordance 
with the Nexus protocol for the analysis of Illumina arrays. The IDAT files were loaded 
to GenomeStudio 2.0 and then converted into text-based format by creating a 
Final_Report file. This was then loaded onto Nexus to visualise the data and perform 
copy number segmentation. 
Systematic correction of the arrays was then performed. This is a recommended step 
in the analysis of SNP array data due to the waviness in the probe signals that can 
often be seen across the genome (Diskin et al., 2008). This is partly related to GC 
content as probes with high GC content will bind better to their target sequence, 
producing a higher signal intensity. As such, systematic correction was performed in 
Nexus using the recommended Illumina and Affymetrix correction files as provided by 
the manufacturer.  
 
2.6.1.6 Copy number segmentation 
Copy number analysis using SNP arrays relies on dividing the genome into segments 
of different copy number. Breakpoints of abrupt copy number change (from diploid) 
need to be identified to delineate regions of the genome that have been deleted or 
gained. This process of segmentation is performed computationally within SNP array 
analysis software and is achieved using two broad mathematical models, namely the 
Hidden Markov Model (HMM) and circular binary segmentation (CBS). Pure HMM-
based segmentation assumes fixed integers of copy number within a sample (Seiser 
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and Innocenti, 2015, Fridlyand et al., 2004) and therefore relies on high tumour purity 
and lack of clonal heterogeneity. However, tumour samples frequently contain a 
mixture of tumour and normal DNA, as well as subclonal mutations within the cancer-
cell population, which means that fixed integer levels of copy number state may not be 
apparent. In comparison, CBS models (Olshen et al., 2004) recursively partitions the 
genome into segments until no further statistically significant splits are possible 
between two adjacent segments (Tai et al., 2010). As such, copy number change is 
driven by observed variation between adjacent regions rather than assumption of fixed 
integer copy number states.  
Nexus employs a hybrid segmentation algorithm termed Fast Adaptive States 
Segmentation Technique (FASST2). This is based on HMM-segmentation but does 
not assume fixed integer levels of copy number, and instead accepts a large number 
of potential copy number states falling between fixed integer levels.  
 
2.6.1.7 Minimum segment size settings 
Studies using SNP arrays to detect CNAs in ALL have used a number of different 
platforms and the minimum number of probes required for a CNA is highly dependent 
on array probe density. Early studies using the low density Affymetrix 100k and 250k 
arrays have used a minimum of 2 probes per copy number segment (Mullighan et al., 
2007).  
In comparison, the Affymetrix Cytoscan HD array has 2.67 million probes. Using this 
array, one study used a minimum threshold of 25 probes to define a copy number 
segment (Ribera et al., 2017). To strike a balance between the detection of novel 
abnormalities whilst minimising false discoveries, this analysis was performed using a 
minimum of 10 probes per copy number segment for Affymetrix Cytoscan HD data. 
Taking into account the reduced probe density of the Illumina CytoSNP 850k array, a 
threshold of 6 markers was used to create copy number segments from Illumina arrays. 
Log2 ratio thresholds and stringency settings were also adjusted with both Affymetrix 
and Illumina derived-data based on sample quality and degree of normal DNA 
contamination (chapter 4, section 4.3). All SNP array segmentation settings used are 
detailed in supplementary table 2. 
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2.6.1.8 Quality control 
An QC measure is internally computed within Nexus (QC score) with lower values 
indicative of better quality. The QC score is based on the probe to probe variance 
across the genome, and aims to exclude probes where large scale variance is related 
to true copy number breakpoints. As such, the metric reflects short-scale variation 
between adjacent probes and acts as a measure of background “noise” in a SNP array 
profile. Based on the manufacturer’s advice, SNP arrays with QC scores <0.15-0.20 
are likely to yield interpretable copy number profiles. A QC score <0.20 was therefore 
considered a requirement for further SNP array analysis. 
 
2.6.2 Multiplex ligation-dependent probe amplification (MLPA) for the 
validation of CNAs 
2.6.2.1 Patients and samples 
In addition to SNP arrays, MLPA was performed on selected samples with remaining 
DNA to validate specific well-characterised gene deletions. All adults aged 60 years 
and over enrolled in the UKALL14 and UKALL60+ clinical trials were identified. 
Diagnostic patient samples with at least 100ng of DNA available following SNP arrays 
were selected for MLPA analysis. 
 
2.6.2.2 Principle of MLPA 
Multiplex ligation-dependent probe amplification (MLPA) is a targeted technique used 
to interrogate the copy number state of a pre-defined gene panel. The reaction involves 
DNA denaturation and hybridisation of test and reference probes to the denatured 
DNA. Each probe consists of two probe oligonucleotides. In the presence of the target 
sequence, a ligation reaction between the two probe oligonucleotides occurs. A PCR 
amplification step of all ligated probes follows and as each probe generates a uniquely 
sized amplification product, this can be detected by capillary electrophoresis. The 
relative different quantities of test and reference probes as compared to a control 
sample, can then be used to determine the copy number state of the specific genes 
under investigation.  
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2.6.2.3 MLPA technique using P335 kit (MRC Holland) 
The P335 kit covers exons on 9 genes/loci commonly deleted in BCP-ALL, namely 
EBF1 (5q33), IKZF1 (7p12.2), CDKN2A/B (9p21.3), PAX5 (9p13.2), ETV6 (12p13.2), 
BTG1 (12q21.33), RB1 (13q14.2) and the PAR1 region (CRLF2, CSF2RA, IL3RA on 
Xp22.3/Yp11.2) and has been extensively validated in BCP-ALL (Schwab et al., 2010). 
Specific exons covered are detailed in table 2.10.  
Cytoband Gene Number of probes Exons covered 
5q33 EBF1 4 16, 14, 10, 1 
7p12.2 IKZF1 8 1, 2, 3, 4, 5, 6, 7, 8 
9p24 JAK2 1 23 
9p21.3 CDKN2A 2 5, 2A 
9p21.3 CDKN2B 1 2 
9p13.2 PAX5 7 10, 8, 7, 6, 5, 2, 1 
12p13.2 ETV6 6 1, 2, 3, 5, 8 
12q21.33 BTG1 4 1, 2 
13q14.2 RB1 5 6, 14, 19, 24, 26 
Xp22.3/Yp11.2 SHOX 1 NA 
Xp22.3/Yp11.2 CRLF2 1 4 
Xp22.3/Yp11.2 CSF2RA 1 10 
Xp22.3/Yp11.2 IL3RA 1 1 
Xp22.3/Yp11.2 P2RY8 1 2 
Table 2.10. Details of individual exons covered by MLPA probes in IKZF1-P335 kit.  
 
The protocol required an optimum input of 100ng of DNA in 5 ul TE buffer. Three 
controls (normal DNA from 2 females and 1 male) and a blank sample (TE buffer only) 
were prepared alongside the diagnostic DNA samples to be tested. Table 2.11 details 
composition of all master mixes used for the MLPA assay.  
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Reagent Composition Volume (ul) 
Hybridisation master mix MLPA buffer 1.5 
SALSA probemix 1.5 
Ligase master mix 
Ligase-65 buffer A 3 
Ligase-65 buffer B 3 
Nuclease free water 25 
Ligase-65 1 
Polymerase master mix 
SALSA PCR primers 2 
Nuclease free water 7.5 
SALSA polymerase  0.5 
Table 2.11. Composition of MLPA master mixes. Quantities listed refer to volumes required per 
sample.  
 
The samples were placed in a thermocycler and heated to 98⁰C for 5 minutes to 
denature the DNA and then cooled to 25⁰C. Once cooled, 3 ul of hybridisation master 
mix was added to each sample. The thermocycler was heated to 95⁰C for 1 minute and 
then maintained at 60⁰C for 16 hours to allow probe hybridisation to target DNA.  
A ligase master mix was then prepared as shown in table 2.11. The thermocycler was 
set to 54⁰C and 32ul of ligase master mix was added to each sample. The samples 
were held at 54⁰C for 15 minutes to permit the ligation reaction, then heated to 98⁰C 
for 5 minutes and finally cooled to 20⁰C.  
A polymerase master mix was then prepared as shown in table 2.11. Once the samples 
were cooled to 20⁰C, 10ul of polymerase master mix was added to each sample and a 
PCR amplification of ligated probes was carried out for 35 cycles of 95⁰C for 5 minutes, 
60⁰C for 30 seconds, 72⁰C for 60 seconds, followed by 72⁰C for 20 minutes and finally 
cooling to 15⁰C for a further 3-4 hours. Samples were then refrigerated and sent to 
DBS Genomics for PCR fragment separation by capillary electrophoresis using the 
Applied Biosystems 3730 DNA Analyser and copy number analysis was performed 
using GeneMarker software. Peaks were normalised against control samples. 
Deletions and gains were identified when probe ratios for individual exons were <0.75 
or >1.3 respectively and a CNA was called when at least 2 consecutive probes showed 
a consistent pattern (either deletion or gain).  
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2.7 Customised targeted NGS for validation of novel 
abnormalities 
A customised NGS approach was developed to validate novel lesions. First, all genes 
that recurrently contained a copy number breakpoint were examined to create a list of 
potential target lesions for validation. Novel and highly recurrent genes or those with 
potential functional relevance in leukaemia were primarily targeted. To facilitate 
discovery of novel abnormalities, recurrent lesions with even ambiguous or subclonal 
copy number loss by SNP array were considered. Proximal and distal breakpoints of 
all deletions for validation were recorded. For each gene or locus of interest, a common 
region up to 200 kb was identified that spanned at least 1 breakpoint in all samples 
bearing the specific deletion. These regions of interest were selected to ensure at least 
one breakpoint (proximal or distal) of the deleted segment was covered for each of the 
affected genes in the relevant cases. An overview of the principles of the targeted NGS 
design and experimental process is shown in figure 2.3. 
 
Figure 2.3. Simplified overview illustrating principle of SureSelect XT2 workflow to validate 
genomic deletions. Breakpoint regions of interest are first identified (either proximal or distal 
breakpoints). Complementary RNA baits are designed, and DNA is sheared to 800 bp fragments. 
During library prep, RNA baits are hybridised to their complementary regions thereby capturing 
fragments containing the breakpoint of interest. These fragments are selected using magnetic 
beads and finally sequenced using paired-end chemistry. 
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2.7.1 SureSelect XT2 target design 
Once a common breakpoint region had been identified for each deletion of interest, the 
genomic co-ordinates were loaded and viewed in the SureDesign web portal 
(https://earray.chem.agilent.com/suredesign/)  to design RNA baits complementary to 
the regions of interest. The coverage of all designs was viewed in the University of 
California Santa Cruz (UCSC) genome browser to ensure highly repetitive regions of 
the genome were avoided. The relevant genomic co-ordinates were then submitted to 
Agilent to manufacture the customised SureSelect XT2 capture library consisting of 
RNA baits covering the breakpoint regions of interest, together with the coding exons 
of several genes frequently mutated in BCP-ALL. The capture library would hybridise 
to and capture the regions of interest, thereby permitting subsequent sequencing of 
the breakpoint regions (figure 2.3). All target regions used to design the capture library 
can be found in supplementary tables 3 and 4. 
The method is based on the principle that a deletion results in the juxtaposition of 
normally genomically distant loci. By capturing and then sequencing DNA fragments 
containing a deletion breakpoint, sequencing reads that overlap either the proximal or 
distal breakpoint map to non-consecutive genomic co-ordinates, resulting in a 
structural variant. In the case of a simple deletion, reads map to co-ordinates 
immediately proximal and distal to the deleted segment. Where the deletion has 
occurred as part of an unbalanced translocation, reads spanning the breakpoint map 
to different chromosomes. 
To provide sufficient breadth of coverage to span both sides of breakpoints and 
successfully map these to the reference genome, DNA shearing was performed to 
yield fragments of approximately 800bp for library prep, rather than the standard 150-
200bp fragments recommended by the manufacturer. 
 
2.7.2 SureSelect XT2 library prep 
Following manufacture of the customised capture library, a SureSelect XT2 library prep 
was then performed on all samples with at least 1ug of DNA following WGA (section 
2.4.4). All incubation steps were performed in a Thermal Cycler ensuring the heated 
lid was kept open unless stated otherwise. Samples were first made up to 100 ul with 
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TE buffer and the DNA was sheared by ultrasonication using the Bioruptor Pico 
sonication system inputting shearing settings as follow – time on: 7 seconds; time off: 
90 seconds; number of cycles: 4. 
These settings aimed to shear the sample DNA into 800-1000 bp fragments, and had 
previously been trialled and validated by Dr Sarra Ryan and James Murray. Sample 
quality and fragment size were then assessed on the 2100 Bioanalyzer (Agilent) using 
a Bioanalyzer DNA 1000 chip, to ensure that a fragment peak was visible around 800-
1000 bp (section 2.4.5.4).  
Following this, an end repair reaction was performed using 50ul of sheared DNA mixed 
with 40ul of SureSelect End Repair Enzyme Mix and 10ul of SureSelect End Repair 
Nucleotide Mix. The 100ul mixture was incubated for 30 minutes at 20⁰C. The DNA 
was then purified by mixing the 100ul sample with 180ul of magnetic AMPure XP beads 
and performing repeated washes with freshly prepared 70% ethanol whilst the samples 
were held in a Dynamag magnetic separation rack. Residual ethanol was carefully 
removed and finally allowed to evaporate at 37⁰C. The purified DNA was then eluted 
from the beads in 22ul nuclease free water and the beads were discarded.  
Next, dA tailing the 3’ end of the purified DNA fragments was performed by adding 20 
ul of dA-Tailing Master Mix and incubating the sample at 37⁰C for 30 minutes. The DNA 
was then ready for ligation to the pre-capture indexing adaptors.  
For this, samples were held on ice and 5 ul of SureSelect Ligation Master Mix followed 
by 5 ul of Pre-capture Indexed Adaptor Solution was added to each sample. At this 
point special care was taken to ensure a different well of the Pre-capture Indexed 
Adaptor Solution was added to each sample without cross-contamination as this 
contained the unique barcode sequence to successfully de-multiplex the pooled 
samples during sequencing. The ligation reaction was performed by incubating the 
samples at 20⁰C for 15 minutes. A further bead purification was performed using 
AMPure XP beads as described previously. Half of the indexed library was then 
amplified by PCR using a 25 ul of Herculase II PCR Master Mix and 1 ul of XT2 primer 
mix for each sample and the Thermal Cycler program described in table 2.12.  
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Segment Number of cycles Temperature Time 
1 1 98⁰C 2 mins 
2 5 
98⁰C 30 secs 
60⁰C 60 secs1 
72⁰C 2 mins2 
3 1 72⁰C 10 mins 
4 1 4⁰C Hold 
Table 2.12. Pre-capture PCR thermal cycler program. Annealing1 and elongation times2 were 
extended compared to manufacturer’s protocol to optimise amplification of longer DNA 
fragments. 
 
The amplified library was then purified using magnetic AMPure XP beads as described 
previously. Here, the ratio of beads: DNA was reduced to 0.7, when compared to the 
manufacturer’s protocol, to optimise bead-binding to the longer DNA fragments in the 
library. Following this, the DNA fragment size and concentration were measured on 
the 2100 Bioanalyzer (Agilent), aiming for an average fragment size >650-700 bp.  
Libraries were then pooled together by combining 15 samples, with 100ng of each 
sample. Using a vacuum concentrator held at 45⁰C, the pools were then concentrated 
to a volume of 7 ul. To each of these 7 ul indexed DNA pool, 9 ul of SureSelect XT2 
blocking mix was added and the samples were heated to 95⁰C for 5 minutes followed 
by 65⁰C for at least a further 5 minutes. 
Next, the custom-designed capture library was prepared for hybridisation to the pooled 
DNA samples. Concentrated SureSelect RNase block was first diluted 1:9 with 
nuclease free water and 5 ul of this diluted RNase block was combined with 2 ul of the 
capture library. Subsequently, 37 ul of SureSelect XT2 hybridisation buffer was mixed 
with the RNase block/capture library solution to complete preparation of the capture 
library for hybridisation to the pooled DNA. 
With the pooled DNA samples kept at 65⁰C, 44 ul of the capture library mixture was 
added to these and pipette mixed rapidly to minimise evaporation, before sealing the 
sample wells and then incubating the DNA/capture library mixtures at 65⁰C for 24 
hours. During this step, the customised RNA baits in the capture library hybridised to 
their complementary sequences in the pooled genomic DNA samples. 
The hybridised DNA fragments were then captured using streptavidin beads. 
Dynabeads MyOne Streptavidin T1 coated beads were first resuspended using a 
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vortex mixer and washed in SureSelect XT2 Binding Buffer. For each pool of DNA 
samples, 200ul of Binding Buffer was first mixed with 50 ul of resuspended beads and 
a magnetic separation device was used to isolate the beads and discard the buffer. 
The procedure was repeated for a total of 3 washes and the beads were re-suspended 
in a fresh 200 ul volume of SureSelect XT2 Binding Buffer. Meanwhile, 200 ul of 
SureSelect XT2 Wash 2 was heated to 65⁰C for each pooled library. The pooled DNA 
libraries were then added to the washed Streptavidin coated beads and the samples 
were continually mixed on a Nutator mixer for 30 minutes at room temperature. The 
samples were then placed in a magnetic separation device to isolate the streptavidin-
coated beads, which were now bound to the DNA fragments that had hybridised to the 
capture library. The supernatant was then removed and the beads were re-suspended 
in SureSelect XT2 Wash 1. The samples were again placed in a magnetic separation 
device and the cleared supernatant was discarded. The beads were then washed with 
the pre-warmed SureSelect XT2 Wash 2. The beads were re-suspended in 200ul 
SureSelect XT2 Wash 2 and incubated at 65⁰C for 5 minutes before placing the 
samples in the magnetic separation device and discarding the supernatant. The 
procedure was repeated for a total of 6 washes ensuring that samples were kept on a 
heating block at 65⁰C when not in the magnetic separation device. The beads were 
then fully re-suspended in 30ul nuclease-free water. 
The bead-bound captured library pools were then ready for PCR amplification. Half of 
each pool (15 ul) was used and the remainder stored at -20⁰C. For each pooled library, 
a PCR master mix was prepared consisting of 50 ul of LongAmp polymerase (New 
England Biolabs), 2 ul XT2 primer mix and 33 ul nuclease free water. This was mixed 
with 15 ul of the bead-bound library pool, placed in a thermal cycler and the program 
was started as detailed (table 2.13).  
Segment Number of cycles Temperature Time 
1 1 95⁰C 3 mins 
2 8 
98⁰C 20 secs 
60⁰C 15 secs 
65⁰C 2 mins 
3 1 65⁰C 10 mins 
4 1 4⁰C Hold 
Table 2.13. Post-capture PCR thermal cycler program. Settings were modified compared to 
manufacturer’s protocol due to use of Longamp polymerase instead of Herculase II polymerase 
(discussed in chapter 4, section 4.3.4).  
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A final magnetic bead purification was then performed using AMPure XP magnetic 
beads and freshly prepared 70% ethanol at room temperature as previously described. 
Again, the ratio of beads: sample was reduced to 0.7 to optimise bead-binding to the 
longer DNA fragments in the library. Each pooled library was finally eluted in 30 ul 
nuclease free water and the quality of the DNA for sequencing was assessed on the 
Bioanalyzer using the 2100 Bioanalyzer High Sensitivity DNA Assay (section 2.4.5.4). 
The 2 pooled libraries were then sequenced on two runs on the Illumina NextSeq 550 
at the Core Genomics Facility, Newcastle University. 
 
2.7.3 Analysis of sequencing data 
Each pooled library was sequenced using a mid-output kit on the Illumina NextSeq 550 
with 150bp paired end reads. Initial processing of FASTQ files was performed by the 
Bioinformatic Support Unit, Newcastle University. BAM files were deduplicated and re-
aligned to the reference genome (hg19/GRCh37). The kit had been designed to cover 
the proximal and/or distal breakpoint regions of the deletions to be validated. These 
regions were then directly examined in the Integrative Genomics Viewer (IGV) by 
loading the BAM files of affected cases. In IGV, reads were coloured according to insert 
size. The sequencing library had been prepared for an intended insert size of ~800bp 
as described above. As such mate pairs were anticipated to map to regions <1kb apart. 
Genomic deletions result in the juxtaposition of normally distant loci, resulting in mate 
pairs mapping to regions further apart than the anticipated insert size. Where paired 
reads were >10kb apart, the reads were flagged in IGV and a breakpoint was 
suspected when numerous flagged reads were all present around the same genomic 
co-ordinate (example figure in chapter 4, figure 4.6). If the mate reads then mapped to 
the same distant genomic locus, a deletion was confirmed. Where the mate reads 
mapped to a consistent region on a different chromosome, the findings were consistent 
with a chromosomal translocation. Using SNP array derived deletion breakpoints, a 
targeted analysis was initially performed in IGV to either validate or refute the deletion 
under investigation. Where the deletion could not be validated in the vicinity of the SNP 
array derived breakpoints, the remainder of the gene was screened for structural 
variants. Additionally, specific genes had been included in the capture library due to 
their involvement in recurrent gene fusions (ABL1, ABL2, PDGFRB, CSF1R, JAK2, 
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TCF3). The entire sequence of each of these genes was screened for structural 
variants in IGV for all cases to identify or validate fusion genes (e.g. BCR-ABL1). 
 
2.8 Identifying and tracking variants through treatment 
Patients were recruited prospectively from the Newcastle-upon-Tyne Hospitals NHS 
Foundation Trust (section 2.3) and diagnostic bone marrow and germline DNA were 
isolated as described (sections 2.4.1, 2.4.2 and 2.4.3). 
 
2.8.1 Exome sequencing 
2.8.1.1 Library prep and sequencing 
Samples for exome sequencing consisted of diagnostic and matched germline DNA 
for each patient. QC checks were performed to ensure each sample had at least 150ng 
dsDNA determined by Quant-iT picogreen, with DIN >7 and A260/A280 ratio of 1.75-
2.04 (section 2.4.5). Library prep and sequencing were performed at the Core 
Genomics Facility, Newcastle University.  
Library prep was performed using the Twist Human Core Exome kit. Libraries were 
sequenced on the Illumina NovoSeq using 100 bp paired end reads, generating on 
average 90x raw read depth per sample. To achieve a higher depth of sequencing for 
diagnostic samples with the aim of detecting low VAF abnormalities, these were put 
through two preparations, thereby generating an average 180x read depth. Data were 
returned in the form of FASTQ files. 
 
2.8.1.2 Analysis of exome sequencing data 
Raw sequencing data in the form of FASTQ files were initially processed by Dr Matthew 
Bashton and/or the Bioinformatics Support Unit, Newcastle University. Using the 
diagnostic and matched germline exomes for each case, established somatic variant 
calling pipelines (GATK Mutect and Mutect 2) were used to produce a list of somatic 
variants. Further variant annotations using Ensembl Variant Effect Predictor (VEP) 
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(McLaren et al., 2016) were generated to identify population level variant allele 
frequencies, together with reports from dbSNP and Catalogue of Somatic Mutations in 
Cancer (COSMIC) databases as well as the SIFT and PolyPhen variant prediction tools 
(Sherry et al., 2001, Tate et al., 2019, Sim et al., 2012). The resultant VEP file was 
used for subsequent analyses. 
To generate a final list of the most likely candidate pathogenic mutations, any variants 
present in >1% of the general population were first excluded (MAX_AF column of VEP 
file). Next, the variant consequence column of the VEP file was examined and 
synonymous variants, intron variants, downstream gene variants, upstream gene 
variants, 5’ UTR and 3’ UTR variants were all filtered out. Subsequently, variants that 
were classed as both tolerated in SIFT and benign in PolyPhen were also removed. 
This created a final list of candidate pathogenic mutations in each diagnostic bone 
marrow specimen. These were examined in detail to select specific variants to track in 
subsequent follow up bone marrow samples. 
 
2.8.2 Selecting mutations to design SureSelect XT HS2 kit   
Single nucleotide variants (SNVs) generated through Mutect were identified and 
filtered as described above. Specific SNVs within each sample were then selected to 
design a customised capture library to target and sequence these regions to high depth 
in follow up samples.  
A limited number of SNVs per patient (5-6) were selected for this study. Variants in 
genes involved in key pathways known to be deregulated in ALL were first identified 
and selected. Based on COSMIC data, SNVs reported as somatic variants in other 
cancer-types were also chosen, along with variants that appeared to be recurrently 
seen in the patient cohort. To identify potential low frequency variants associated with 
clonal haematopoiesis, all exons of DNMT3A and TET2 were also included, together 
with exons 11 and 12 of ASXL1. Similarly, due to its prevalence in relapsed disease, 
the coding regions of TP53 were also added to the design.   
Using the SureDesign web portal (https://earray.chem.agilent.com/suredesign/), the 
selected SNV co-ordinates (chapter 6, table 6.5) were uploaded together with selected 
regions of DNMT3A, TET2, ASXL1, TP53, KRAS, NRAS and PTPN11 due to their 
prevalence in clonal haematopoiesis or relapsed disease.  
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To identify variants at potentially very low VAF in remission samples, the SureSelect 
XT HS2 kit was chosen. This incorporates unique molecular identifiers (UMIs). 
Normally, the sensitivity of sequencing techniques to the detection of low VAF variants 
is hampered by PCR duplication. During library prep, PCR amplification of the DNA 
adaptor-ligated fragments is performed, generating multiple identical copies of the 
original DNA molecule. When more than one copy of the starting unique DNA molecule 
hybridises to the flow cell, this is sequenced multiple times, which generates duplicate 
reads. This biases sequencing coverage and if unaccounted for, can greatly 
exaggerate a potential artefactual variant that has arisen from sequencing error 
(Ebbert et al., 2016). As there is no way of telling whether identical reads have occurred 
by chance from 2 different DNA molecules or as a result of PCR amplification of a 
single unique DNA molecule, most bioinformatics tools opt to remove them from 
downstream analysis (de-duplication) (Ebbert et al., 2016). This limits the detection of 
mutations in typical NGS experiments to a VAF plateau of ~1% even with very high 
read depth. However, the use of UMIs is able to resolve this issue. These are short 
DNA sequences, which ligate to the DNA fragments in the library prior to PCR 
amplification. Identical reads that have occurred through PCR amplification can 
therefore be identified as they will possess the same UMIs, as opposed to those that 
have arisen from different starting DNA molecules. This permits the detection of 
mutations with a VAF <0.1%. 
The target designs were submitted to Agilent to manufacture customised RNA baits to 
capture the single nucleotide sequences in an attempt to identify the variants present 
at diagnosis in the follow up samples taken on treatment. Unfortunately, due to the 
COVID-19 pandemic, it was not possible to subsequently proceed to library prep at 
this stage (discussed in chapter 6, section 6.4.7 and chapter 7, section 7.5). 
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Chapter 3. Genetic characterisation of 
older adults with B-other ALL 
 
3.1 Introduction 
Primary chromosomal abnormalities are one of the hallmarks of ALL and greatly 
influence treatment decisions and prognosis. Well defined genetic subgroups include 
large scale ploidy shifts resulting in high hyperdiploidy (51-67 chromosomes), low 
hypodiploidy (30-39 and/or 60-78 chromosomes) or near haploidy (23-29 and/or 46-58 
chromosomes) and chromosomal translocations resulting in oncogenic gene fusions, 
specifically BCR-ABL1, ETV6-RUNX1, TCF3-PBX1, TCF3-HLF or KMT2A-v (chapter 
1, section 1.8). The relative frequencies of these recurrent primary abnormalities have 
been extensively studied in children and young adults but are poorly described in older 
patients (Schultz et al., 2007, Gökbuget, 2013).  
Moreover, a proportion of patients do not harbour a cytogenetically visible disease-
defining lesion. In 2009, two publications described a subgroup of patients with a gene 
expression profile similar to Philadelphia positive ALL (Philadelphia-like or BCR-ABL1-
like ALL) (Mullighan et al., 2009b, Den Boer et al., 2009). Subsequently, whole genome 
and transcriptome sequencing studies have identified a variety of kinase-activating 
gene rearrangements responsible for leukaemic transformation, detectable in up to 
91% of such cases (Roberts et al., 2012, Roberts et al., 2014). The majority of patients 
studied were children and young adults, although a subsequent study did include some 
older adults (Roberts et al., 2017).  
Approximately 50% of Ph-like patients have high CRLF2 expression on their leukaemic 
blasts, which is driven by cytogenetically-cryptic IGH-CRLF2 or P2RY8-CRLF2 
rearrangements. Other recurrent gene rearrangements include ABL-class fusions 
(affecting ABL1, ABL2, PDGFRB or CSF1R) in 9-13% of cases and the JAK-STAT 
pathway activating rearrangements of JAK2 or EPOR in 7-10% and 3-6% of patients 
respectively. Importantly, age-related differences in the distribution of these 
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abnormalities have also been noted, with ABL-class fusions seen more commonly in 
childhood Ph-like ALL patients and JAK2 or EPOR rearrangements more frequent in 
adult cases.  
More recently, recurrent oncogenic fusions affecting ZNF384 and MEF2D have also 
been identified (Hirabayashi et al., 2017, Gu et al., 2016a), and result in distinct gene 
expression profiles, separate from the Ph-like signature. These rearrangements are 
reported in approximately 2-6% of BCP-ALL cases, and have also predominantly been 
characterised in paediatric cohorts.  
 
3.2 Aims and objectives 
The principle aim of this work package was to define the primary genetic abnormalities 
in older adults with ALL. To achieve this, the following objectives needed to be 
addressed. 
1. Discern a large clinical trial cohort of older adults with ALL 
2. Categorise primary chromosomal abnormalities based on diagnostic analyses 
performed in regional cytogenetic centres 
3. Identify all BCP-ALL patients lacking a primary chromosomal abnormality (B-
other ALL) 
4. Perform extended fluorescence in situ hybridisation (FISH) studies to identify 
cytogenetically cryptic rearrangements in B-other patients 
 
3.3 Methods 
The Leukaemia Research Cytogenetic Group (LRCG) database was searched for 
adults with ALL aged ≥60 years at diagnosis enrolled in the UKALL14 or UKALL60+ 
clinical trials. All karyotypes and primary chromosomal abnormalities that had been 
identified by the diagnostic cytogenetic laboratories were first recorded and their 
individual frequencies calculated. Next, all cases lacking a primary chromosomal 
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abnormality, hereafter termed B-other ALL, were identified. Specifically, this included 
cases with normal, failed or complex karyotypes or those with non-specific 
chromosomal abnormalities. Karyotypes required the analysis of at least 20 normal 
metaphase cells to be classed as normal. Failed karyotypes were defined as those 
where no clonal abnormality was detected and fewer than 20 metaphases were 
present (Medeiros et al., 2014). Additionally, failed karyotypes were required to have 
had BCR-ABL1 and KMT2A fusions excluded by fluorescence in situ hybridisation 
(FISH) to be classed as B-other ALL. Complex karyotypes were defined by the 
presence of at least 5 unrelated chromosomal abnormalities in the absence of another 
primary abnormality (Moorman et al., 2007). All B-other cases with available fixed cells 
samples were specifically identified for the investigation of cytogenetically cryptic 
abnormalities. 
FISH permits rapid identification of ABL1, ABL2, PDGFRB/CSF1R, JAK2, CRLF2, 
IGH@ and ZNF384 rearrangements (chapter 2, 2.5). Dual colour breakapart probes 
consist of red and green fluorochromes that flank either side of a gene of interest. Due 
to their genomic proximity, the fluorochromes generate two fused signals under 
fluorescence microscopy when neither copy of the gene is disrupted. However, a gene 
rearrangement results in a variant signal pattern, based on the type of structural 
variation that has occurred. Typically, ABL1, ABL2, JAK2, IGH@ and ZNF384 
rearrangements occur through chromosomal translocations. In the simplest scenario, 
when visualised by fluorescence microscopy, this produces clear separation in the red 
and green signals of the affected allele, as the telomeric portion of the gene of interest 
has translocated to a different chromosome. In comparison, PDGFRB rearrangements 
most commonly occur through an interstitial deletion on 5q33, resulting in EBF1-
PDGFRB fusion. In this situation, the telomeric (green) signal of the affected PDGFRB 
allele is lost, leaving a single fused signal signifying the undisrupted allele and a single 
red signal representing deletion of the telomeric portion of the affected allele, and 
subsequent juxtaposition of exon 11 of PDGFRB and exon 15 of EBF1 (Schwab et al., 
2016). EBF1-PDGFRB fusion is then confirmed through reciprocal demonstration of 
deletion of the centromeric signal of an EBF1 break apart probe. CRLF2 
rearrangements can occur either through chromosomal translocations or interstitial 
deletions of PAR1, and can therefore generate either variant signal pattern. MEF2D 
rearrangements can be more challenging to detect by FISH. These most commonly 
occur as a result of a small interstitial insertion at 1q21.22-22, resulting in MEF2D-
BCL9 fusion. However, due to the proximity of these two genes, only a subtle 
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separation of the red and green signals is seen when this type of rearrangement has 
occurred.  
In comparison EPOR rearrangements most commonly involve insertion of a truncated 
EPOR locus to a region distal to the IGH@ enhancer, which cannot be detected by 
FISH (Iacobucci et al., 2016).  
Dual colour break-apart probes were therefore used to detect rearrangements in ABL1, 
ABL2, PDGFRB/CSF1R, CRLF2, IGH@, ZNF384 and MEF2D (chapter 2, section 
2.5.3). Rearrangements in these genes are usually considered to be primary 
abnormalities in the majority of cases, hence there is little overlap between these 
events. With the notable exception of IGH@, cases were therefore not screened for 
further abnormalities in these genes if one had already been detected. In contrast to 
the other gene rearrangements described, IGH@ translocations result in over-
expression of the partner gene, which is responsible for the leukaemic properties. 
Hence, the biological significance of these events usually rests with the translocation 
partner (most commonly CRLF2), so these were not considered mutually exclusive of 
the other gene rearrangements.  
 
3.4 Results 
3.4.1 Established primary chromosomal abnormalities 
A total of 210 patients were identified from UKALL14 (n=94) and UKALL60+ (n=116). 
Median patient age was 64 years (range 60-83) and 24% (n=50) were over 70 years 
old at diagnosis. Male: female ratio was 1:1. Overall, 200 patients (95%) had 
cytogenetic results available from diagnosis, or had T-cell disease. Baseline patient 


































64  64 64 64 64 64 65 63 64 
Table 3.1. Genetic subgroups of 200 adults aged ≥60 years recruited to UKALL14 or UKALL60+. 
KMT2A included t(4;11)(q21;q23)/KMT2A-AFF1 (n=8); t(11;19)(q23;p13.3)/KMT2A/MLLT1 (n=2) 
and t(1;11)(p32;q23) (n=1);  
KMT2A: KMT2A fusion with any partner; HeH: high hyperdiploidy (51-67 chromosomes); HoTr: 
low hypodiploidy or near triploidy (30-39 or 60-78 chromosomes); T-cell: T-cell ALL; B-other: 
BCP-ALL with no primary chromosomal abnormality identified. 
 
The distribution of individual genetic abnormalities by age is shown in figure 3.1. Trial 
recruitment decreased with age, although this may have been confounded by the fact 
that patients aged 60-64 years could be recruited to UKALL14 or UKALL60+ so it is 
possible that more centres had a trial available for these patients. This may partly 
explain why patients aged 60-64 years are over-represented in the cohort.  
 
Figure 3.1. Distribution of primary chromosomal abnormalities by age groups across 200 adults 
aged ≥60 years (10 cases lacking sufficient cytogenetic data excluded). Left panel represents 
cytogenetic subgroups across age groups and right panel illustrates proportion of cases within 
each individual age groups.  
HoTr: low hypodiploidy/near triploidy; HeH: high hyperdiploidy; T-cell: T-cell ALL; B-other: BCP-
ALL with no primary chromosomal abnormality identified. 
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Overall, no association was seen between the individual 5 year age groups and specific 
cytogenetic subgroups (Pearson’s Chi-squared, X2 = 23.894, p = 0.47). To further 
investigate any association between BCR-ABL1 positivity and age, the cohort was split 
into a younger half (median 63 years of age, range 60-64) and an older half (median 
69 years of age, range 65-83). Of BCP-ALL cases with sufficient cytogenetic data 
(n=189), these contained 34% (32/95) and 24% (23/94) of BCR-ABL1 positive cases 
respectively. Using Fisher Exact Test, there was no significant difference in the 
proportion of BCR-ABL1 positive cases between these two groups (p=0.2).  
 
3.4.2 Gene rearrangements in B-other ALL patients 
B-other ALL patients were defined as those with normal or failed karyotypes, or other 
non-recurrent chromosomal abnormalities, including complex karyotypes, in the 
absence of any known risk-stratifying primary cytogenetic abnormality. Cytogenetic 
results for B-other patients is shown in figure 3.2.  
  
Figure 3.2. Cytogenetic details of 89 B-other ALL patients with number of cases and percentage 
of all B-other displayed.  
Failed: failed karyotype (no cytogenetic abnormality and <20 normal metaphases available); 
Normal: normal karyotype (≥20 normal metaphases); dic(9;12): dicentric translocation between 
chromosomes 9 and 12; Other: non-recurrent or non-specific chromosomal abnormality (e.g. 
del(9p)) seen; Complex: ≥5 unrelated chromosomal abnormalities present on karyotype. 
 




IGH@ translocation, 5, 6%
Complex, 5, 6% dic(9;12), 2, 2%
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3.4.2.1 CRLF2 rearrangements 
CRLF2 break apart FISH testing was successfully performed in 74% (48/65) of the B-
other samples with fixed cells. FISH was attempted in a further three cases but did not 
yield interpretable results and in the remaining cases, insufficient numbers of fixed cells 
were seen to perform FISH studies (n=12) or another primary gene rearrangement had 
already been identified (n=2).  
CRLF2 rearrangements were identified in 17% (8/48) of successfully screened B-other 
ALL patients. Patient details and FISH results are displayed in table 3.2. The principal 
CRLF2 rearrangement partners were IGH@ on 14q32.33 (n=5) or P2RY8 (n=2) on 
Xp22.33/Yp11.3. Importantly, these two rearrangements result in distinct FISH signal 
patterns. IGH-CRLF2 occurs following a chromosomal translocation and both IGH@ 
and CRLF2 show a typical rearrangement pattern consisting of a single fused signal 
and split red and green signals. In comparison, P2RY8-CRLF2 occurs following an 
interstitial deletion on Xp22.33/Yp11.3, resulting in a lost red signal (telomeric to 
CRLF2) on FISH. 
Patient 





25130 62 F 46,XX[20] IGH@ 12% 
25246 64 M 46,XY,der(19)t(1;19)(q12;p13.3)[2]/ 46,idem,t(5;18)(q33:q23)[8]/46,XY[10] P2RY8 24% 
25371 60 F 46,XX[20] IGH@ 76% 
28039* 76 M 45,XY,-7,-15,-17,+mar[10]/46,XY[1] P2RY8 57% 
28235 65 F 46,XX,der(19)t(1;19)(q12;q13)[4]/ 46,XX[6] IGH@ 30% 
30102 67 F 46,XX,del(9)(p1p2)[9]/46,XX[1] IGH@ 62% 
30297 64 F 46,XX,t(X;9)(p22;p13),der(15)t(1;15) (q21;p13)[cp8]/46,XX[4] Unknown
† 30% 
30299 74 F Not known IGH@ 17% 
Table 3.2. CRLF2 rearrangements. *Patient 28039 also had a separate IGH@ rearrangement but 
the signal pattern was consistent with P2RY8-CRLF2 fusion. †Patient 30297 had a CRLF2 
rearrangement pattern consistent with a chromosomal translocation (see karyotype and FISH 
signal pattern). However, IGH@ FISH was normal. Based on the karyotype, PAX5 was also tested 
but found to be normal.  




IGH@ was the most common CRLF2 rearrangement partner, present in 63% (5/8) of 
cases. In one case, the CRLF2 rearrangement partner could not be identified, although 
the karyotype suggested this was located on 9p13.  
 
3.4.2.2 IGH@ rearrangements 
Guided by karyotype abnormalities, regional cytogenetic centres had already 
performed IGH@ breakapart FISH in 7 of the B-other ALL patients, and 
rearrangements had been detected in 5 cases (figure 3.2).  
Of the remaining cases with available fixed cells, IGH@ breakapart FISH was 
attempted in 77% (49/64) and successful in 46 cases. In total, IGH@ translocations 
were present in 26% (14/53) of patient samples tested. Median patient age was 65 
years and 57% (8/14) were male. Five cases accounted for patients with IGH-CRLF2 
translocations as detailed above (table 3.2). The remaining 9 cases involved other 
rearrangement partners as detailed in table 3.3. Interestingly, the vast majority (8/9) of 









25552 61 M 46,XY[20] Not tested 24% 
25894 63 M 44,XY,-8,-13,der(14)t(8;14)(q11;q32)[13] /44,idem,add(19)(p13.3)[4]/46,XY[3] CEBPD*
 91% 
25907 70 M 47,XY,+X,?t(18;22)(q11;q21)[1]/46,XY[3] Unknown 93% 
27181 65 M 46,XY,inv(14)(q11q32)[2]/46,XY[18] CEBPE 43% 
27833 73 F Failed BCL2 94% 
28039† 76 M 45,XY,-7,-15,-17,+mar[10]/46,XY[1] Unknown 54% 
29808 66 M 46,XY,add(2)(q?37),add(8)(q13),add(14) (q32) [10]/46,XY[7] Unknown 91% 
30487 60 M 47,XY,+X,t(14;19)(q32;q13)[8]/46,XY[2] CEBPA* 71% 
25451† 63 M 46,XY[20] Unknown 19% 
Table 3.3. IGH@ translocations (IGH@-CRLF2 cases not shown). 
*Partner genes based on karyotype and evidence from literature (Akasaka et al., 2006, Chapiro 
et al., 2006).  
†These patients had another primary abnormality detected by FISH (tables 3.2 and 3.4) and IGH@ 
translocations were therefore likely secondary events. All cases with unknown IGH@ partner 
had CRLF2, CEBPA, CEBPB and CEBPE partners excluded by FISH.  
M: male; F: female; Abn. cells: percentage of nuclei showing gene rearrangement on FISH slide. 
 
3.4.2.3 ZNF384 rearrangements 
ZNF384 FISH was successfully performed in 65% (40/65) of the B-other ALL samples 
with available fixed cells. ZNF384 rearrangements were identified in 8% (3/40) of these 
tested patients (table 3.4). All patients were male, with a median age of 63 years.  
Patient 





25235 63 M Failed Unknown* 34% 
25451 63 M 46,XY[20] EP300 35% 
30085 67 M 46,XY[20] Unknown* 22% 
Table 3.4. ZNF384 rearranged cases. In patients 28235 and 30085, the rearrangement partner was 
not identified. *FISH for translocations involving EP300 and TCF3 were normal in both cases.  
M: male; Abn. cells: percentage of nuclei showing gene rearrangement on FISH slide. 
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3.4.2.4 MEF2D rearrangements 
FISH using the MEF2D breakapart probe was attempted in 60% (39/65) of the B-other 
cohort with fixed cells available. A single MEF2D rearranged case was identified in the 
cohort (3%, 1/39) (table 3.5).  
Patient 





25267 63 F 45~47,XX,+1,dic(1;17)(p32;q25),inc[cp3] Unknown 24% 
Table 3.5. MEF2D rearranged case. Partner gene could not be established due to insufficient 
material.  
F: female; Abn. cells: percentage of nuclei showing gene rearrangement on FISH slide. 
 
3.4.2.5 PDGFRB/CSF1R, ABL1, ABL2, JAK2 rearrangements 
Across the B-other cohort tested, no variant ABL1 (0/83), PDGFRB (0/56), JAK2 (0/53) 
or ABL2 (0/52) were identified. 
ABL1 translocations had either been excluded based on a normal BCR-ABL1 FISH 
result from the diagnostic analyses performed in the regional cytogenetic centres 
(n=71) or by dedicated ABL1 break apart FISH (n=12) performed as part of the 
extended FISH screening in this study.  
 
3.4.3 Clinical and demographic characteristics 
Median patient age of CRLF2, IGH@ and ZNF384 rearranged patients was 64.5, 65 
and 63 years respectively. The majority of patients with CRLF2 rearrangements were 
female (75%, 6/8), whereas 89% (8/9) of non-CRLF2 IGH@ and all (3/3) ZNF384 





ID Trial Abnormality 
WCC 
(x109/L) Outcome 
25130 UKALL14 CRLF2-r 33.6 Died after 1 month 
25246 UKALL14 CRLF2-r 6.3 Died within 1 month 
25371 UKALL14 CRLF2-r 47.7 Alive >5 years 
28039 UKALL60 CRLF2-r Not known Died after 9 months 
28235 UKALL60 CRLF2-r 5.3 Relapsed and died after 2 years 
30102 UKALL60 CRLF2-r Not known Relapsed and died after 5 months 
30297 UKALL60 CRLF2-r Not known Alive >2 years 
30299 UKALL60 CRLF2-r Not known Died after 4 months 
25552 UKALL14 IGH@-r 2.9 Died after 4 months 
25894 UKALL60 IGH@-r 0.8 Alive >5 years 
25907 UKALL60 IGH@-r 2 Died after 1 year 
27181 UKALL14 IGH@-r 1.2 Died after 3 months 
27833 UKALL60 IGH@-r 14.5 Died after 2 years 
29808 UKALL60 IGH@-r Not known Relapsed and died after 1 year 
30487 UKALL14 IGH@-r 11.7 Alive after 1 year 
25235 UKALL14 ZNF384-r 3.5 Alive >5 years 
25451 UKALL14 ZNF384-r 34.2 Relapsed and died >5 years 
30085 UKALL60 ZNF384-r Not known Alive >2 years 
25267 UKALL14 MEF2D-r 1.4 Alive >5 years 
Table 3.6. White cell count (WCC) at diagnosis and outcome for all B-other patients with gene 
rearrangement detected (n=19).  
WCC: white cell count; CRLF2-r: CRLF2 rearrangement; IGH@-r: IGH@ rearrangement 
(excluding CRLF2 partner); ZNF384-r: ZNF384 rearrangement; MEF2D-r: MEF2D rearrangement. 
 
3.4.4 Summary of B-other ALL screening 
In total, gene rearrangements were identified in 21% (19/89) of the B-other patient 
cohort as detailed in figure 3.3, demonstrating genetic landscape following standard 
and extended genetic analyses.  
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Figure 3.3. Genetic landscape of ALL in 210 older adults enrolled in UKALL14 and UKALL60+ 
clinical trials. Abnormalities were detected following routine cytogenetic analyses at trial entry 
(A) and following extended FISH screening for cytogenetically cryptic lesions (B).  
HeH: high hyperdiploidy; HoTr: low hypodiploidy/near triploidy; B-other: BCP-ALL with no 
primary chromosomal abnormality identified; T-cell: T-cell ALL. CRLF2-r: CRLF2 rearrangement; 
IGH@-r: IGH@ rearrangement (excluding CRLF2 partner); ZNF384-r: ZNF384 rearrangement; 
MEF2D-r: MEF2D rearrangement. 
 
To account for the variation in the number of cases successfully tested for each 
abnormality, adjusted frequencies were then calculated (table 3.7). Most of the 
samples without cytogenetic data had diagnostic immunophenotyping performed, 
permitting the detection of T-ALL as well as RT-PCR for BCR-ABL1. The denominator 
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for IGH@, CRLF2, ZNF384 and MEF2D rearrangements was the sum of B-other cases 
successfully screened and all cases belonging to other genetic subgroups, as the 
presence of one primary genetic abnormality is generally considered sufficient 
evidence to rule out another, with the exception of occasional IGH@ translocations 
(Jeffries et al., 2014).  
Abnormality Cases detected/ Total screened Adjusted frequency 
BCR-ABL1 55/207 27% 
HoTr 28/200 14% 
KMT2A fusion 12/203 6% 
T-ALL 11/206 5% 
IGH@-r 9/164 5% 
CRLF2-r 8/159 5% 
ZNF384-r 3/151 2% 
MEF2D-r 1/150 <1% 
Table 3.7. Adjusted frequencies of individual genetic abnormalities, based on variation in the 
number of cases successfully screened for each abnormality.  
HoTr: low hypodiploidy/near triploidy; IGH@-r: IGH@ rearrangement; CRLF2-r: CRLF2 
rearrangement; ZNF384-r: ZNF384 rearrangement; MEF2D-r: MEF2D rearrangement. 
 
3.5 Discussion 
In total, 200 older adults with ALL were genetically characterised. Consistent with 
published data, the most prevalent primary abnormality was BCR-ABL1, which was 
seen in 26% of patients (29% of the BCP-ALL patients without missing data). To date, 
there have been some conflicting data regarding the frequency of BCR-ABL1 positive 
disease with advancing age. One of the largest studies of over 2500 BCP-ALL patient 
samples clearly reported a trajectory of an increasing proportion of BCR-ABL1 positive 
cases up to the age of 44 years. Thereafter, this plateaued at 42-44% of all BCP-ALL 
cases (Burmeister et al., 2008). In contrast, smaller studies demonstrated a persistent 
increase in the proportion of BCR-ABL1 positive patients, to ~50% in older adults 
(Herold et al., 2014, Byun et al., 2017). In the present analysis, there was no evidence 
of an increasing proportion of BCR-ABL1 ALL with advancing age in patients 60 years 
of age and above at diagnosis.  
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Interestingly, the second most frequent primary cytogenetic abnormality was low 
hypodiploidy/near triploidy, observed in almost 15% of patients. This contrasts sharply 
with children and adults aged <60 years, where it is encountered in <1% (Raimondi et 
al., 2003, Pui et al., 1990) and 2-4% of cases respectively (Moorman et al., 2007, 
Charrin et al., 2004, Moorman et al., 2010). Low hypodiploidy/near triploidy constitutes 
a high risk subgroup of BCP-ALL with a very poor prognosis and 5-year survival <20% 
in adults (Moorman et al., 2007). The overrepresentation of such high-risk genetic 
subtypes adds to the challenge of managing older adults with ALL as the default 
recourse to intensified risk-adapted treatment will often not be tolerated in older adults. 
Indeed, many protocols for older adults are based on an initial assessment of maximum 
tolerated treatment to optimise depth and duration of remission, meaning the concept 
of subsequent treatment intensification based on response is unsuitable for managing 
these patients. 
Although they have no single defining genetic lesion, complex karyotypes have also 
consistently been associated with poor prognosis in both AML and ALL (Byrd et al., 
2002, Mrózek et al., 2009). In AML, complex karyotypes are found in 10-12% of de 
novo diagnoses, with a frequency that correlates with advancing age, rising to around 
20% in adults aged 60 years and over at diagnosis (Mrózek, 2008). A large analysis of 
chromosomal abnormalities in adults aged between 25-65 years identified complex 
karyotype in 5% of BCP-ALL cases (Moorman et al., 2007). In comparison, in this 
analysis of older adults with ALL, this entity was seen in just 3% (5/199) of BCP-ALL 
cases, indicating that unlike in AML, the frequency of complex karyotype does not 
increase with advancing age. 
T-cell ALL was also rare in this unselected cohort of older adults, seen in only 5% of 
cases. This confirms that after a peak in adolescents and young adults, where it 
accounts for around 25% of new diagnoses, the incidence of T-cell ALL continues to 
reduce with advancing age (Ferrando et al., 2002, Marks et al., 2009). As a group, 
older adults with ALL seem to have one of the lowest frequencies of T-cell disease.  
Regarding the more recently described cytogenetically cryptic abnormalities, a large 
US study has identified Ph-like ALL in 24% in older adults (Roberts et al., 2017), 
although this was seen in <10% of similar patients in a German study (Herold et al., 
2014). Most studies agree the subtype peaks in young adults aged 21-39 years with 
estimated frequencies ranging between 25-42% of BCP-ALL cases in this age group 
(Roberts et al., 2017, Jain et al., 2017b, Herold et al., 2014). Interestingly the lower 
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estimates are usually obtained from Northern European studies, where patients of 
Hispanic ancestry, who are known to have higher rates of Ph-like ALL, are 
underrepresented compared with US derived datasets (Jain et al., 2017b). Importantly, 
Ph-like ALL is defined primarily by its characteristic gene expression profile, which has 
not been assessed in this study. However, identifying the principal kinase-activating 
gene rearrangements that produce the Ph-like signature provides a useful comparison 
between studies and in this large UK cohort of older adults, one of the main findings is 
the complete absence of ABL-class fusions. This contrasts with ALL in children and 
younger adults, where ABL-class fusions have been reported in 3-5% and 2-3% of 
cases respectively (Tasian et al., 2017, Roberts et al., 2014, Roberts et al., 2017). 
To date, the US study provides the largest cohort with detailed transcriptomic profiling 
of older adults with these abnormalities (Roberts et al., 2017). Among 798 patients, 
150 older adults (aged 60-86 years) were included. The study only comprised adults 
with BCP-ALL and excluded those with a primary ploidy shift. When restricted to similar 
patients, a trend towards a lower frequency of CRLF2 rearrangements in this UK 
dataset was observed (table 3.8). This may be related to ethnic differences between 
UK and US patients as CRLF2 rearranged ALL is significantly associated with 
Hispanic/Latino ancestry (Harvey et al., 2010).  
Gene 
rearrangements This study 
US study 
(Roberts et al., 2017)  p-value 
CRLF2 7% (8/118) 14% (21/150) 0.07 
PDGFRB 0% (0/126) <1% (1/150) 1 
ABL1 0% (0/153) 0% (0/150) 1 
ABL2 0% (0/122) 0% (0/150) 1 
JAK2 0% (0/123) 1% (2/150) 0.50 
EPOR Not tested <1% (1/150) NA 
Table 3.8. Comparison of frequency of kinase-activating rearrangements between UK and US 
cohorts in older adults. Data from Roberts et al restricted to adults >60 years at diagnosis. 
Denominators are based on BCP-ALL patients without primary ploidy shift. No statistically 
significant difference in the frequency of individual rearrangements was seen between patients 
aged over 60 years in the UK and US cohorts (Fisher’s Exact test), although there was a trend 
towards lower incidence of CRLF2 abnormalities in UK patients. 
 
IGH@ translocations were the most frequent abnormality identified in B-other ALL 
patients and were present in 26% (14/53) of tested patients. As discussed previously, 
IGH@ translocations are not considered a single genetic subgroup. Proximity to the 
IGH@ enhancer overexpresses oncogenes, and as such the IGH@ partner is 
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responsible for leukaemic transformation rather than the IGH@ locus itself. Consistent 
with larger studies (Russell et al., 2014), the most common IGH@ translocation partner 
was CRLF2, present in 36% (5/14) of cases. CEBP family genes were implicated in a 
further 21% (3/14) of IGH@ translocations and a BCL2 translocation was identified in 
a single case.  
Fewer patients were tested for ZNF384 and MEF2D rearrangements as many samples 
had already been depleted following all prior FISH experiments. However, ZNF384 
translocations were still detected in 8% of B-other cases (2% of all cases), making this 
the second most prevalent of the primary B-other rearrangement genes, with a 
frequency similar to that seen in younger adult and paediatric cohorts (3% and 4% of 
BCP ALL patients respectively) (Moorman et al., 2019, Hirabayashi et al., 2017). 
Interestingly, these patients seemed to have a more favourable outcome compared to 
their B-other counterparts. Although the number of patients is small, two are still alive 
at 2 and 5 years of follow up respectively and the patient who has died relapsed more 
than 7 years after initial diagnosis. In comparison, only 2/8 CRLF2 rearranged patients 
and 2/9 IGH@ rearranged (excluding IGH@-CRLF2) patients are still alive.  
The percentage of abnormal cells identified by FISH varied considerably between 
samples. The gene rearrangements screened are typically considered to be primary 
leukaemogenic events, with the exception of IGH@ translocations which sometimes 
co-occur with other abnormalities (Jeffries et al., 2014). It is therefore more likely that 
lower percentages of rearranged cells represented normal cell contamination rather 
than subclonal populations, although this could not be confirmed. 
Overall, 22% (19/87) of older adults with B-other ALL had a gene rearrangement 
identified. A significant proportion of B-other patients therefore still remain 
uncharacterised following cytogenetic and FISH studies. The targeted nature of FISH 
experiments only permits very limited discovery of other relevant “off-target” 
abnormalities and it is possible that novel gene fusions are present in this cohort of 
older adults with B-other ALL. Additionally, the primary abnormalities may be smaller 
genomic lesions such as mutations and microdeletions, which are not captured by 
cytogenetic analyses and techniques with a much higher resolution may be required 
to elucidate this further.  
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Chapter 4. Copy number abnormalities 
in older adults with ALL 
 
4.1 Introduction 
Somatic abnormalities are randomly acquired during cell division. In cancer, these can 
range from a single base substitution to aberrations affecting entire chromosomes. 
Copy number abnormalities (CNAs) refer to the loss or gain of genetic material during 
oncogenesis, and constitutes one of the most frequently encountered classes of 
somatic variation in cancerous cells. Not all CNAs produce a functional impact on the 
cancerous cell. Driver lesions are those that are beneficial to cell survival and 
malignant transformation, and are positively acquired during Darwinian natural 
selection. In comparison, passenger abnormalities arise non-specifically during the 
malignant process, and are either neutral or only weakly deleterious (Mermel et al., 
2011). Due to their biological importance, when a cohort of cancer samples is 
examined, a specific driver abnormality will be encountered more frequently than a 
specific passenger abnormality (Beroukhim et al., 2010). Although CNAs can contain 
large numbers of genes, the selective advantage of driver alterations is often mediated 
through one or a small number of candidate oncogenes or tumour suppressor genes 
within the regions of copy number change (Mermel et al., 2011).  
CNAs are common secondary events in ALL. They often co-operate with primary 
chromosomal abnormalities to drive leukaemogeneis (Mullighan et al., 2007). Specific 
CNAs can be associated with genetic subtypes. For example, BCR-ABL1+ and ETV6-
RUNX1+ ALL are associated with a high frequency of IKZF1 and ETV6 deletions 
respectively (Mullighan et al., 2008a). Importantly, particular combinations of CNAs 
have an impact on prognosis. Two validated copy number profiles, namely IKZF1plus 
(Stanulla et al., 2018) and UKALL-CNA (Moorman et al., 2014, Hamadeh et al., 2019) 
have been developed as prognostic biomarkers in childhood ALL.  
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IKZF1 on 7p12.2 encodes a zinc-finger DNA-binding transcription factor that is 
associated with chromatin remodelling and is required for the development of all 
lymphoid lineages (Wang et al., 1996). As a result of alternative splicing, different 
IKZF1 isoforms exist. These share a common C-terminal domain, which contains two 
zinc-finger motifs. These are required for dimerization and interaction with other 
proteins and are present in all isoforms of the protein (IK1-IK8). However, some 
isoforms do not contain the three or more N-terminal zinc finger motifs that are required 
for DNA-binding, and hence may function as dominant negative isoforms (Marke et al., 
2018). IKZF1 is essential for the development of all lymphoid lineages, as well as other 
haematopoietic lineages to a lesser extent (Marke et al., 2018) and mice with 
homozygous IKZF1 deletions fail to develop any lymphoid tissue (Georgopoulos et al., 
1994). IKZF1 is frequently disrupted in ALL, most commonly through a range of 
different deletions, which are seen in around 15% of childhood and 40% of adult cases 
(Boer et al., 2016). One copy of IKZF1 can be lost through a focal deletion affecting 
the entire gene or large deletions of 7p. Additionally, recurrent small intragenic 
deletions also result in loss of function. Exons 4-6 encode the N-terminal DNA binding 
domain of the protein and intragenic deletions affecting exons 4-7 are recurrent events 
in ALL and produce a dominant negative isoform (IK6), lacking all DNA-binding zinc 
finger motifs (Boer et al., 2016). IKZF1 deletions were the first CNAs found to have an 
adverse impact on prognosis in ALL (Mullighan et al., 2009b), and have since been 
defined as one of the principle components in the prognostic risk scores mentioned 
above (IKZF1plus and UKALL-CNA).  
In ALL, focal CNAs also frequently target genes that are involved in cell cycle regulation 
and have prominent tumour suppressor activity. CDKN2A and CDKN2B are adjacent 
genes on 9p21.3 that generate multiple isoforms. One of their principal functions is the 
inhibition of CDK kinases, thereby regulating cell cycle G1 progression. CDKN2A also 
encodes an alternate open reading frame (ARF) transcript, that functions to stabilise 
p53 through the sequestration of MDM2 activity (Zhao et al., 2016). CDKN2A and 
CDKN2B are targeted by deletions in many cancer, and frequent homozygous loss is 
observed in ALL, often occurring through a large 9p deletion affecting one allele and a 
more focal isolated CDKN2A/B deletion on the other allele (Sulong et al., 2009). RB1 
on 13q14.2 is another prominent tumour suppressor gene that acts as a negative 
regulator of the cell cycle and is recurrently deleted in numerous cancers including ALL 
(Mullighan et al., 2007). Similarly, PTEN is a tumour suppressor implicated in 
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numerous cancers and is specifically deleted in T-cell rather than BCP-ALL (Mendes 
et al., 2016). 
ETV6 encodes a transcription factor that plays an essential role in normal 
haematopoiesis (Wang et al., 1998). It is one of the most frequently implicated genes 
in the pathogenesis of childhood ALL, most commonly through ETV6-RUNX fusion 
(chapter 1, section 1.8.2.1). In this genetic subtype, the wild type ETV6 allele is often 
deleted, which is thought to be one of the important secondary events transforming the 
pre-leukaemic ETV6-RUNX1+ clone into overt leukaemia (Cavé et al., 1997). 
Heterozygous ETV6 loss is seen in other genetic subtypes, consistent with a broader 
role in the pathogenesis of ALL.  Specific to BCP-ALL, deletions are additionally 
observed in genes involved in B-cell development, most commonly PAX5, EBF1 and 
TCF3 as well as BTG1, which has a range of functions including tumour suppressor 
activity (Mullighan et al., 2007, van Galen et al., 2010).  
CNAs can vary from small intragenic deletions to abnormalities affecting entire 
chromosomes. However, the size of somatic CNAs is not random. A landmark study 
across multiple tumour types demonstrated that these were either very small (focal) or 
the length of a whole chromosome or chromosome arm (arm level) (Beroukhim et al., 
2010). As such, these abnormalities need to be viewed in the context of their size and 
the detection method. CNAs can be identified through targeted techniques such as 
FISH and MLPA or genome-wide techniques such as SNP arrays and whole genome 
sequencing. Using MLPA, gene deletions that have arisen focally compared with those 
where a whole chromosome has been lost, will often not be differentiated. In 
comparison, this detail is appreciable through SNP arrays analysis and several studies 
have highlighted the important role of SNP arrays in identifying clinically relevant 
prognostic and therapeutic targets in ALL patients (Wang et al., 2016, Baughn et al., 
2015).  
One of the earliest large studies to report CNAs in ALL identified a mean of 6.46 (range 
0-39) CNAs per case in a cohort of 242 paediatric ALL patients (Mullighan et al., 2007). 
The SNP arrays used interrogated around 350,000 loci and most recurrent CNAs were 
focal events <1Mb in size. Of these, deletions outnumbered gains 2:1. Recurrent 
segments of copy number loss had a mean size of 166 kb (range 4 – 889 kb) and 44% 
(24/54) of recurrent deletions affected single genes. Another study using the same 
platform in a subgroup of 221 high risk childhood BCP-ALL patients identified a mean 
of 8.36 CNAs per patient (Mullighan et al., 2009b). Similar studies of adolescent and 
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adult patients have reported a median of 6-8 CNAs per sample (Okamoto et al., 2010, 
Paulsson et al., 2008). Adults were found to have a similar pattern of focal 
microdeletions to paediatric patients, although one study additionally identified a higher 
frequency of 17p losses (Okamoto et al., 2010).  
Importantly, much of the literature on CNAs in ALL has been derived from 
comparatively low density SNP arrays by current standards (Iacobucci et al., 2013). 
The use of newer high-density arrays has permitted the detection of smaller and 
smaller abnormalities, albeit with a risk of increasing the rate of false positive calls 
(Bernardini et al., 2010).  Using the Affymetrix Cytoscan HD array, a more recent study 
identified a mean of 12.3 CNAs in adult ALL patients at diagnosis, comprising 9.6 
deletions, 2.3 duplications and 0.4 regions of CNN-LOH per sample (Ribera et al., 
2017). To minimise false positive calls, the authors applied a minimum segment size 
of 25 markers for CNAs and 20 Mb for CNN-LOH, so smaller events could not be 
excluded. Another study analysed SNP arrays across multiple institutions and multiple 
array platforms (Baughn et al., 2015). This combined analysis was performed using 
the Nexus software, which is able to derive copy number and B-allele frequency data 
from a wide range of array platforms (chapter 2, section 2.6.1.5). The authors reported 
on average 2-6 CNAs per case in various cytogenetic subgroups of paediatric ALL 
including ETV6-RUNX1+, high hyperdiploidy and normal karyotypes. The significance 
of setting appropriate platform-specific thresholds for calling CNAs was also 
highlighted. In the study, a minimum of 25 probes was used for Affymetrix Cytoscan 
HD arrays and 15 probes for Illumina Infinium 850k microarray, reflecting the 
importance of appreciating differences in array probe density. Additionally, log2 ratio 
thresholds were adjusted based on the percentage of leukaemic cells in the primary 
sample to optimise detection of relevant CNAs even in samples with lower blast 
percentages.  
Guidelines from the American College of Medical Genetics and Genomics (ACMG) 
have suggested that a minimum sample tumour content of 25% is required before 
embarking on SNP array analysis, although this is likely to vary between platforms and 
internal laboratory validation processes (Cooley et al., 2013, Schoumans et al., 2016). 
Similarly, even in pure samples, CNAs may be difficult to detect if present at subclonal 
levels (Puiggros et al., 2013). Moreover, to date, the principle of identifying genetic 
mosaicism using SNP arrays has principally been explored and validated in the context 
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of constitutional genetic disorders, rather than in the detection of subclonal somatic 
CNAs (Biesecker and Spinner, 2013). 
Overall, the existing SNP array literature therefore confirms the importance of 
integrating information on sample quality, clonality, constitutional copy number 
variation and probe density when analysing SNP arrays to optimise the detection of 
clinically relevant aberrations.  
 
4.2 Aims and objectives 
The overarching aim of this work package was to produce a comprehensive copy 
number profile of ALL in older adults. To achieve this, the following objectives needed 
to be addressed: 
1. Create a SNP array cohort broadly representative of older adults with ALL 
2. Optimise SNP array segmentation to facilitate discovery of novel lesions while 
minimising false positive calls 
3. Perform MLPA to validate SNP array segmentation in specific genes 
4. Identify potential novel driver genes affected by CNAs in the cohort 




4.3.1 SNP array segmentation settings 
The SNP array cohort incorporated all patients aged ≥60 years enrolled in the 
UKALL14 or UKALL60+ trials with DNA extracted from the diagnostic bone marrow 
sample. Demographic and cytogenetic information for all included patients can be 
found in supplementary table 1.  
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Bone marrow DNA samples were sent to the Northern Genetics Centre, Newcastle 
Hospitals NHS Foundation Trust, and SNP arrays were performed using the Illumina 
850k CytoSNP or Affymetrix Cytoscan HD array (chapter 2 section 2.6.1.3). Raw signal 
intensity files (CEL and IDAT files) were transferred back and used for all subsequent 
analyses. These were loaded into Nexus Copy Number 10 (chapter 2 sections 2.6.1.5 
– 2.6.1.8) and prepared for copy number segmentation.  
Accurate generation of copy number segments is based on three primary 
considerations: 
1. The minimum positive and negative log2 ratio deflection required.  
Nexus copy number uses a segmentation algorithm based on the Hidden 
Markov Model (HMM). However, in comparison to the classic HMM, integer 
levels of copy number are not assumed. Instead, either default or customised 
log2 ratio thresholds are defined, and if a group of probes falls above or below 
these boundaries, a copy number segment may be generated. The degree of 
deviation of the probe log2 ratio from the sample baseline in a CNA segment is 
based on a number of factors, including sample purity, the proportion of tumour 
DNA affected (intratumoural heterogeneity) and the SNP array platform that has 
been used to generate the raw data. A judgment therefore needs to be made to 
define the degree of positive or negative deflection in probe log2 ratio required 
to generate a segment of copy number gain or loss respectively. Based on 
assessments of sample purity and objective measures of quality, these 
thresholds needed to be adjusted to generate meaningful data, as described 
below. 
 
2. The minimum defined size of a copy number segment. 
Probe density varies both across the genome and between different SNP array 
platforms. This needs to be taken into account when defining minimum copy 
number segment sizes to ensure that small intragenic lesions can be detected 
whilst minimising false positive calls if a very small number of probes are used 
to generate a copy number segment. 
 
3. The permitted scattering of probes in the log2 space within a copy number 
segment (significance threshold). 
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Copy number data are inherently noisy. Probe signal intensity is influenced by 
a number of factors including DNA quality, GC content and the proportion of the 
genome affected by copy number variation. Additionally, genuine copy number 
changes may represent germline copy number variation (CNV), unrelated to the 
leukaemia genome. As such, quality control measures need to be taken into 
account during segmentation to ensure false positive and false negative calls 
are kept to a minimum. Once loaded to Nexus, a SNP array Quality score is 
generated. This is computed through ordering by magnitude the difference 
between signals from adjacent probes and then removing 1.5% of probes at 
each end of the variance spectrum. The smaller this final quality metric, the 
better quality the sample as adjacent probes will be producing a similar signal 
intensity. Conversely, higher Quality scores are associated with a greater 
spread of probes in the log2 space and more noisy data. To reduce the rate of 
false positive calls, a more stringent significance threshold can be applied to 
reduce the probability of random fluctuations in probe intensity generating a 
copy number segment. Adjusting the significance threshold controls the number 
of copy number segments generated through segmentation of the genome, with 
smaller significance threshold values being more stringent and generating fewer 
segments. In general, samples from higher density arrays and those with poorer 
(higher) quality scores require smaller, more stringent significance thresholds to 
minimise false positive copy number calls. 
 
Based on sample quality and SNP array platform, Nexus segmentation settings were 
customised to account for different array types and varying levels of noise across the 
cohort. Minimum numbers of 10 probes for Affymetrix arrays and 6 probes for Illumina 
arrays were used for genome segmentation. 
The significance thresholds used for genome segmentation in this study are shown in 
figure 4.1, based on SNP array type and quality score. Affymetrix SNP arrays had 
poorer quality scores than Illumina arrays and significance thresholds were set to more 
stringent levels with increasing (worsening) quality scores. Benchmark significance 
thresholds and log2 ratio deflections for segmentation were 1x10-12 and ±0.08 
respectively for Illumina arrays and 1x10-20 and ±0.15 for Affymetrix arrays. All 
customised SNP array segmentation settings used for each sample can be found in 
supplementary table 2. 
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Figure 4.1. Significance thresholds used for SNP array segmentation based on array type and 
quality score. Samples with higher (worse) quality scores were segmented using lower (more 
stringent) significance thresholds to minimise the false positive call rate. 
 
4.3.2 SNP array analysis 
Following copy number segmentation, SNP arrays were analysed both visually and 
computationally. Initially, large abnormalities affecting whole chromosome arms were 
identified and described by standard visual analysis of the SNP array traces. Next, 
CNAs in eight well-described driver genes, namely EBF1, IKZF1, CDKN2A, CDKN2B, 
PAX5, ETV6, BTG1 and RB1, were scrutinised case-by-case and recorded. Finally, a 
computational SNP array analysis method was developed using the Nexus output to 
identify potential novel driver abnormalities within the cohort. Often, driver lesions 
targeted by CNAs are either present as the only disrupted gene in a copy number 
segment or have breakpoints within the relevant gene (e.g. IKZF1 exon 4-7 deletion). 
Therefore, to detect recurrent focal CNAs, including novel abnormalities, genes at the 
breakpoints of deletions were specifically extracted using a customised automated 
pipeline, which was created and executed in R (figure 4.2). The input file was a readily 
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available results file exported from Nexus, whereby each aberration within the entire 




Figure 4.2. Pipeline to extract candidate driver genes from complete SNP array dataset. 
Individual segment information from Nexus included percentage overlap with regions of known 
CNV reported in the Toronto Database of Genomic Variants (MacDonald et al., 2014), which 
permitted the exclusion of calls with ≥50% overlap with CNVs (step 2 in pipeline). Due to sex-
related inconsistencies in segmentation, all calls on chromosome Y and the pseudoautosomal 
regions (PAR) of chromosome X were filtered out (steps 3 and 4). Additionally, all abnormalities 
present in the telomeric cytobands of each chromosome were also filtered out due to inherently 
noisy data on these regions (step 7). Breakpoint genes in centromeric genes were discarded as 
these were automatically present in any arm-level or whole-chromosome abnormalities, hence 
did not specifically reflect the presence of driver genes (step 10).  
CNV: copy number variation; PAR: pseudoautosomal regions. 
 
4.3.3 MLPA validation 
To ensure segmentation had been optimised, copy number abnormalities in 8 
genes/regions were validated against MLPA, using the IKZF1-P335 kit (chapter 2, 
section 2.6.2). This comprised probes covering EBF1, IKZF1, CDKN2A/B, PAX5, 
ETV6, BTG1, RB1 genes together with the PAR1 region of Xp22.3/Yp11.2. MLPA 
results were analysed using GeneMarker software (chapter 2, section 2.6.2.3). 
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Deletions or gains were called when probe ratios of <0.75 or >1.3 respectively were 
present in 2 consecutive probes in a gene.  
 
4.3.4 SureSelect XT2 NGS validation and protocol optimisation 
Whole genome amplification (WGA) and SureSelect XT2 library prep were performed 
as described to validate biologically relevant and potential novel CNAs from the SNP 
array analysis (chapter 2 sections 2.4.4 and 2.7).  
Following WGA, double stranded DNA (dsDNA) concentrations were measured using 
the Quant-iT Picogreen assay and FLUOstar Omega microplate reader (chapter 2, 
section 2.4). Of the 28 initial validation samples, 24 had sufficient amounts of dsDNA 
following WGA to proceed to library prep.  
For each case 1-2ug of sample DNA (depending on availability) was diluted in TE 
buffer to a volume of 100ul. The DNA was sheared by sonication using the Bioruptor 
Pico with a target fragment size of 800bp. Following shearing DNA fragment sizes were 
assessed on the Bioanalyzer (chapter 2, section 2.4.5.4) to ensure fragment peaks 
were present around 800 bp (figure 4.3).  
 
Figure 4.3. Example Bioanalyzer electropherogram following DNA shearing showing DNA 
fragment peak ~800bp (patient 24813). DNA fragment size shown on x-axis and fluorescence 
intensity on y-axis. 
 
Electropherograms of the input material confirmed suitable DNA shearing with an 
acceptable fragment size in all cases. 
 95 
However, following the PCR amplification stage of library prep using the Herculase II 
DNA polymerase (chapter 2, section 2.7.2), DNA samples showed suboptimal 
amplification and an over-representation of shorter DNA fragments (see figure 4.4). 
 
Figure 4.4. Example Bioanalyzer electropherogram following PCR amplification stage of library 
prep using Herculase II DNA polymerase (patient 25247). Trace demonstrates very low peak at 
~550bp indicating low DNA concentration and small fragment size. DNA fragment size shown on 
x-axis and fluorescence intensity on y-axis. 
 
The PCR amplification was therefore trialled using the Longamp Taq polymerase 
enzyme, which is optimised for amplification of longer DNA fragments. This resulted in 
much better amplification of the DNA samples at the PCR amplification stage (figure 
4.5) and the Longamp enzyme was therefore used for all subsequent samples, as well 




Figure 4.5. Example Bioanalyzer electropherogram following PCR amplification stage of library 
prep using Longamp polymerase (patient 25247). Trace demonstrates clear peak at ~800bp 
indicating sufficient DNA concentration and large fragment size. DNA fragment size shown on 
x-axis and fluorescence intensity on y-axis. 
 
To account for the alteration in the polymerase enzyme used, the thermal cycler 
settings were also adjusted to optimise amplification of longer DNA fragments (table 
4.1). 
Segment Number of cycles Temperature Time 
1 1 95⁰C 3 mins 
2 5 
98⁰C 20 secs 
60⁰C 15 secs 
65⁰C 2 mins 
3 1 65⁰C 10 mins 
4 1 4⁰C Hold 
Table 4.1. Pre-capture PCR thermal cycler program using Longamp Taq polymerase in place of 
Herculase II DNA polymerase.  
 
In total, 23/24 samples were successfully put through the full library prep. One sample 
(27181) had to be excluded due to poor PCR amplification. Thus, the final NGS 
validation cohort comprised 23 samples as detailed in table 4.2.  
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Patient ID Genetic subtype Post WGA concentration (ng/ul) Library prep 
25267 B-other 103.8 Successful 
26614 B-other 27.4 Successful 
28335 B-other 29.7 Successful 
24890 B-other 94.6 Successful 
25082 BCR-ABL1 39.7 Successful 
25208 BCR-ABL1 97.4 Successful 
25247 BCR-ABL1 100.1 Successful 
28057 BCR-ABL1 45.8 Successful 
28182 BCR-ABL1 20.5 Successful 
28350 BCR-ABL1 95 Successful 
28670 BCR-ABL1 81.1 Successful 
26660 BCR-ABL1 93.2 Successful 
25346 BCR-ABL1 -26.7 Insufficient DNA 
25793 BCR-ABL1 -21.3 Insufficient DNA 
25967 Complex 99.6 Successful 
25437 HoTr 91.6 Successful 
29407 HoTr 94.7 Successful 
27833 IGH-BCL2 16.4 Successful 
27181 IGH-CEBPE 36.1 Failed amplification 
25130 IGH-CRLF2 63.8 Successful 
25552 IGH@-r 64.4 Successful 
28581 KMT2A-AFF1 47.9 Successful 
29908 KMT2A-AFF1 12.1 Insufficient DNA 
25100 KMT2A-v 74.7 Successful 
27389 KMT2A-v 4.4 Insufficient DNA 
27642 T-ALL 76.7 Successful 
24813 Unknown 85.3 Successful 
25451 ZNF384-r 40.1 Successful 
Table 4.2. DNA concentrations (in 50ul) following whole genome amplification and subsequent 
outcome following SureSelect XT2 library prep. Negative values represent <5ng/ul. 
WGA: whole genome amplification; B-other: BCP-ALL with no primary chromosomal 
abnormality identified; HoTr: low hypodiploidy/near triploidy; Complex: 5 or more unrelated 
chromosomal abnormalities on karyotype; IGH@-r: IGH@ rearrangement; KMT2A-v: KMT2A 
fusion with non-AFF1 partner; ZNF384-r: ZNF384 rearrangement. 
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All samples successfully put through the library prep (n=23) were then sequenced on 
the NextSeq 550 using 150 bp paired end-chemistry and deletion breakpoints were 
directly visualised in IGV (chapter 2, section 2.6.4). Individual deletions could then be 
validated when concordant reads flagged a structural variant as shown in figure 4.6. 
 
 
Figure 4.6. Example of validated breakpoint in RAG1 viewed in IGV (patient 25130). Each 
individual segment represents a single sequencing read. Red flagged reads indicate mate pairs 
>10kb apart. Multiple flagged reads within same genomic region (A). Mate pairs all mapped to 
region in C11orf74 indicating deletion involving exon 2 of RAG1 and entirety of RAG2. 






4.4.1 Patient cohort 
SNP arrays were performed on 83 patient samples using Illumina CytoSNP 850k 
(n=52) and Affymetrix Cytoscan HD (n=31) arrays. Median patient age was 64 years 
(range 60-83) and 57% were female. A range of genetic subgroups were included, 
broadly representative of ALL in older adults (figure 4.7). Patient samples were 
obtained from the UKALL14 (n=51) and UKALL60+ (n=32) clinical trials. Detailed 
patient characteristics and genetic data can be found in supplementary table 1. 
Figure 4.7. Representation of genetic subtypes in the complete SNP array cohort (n=83).  
HoTr: low hypodiploidy/near triploidy; KMT2A: KMT2A fusion with any partner; B-other: BCP-
ALL with no primary chromosomal abnormality identified including failed, normal and complex 
karyotypes. 
 
4.4.2 Copy number profile 
4.4.2.1 Total CNAs per patient sample 
Using the customised settings described in section 4.3.1 and supplementary table 2, 
the total number of CNAs generated was assessed per sample and compared between 
array types. Overall, Affymetrix SNP arrays generated significantly more copy number 

















increased probe density and increased false positive call rate relating to poorer quality 
scores, despite increasing the stringency of significance thresholds (figure 4.1 and 
supplementary table 2). 
 
Figure 4.8. Number of CNA segments by SNP array platform. Due to higher probe density, 
Affymetrix Cytoscan HD array samples had on average more CNAs than Illumina 850k array 
samples (before germline copy number variants (CNVs) removed).  
CNA: copy number abnormality. 
 
Accepting this inevitable degree of discrepancy between Affymetrix and Illumina 
arrays, the segmentation settings selected in this analysis were thought to achieve the 
best balance between permitting the detection of novel copy number abnormalities at 
potentially subclonal levels, and minimising false discoveries.  
Based on the customised segmentation thresholds, 4,604 individual copy number calls 
were made across the cohort of 83 patients. Post processing filtering was performed 
as detailed in figure 4.2. A total of 1,975 had at least 50% overlap with regions of known 
constitutional CNV in the Toronto Database of Genomic Variants (DGV) (MacDonald 
et al., 2014) and were removed from further analysis. Importantly, the CDKN2A and 
CDKN2B genes are within a reported CNV region in DGV so were safeguarded from 
this filtering step. Next, due to inherent noise and to remove inconsistencies between 
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male and female patients, calls on chromosome Y (n=213) as well as the 
pseudoautosomal regions of chromosome X (Xp22.33, Xq21.31 and Xq28) (n=106) 
were also discarded. However, as the interstitial deletion leading to P2RY8-CRLF2 
fusion occurs in Xp22.33, all SNP arrays were specifically visually assessed for this 
abnormality, and no cases were identified. Finally, CNA segments that did not include 
any genes (n=292) and those smaller than 10kb were filtered out (n=39).  
This automated sequential filtering process left a total of 1,979 calls of potential interest 
across the 83 patient samples. Of these, 48% (n=942) were heterozygous deletions, 
1% (n=26) were homozygous deletions, 12% (n=243) were one copy gains, 24% 
(n=469) were regions of LOH and 15% (n=299) classed as allelic imbalance. Deletions 
were more frequent than gains in all cytogenetic subgroups apart from high 
hyperdiploidy (figure 4.9). 
 
Figure 4.9. Boxplot displaying number of deletions and gains across cytogenetic subtypes in 81 
older adults with ALL (2 low hypodiploid cases (28644 and 25437) excluded due to poor SNP 
array segmentation). B-other: BCP-ALL with no primary chromosomal abnormality identified; 
HoTr: low hypodiploidy/near triploidy; HeH: high hyperdiploidy; KMT2A-v: KMT2A fusion with 





4.4.2.2 Chromosome arm level copy number abnormalities 
The frequency of arm level events is shown in table 4.3. Arm-level CNAs were 
identified through direct visualisation of SNP arrays in Nexus and were included when 
they affected either an entire chromosome or the majority of a chromosome arm.  
Abnormality  % of all cases (n) Subgroups represented (n) 
del(9p) 21% (15) BCR-ABL1 (11), B-other (4) 
gain of Ph* 12% (9) BCR-ABL1 (9) 
gain 1q 10% (7) B-other (4), BCR-ABL1 (2), TCF3-PBX1 (1) 
-7 10% (7) BCR-ABL1 (5), B-other (2) 
del(7p) 8% (6) BCR-ABL1 (4), B-other (2) 
gain 21q 8% (6) BCR-ABL1 (3), B-other (3) 
del(17p) 7% (5) B-other (4), BCR-ABL1 (1) 
del(12p) 5% (4) B-other (2), BCR-ABL1 (1), T-ALL (1) 
gain 14q 5% (4) BCR-ABL1 (4) 
+5 4% (3) B-other (2), BCR-ABL1 (1) 
-9 4% (3) BCR-ABL1 (3) 
+2 3% (2) BCR-ABL1 (2) 
+4 3% (2) BCR-ABL1 (2) 
+6 3% (2) BCR-ABL1 (1), MLL (1) 
gain 8q 3% (2) BCR-ABL1 (1), B-other (1) 
+11  3% (2) B-other (1), BCR-ABL1 (1) 
del(13q) 3% (2) BCR-ABL1 (2) 
Table 4.3. Number of whole chromosome and arm-level abnormalities across 73 SNP arrays. Low 
hypodiploid (n=9) and high hyperdiploid (n=1) cases excluded. Four BCR-ABL1+ cases had 
multiple chromosomal gains, which is a recognised secondary abnormality in this subgroup and 
accounts for the majority of whole chromosome gains observed.  
*Consistent with extra copy of Philadelphia chromosome in BCR-ABL1+ cases.  
B-other: BCP-ALL with no primary chromosomal abnormality identified.  
 
Next, significance testing was performed using GISTIC (Genomic Identification of 
Significant Targets in Cancer) 2.0 (Mermel et al., 2011). This is a computational 
method that initially models the rate of background copy number alteration and 
separates abnormalities by length into focal or arm-level events. Based on the 
background rate of CNAs in the cohort, p-values are then calculated to determine the 
significance of individual abnormalities. Although, the method relies on regions of 
constitutional CNV having been excluded prior to the analysis, these do not occur on 
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a whole chromosome or arm-level scale without clinical manifestation. The GISTIC 2.0 
analysis was performed on the full cohort of 83 SNP arrays and generated false 
discovery rates (q-values) for each arm level abnormalities, with q-values <0.05 
deemed to be statistically significant (table 4.4). 
CNA type Arm Frequency q-value 
Deletion 
9p 22% 1.30E-14 
7p 19% 3.04E-11 
7q 16% 5.73E-08 
17p 14% 5.03E-06 
9q 12% 0.000226 
16q* 12% 0.000758 
3p* 10% 0.0162 
16p* 10% 0.0203 
17q* 8% 0.0289 
15q* 8% 0.0456 
3q* 8% 0.0474 
Gain 
21q 12% 0.00645 
1q 10% 0.017 
Table 4.4. Gistic 2.0 output for arm level copy number abnormalities and false discovery rates 
(q-values) across all 83 SNP arrays. Only arm level CNAs with significant q-value <0.05 shown. 
*Specifically observed in low hypodiploid cases.  
CNA: copy number abnormality. 
 
These data confirm that several arm level events occur recurrently in older adults with 
ALL. Deletions occurred more frequently than gains and 9p losses were seen in around 
20% of cases. Deletions of chromosome 3, 15 and 16 were recurrent events but 
isolated to low hypodiploid patients so were not representative of the overall cohort.  
 
4.4.2.3 Abnormalities in known driver genes 
As mentioned previously, several driver genes are recurrently affected by CNAs in 









IKZF1 52% (43) 41 2 
CDKN2A 45% (37) 18 19 
CDKN2B 45% (37) 21 16 
PAX5 39% (32) 32 0 
RB1 22% (18) 17 1 
ETV6 21% (17) 16 1 
EBF1 19% (16) 15 1 
BTG1 12% (10) 9 1 
Table 4.5. Deletions affecting known driver genes targeted by CNAs in ALL. Deletions reported 
if present in any coding part of gene (focal and arm-level events).  
 
To examine whether specific events interacted with BCR-ABL1 status, the frequency 
of each gene deletion was considered separately in BCR-ABL1+ and BCR-ABL1 
negative patients and Fisher’s Exact Test was performed (table 4.6). IKZF1 and 
CDKN2A/B were the most commonly deleted genes in BCR-ABL1 positive and BCR-
ABL1 negative cases respectively.  
Gene deletion BCR-ABL1+ % cases (n=33) 
BCR-ABL1- 
% cases (n=50) 
Fisher’s Exact 
Test (p-value) 
EBF1 18% (6) 20% (10) 1 
IKZF1 70% (23) 40% (20) 0.01 
CDKN2A/B 39% (13) 48% (24) 0.50 
PAX5 45% (15) 34% (17) 0.36 
ETV6 6% (2) 30% (15) 0.01 
BTG1 6% (2) 16% (8) 0.30 
RB1 9% (3) 30% (15) 0.03 
Table 4.6. Frequency of individual deletions in known driver genes split by BCR-ABL1 status. 
Significant differences identified between rate of IKZF1, ETV6 and RB1 deletions between BCR-
ABL1 positive (BCR-ABL+) and BCR-ABL1 negative (BCR-ABL1-) cases. 
 
A significantly higher frequency of IKZF1 deletion was observed in BCR-ABL1 positive 
compared to BCR-ABL1 negative patients. Conversely, ETV6 and RB1 deletions had 
a higher prevalence in BCR-ABL1 negative patients. The frequency of other individual 
abnormalities was not significantly impacted by BCR-ABL1 status in this cohort.  
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The combined profile of these deletions was then examined within each patient, and 
subgrouped into the recurrent patterns observed (figure 4.10) and subsequently by 
BCR-ABL1 status (figure 4.11). CDKN2A and CDKN2B deletions were combined as a 
single event, consistent with previous studies (Schwab et al., 2013, Moorman et al., 
2012). In total, 22% (n=18) of patients had no deletions, 20% (n=17) had one deletion, 
19% (n=16) had two deletions, 22% (n=18) had 3 deletions and 17% (n=14) had four 
or more gene deletions. IKZF1 deletions in particular co-occurred with other gene 
deletions much more commonly than in isolation. 
 
Figure 4.10. Patterns of gene deletions observed across full cohort of 83 SNP arrays. 
Combinations of deletions grouped by patterns observed. CDKN2A/B/PAX5 combined deletion 
commonly represents del(9p). Cases with single gene deletions shown in blue segments, cases 
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Figure 4.11. Patterns of gene deletions divided by BCR-ABL1 status. Cases with single gene 
deletions shown in blue segments, cases with 2 deletions in green segments and cases with 3 
deletions in red segments.  
BCR-ABL1+: BCR-ABL1 positive; BCR-ABL1-: BCR-ABL1 negative. 
 
4.4.2.4 Genome-wide identification of driver abnormalities 
Following the analysis of arm-level abnormalities and the specific known driver genes 
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all genes that were recurrently present at the breakpoints of segments of copy number 
loss (figure 4.12).  
 
Figure 4.12. Recurrent genes within breakpoints of deletions (shown if seen ≥3 times in cohort) 
ordered by frequency and primary genetic abnormality. Cases are not included if the breakpoints 
fell outside the specified gene.  
HoTr: low hypodiploidy/near triploidy; HeH: high hyperdiploidy; B-other: BCP-ALL with no 
primary chromosomal abnormality identified. CN Loss: copy number loss. 
 
Reassuringly, this method still extracted all the well-established driver abnormalities 
detailed above, albeit only where they were present as focal deletion, at or adjacent to 
a copy number breakpoint, rather than as an arm-level event. Indeed, IKZF1 remained 
the most frequent gene deletion, and was seen as a focal event in 27% (22/83) of 
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samples. Thus, these accounted for 51% of all IKZF1 deletions, with the remaining 
49% (n=19) resulting from larger deletions of 7p. Breakpoints were also present in 
CDKN2A/B in 24% (20/83) of cases, PAX5 in 10% (8/83) of cases, EBF1 in 8% (7/83) 
of cases, RB1 in 7% (6/83) of cases, ETV6 in 6% (5/83) of cases, and BTG1 in 4% 
(3/83) of cases.  
Less well described and potential novel driver genes within breakpoints of deletions 
included COL11A1 in 13% (11/83) and MEF2C in 10% (8/83) of samples. Additionally, 
MBNL1 deletions were present in 8% (7/83) of patients, all but one in BCR-ABL1+ 
cases. Small intragenic deletions in LEMD3 were identified in 6% (5/83) of cases. 
PTEN, NF1 and KDM6A are known tumour suppressor genes and were targeted by 
small intragenic deletions in 6% (5/83), 5% (4/83) and 5% (4/83) of cases respectively. 
RAG1 and CD200 deletions are described in BCP-ALL and were seen in 5% (4/83) 
and 4% (3/83) of cases respectively. Similarly, ADD3 and TOX deletions were each 
seen in 5% (4/83) of cases, predominantly BCR-ABL1+ patients. 
 
4.4.3 MLPA validation 
Of the 83 patients in the SNP array cohort, MLPA was performed on 67 cases. The 
MLPA-IKZF1-P335 kit contains probes covering EBF1, IKZF1, CDKN2A, CDKN2B, 
PAX5, ETV6, BTG1, RB1 and PAR1. No PAR1 deletions were detected either by 
MLPA or SNP array so this abnormality was not considered further. The frequency of 
individual CNAs in the other genes by MLPA is shown in figure 4.13. 
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Figure 4.13.  CNAs detected by multiplex ligation-dependent probe amplification (MLPA) in 67 
patient samples. Deletions were present in IKZF1 in 43% (n=29), CDKN2A in 42% (n=28), CDKN2B 
in 42% (n=28), PAX5 in 33% (n=22), ETV6 in 15% (n=10), RB1 in 13% (n=9), EBF1 in 10% (n=7) and 
BTG1 in 6% (n=4). No PAR1 deletions were detected (data not shown). 
 
Next, the MLPA results were compared to the SNP array-generated copy number 
abnormality calls in these same genes using the customised Nexus segmentation 




Figure 4.14. Comparison between CNAs detected by multiplex ligation-dependent probe 
amplification (MLPA) and SNP array in 67 patient samples. CNAs were called by SNP array more 
frequently than by MLPA across all 8 genes. 
 
In total, 535 copy number calls of these genes were made by SNP array and MLPA. 
Slightly more CNA calls were made by SNP array than by MLPA (figure 4.14) across 
all 8 genes. Overall, 94% (501/535) were concordant, and the remaining 6% (34/535) 
were discordant. Of these, 14 related to low hypodiploid/near triploid samples. MLPA 
is known to be unsuitable in these samples (Schwab et al., 2010), so these were not 
considered further, leaving 20 discrepancies. Further details of discordant calls are 










Probable reason for 
discrepancy 
25082 BCR-ABL1 EBF1 normal deletion Low VAF or blast % 
26971 B-other EBF1 normal gain Low VAF or blast % 
28350 BCR-ABL1 EBF1 normal gain Low VAF or blast % 
25246 B-other IKZF1 normal deletion Low VAF or blast % 
28581 KMT2A fusion CDKN2B normal deletion Low VAF or blast % 
24813 Not done PAX5 normal deletion Low VAF or blast % 
25130 B-other PAX5 normal deletion Low VAF or blast % 
27509 BCR-ABL1 PAX5 normal deletion Low VAF or blast % 
25246 B-other RB1 normal deletion Low VAF or blast % 
24890 B-other EBF1 normal deletion MLPA probe location 
27754 BCR-ABL1 EBF1 normal deletion MLPA probe location 
29089 BCR-ABL1 EBF1 normal deletion MLPA probe location 
24890 B-other CDKN2A normal deletion MLPA probe location 
25552 B-other ETV6 normal deletion MLPA probe location 
27026* BCR-ABL1 EBF1 normal gain Aneuploidy 
27026* BCR-ABL1 ETV6 normal gain Aneuploidy 
27026* BCR-ABL1 BTG1 normal gain Aneuploidy 
26610† BCR-ABL1 IKZF1 deletion gain Deletion and gain  
27836 BCR-ABL1 CDKN2A deletion normal Uncertain 
27836 BCR-ABL1 CDKN2B deletion normal Uncertain 
Table 4.7. Details of 20 discordant SNP array-MLPA copy number calls. Majority of discrepancies 
were due to a CNA called by SNP array not detected by MLPA. *Case 27026 had BCR-ABL1 and 
significant aneuploidy with 67-73 chromosomes on diagnostic karyotype. †Case 26610 had both 
gain and deletion in IKZF1 on SNP array.  
B-other: BCP-ALL with no primary chromosomal abnormality identified; VAF: variant allele 
frequency 
 
Of the 20 discordant calls, the majority (90%, 18) were related to an abnormality being 
called by SNP array that was not identified by MLPA. Nine calls related to CNAs that 
did not reach the limit of detection for MLPA, although some reduction in the MLPA 
probe ratio could be appreciated in the majority of cases (data not shown). This 
indicated that using the customised Nexus segmentation settings as described above, 
the SNP array appeared to have a higher sensitivity for detecting abnormalities at lower 
variant allele fractions (VAF) – either due to subclonality or admixed non-leukaemic 
DNA – than MLPA. In five cases, the location of the MLPA probes meant the 
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abnormality could not be detected using this method as the CNA did not encompass 
the required minimum of 2 probes. Three of these related to EBF1, which only has 
MLPA probes covering exons 1, 10, 14 and 16 leaving a substantial gap between 
exons 1 and 10.  
SNP array log2 ratio and B-allele frequency traces were carefully examined for all other 
discordant cases, where the discrepancy could not be attributed to large scale ploidy 
shift, and the SNP-array derived call could be confirmed visually in all cases. A single 
case (27836) harboured a CDKN2A and CDKN2B deletion on MLPA, which could not 
be confirmed by SNP array, either visually or through the segmentation algorithm, and 
this discrepancy therefore remains unexplained.  
Overall, the SNP array and MLPA results were concordant in the vast majority of cases. 
The discordant cases were related to a specific cytogenetic subtype (low hypodiploidy), 
where large scale ploidy shift and co-existence of duplicated clones often hamper the 
use of molecular techniques. Where CNAs were detected by SNP array but not by 
MLPA, visual inspection confirmed the SNP array-derived call in all cases, thereby 
validating the customised segmentation settings and most likely permitting the 
detection of potentially subclonal abnormalities. 
 
4.4.4 SureSelect XT2 library prep 
The SureSelect XT2 capture library was designed to cover 30 of the genomic regions 
of interest from the SNP array analysis (partly established from figure 4.12). These had 
been selected to validate as many novel gene deletions as possible in cases with 
remaining diagnostic material. Well-established driver genes were also included as 
internal controls to ensure these could also be adequately detected. In total, the RNA 
bait library was 2.85 MB and encompassed the regions detailed in table 4.8.  
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Cytoband Gene Genomic co-ordinates covering ≥1 breakpoint in all affected cases 
Number of 
cases affected 
7p12.2 IKZF1 chr7:50,343,669 - 50,472,809* 22 
1p21.1 COL11A1 chr1:103,342,013 - 103,574,062* 12 
9p13.2 PAX5 chr9:36,833,262 - 37,034,486* 10 
9q34.12 ABL1 chr9:133,589,258 - 133,763,072* 9 
5q14.3 MEF2C chr5:88,013,965 - 88,199,932* 8 
3q25.1-3q25.2 MBNL1 chr3:151,880,890 - 151,998,320 7 
12p13.2 ETV6 chr12:11,802,778 - 12,048,346* 6 
10q23.31 PTEN chr10:89,622,860 - 89,731,697* 6 
1q31.2 CDC73 chr1:193,071,243 - 193,132,293 5 
17q11.2 NF1 chr17:29,421,935 - 29,709,144* 5 
12q14.3 LEMD3 chr12:65,569,801 - 65,589,942 5 
Xp11.3 KDM6A chrX:44,732,411 - 44,971,867* 4 
5q13.2 NIPBL chr5:36,876,851 - 37,066,525* 4 
11p12 RAG1 chr11:36,532,249 - 36,614,716* 4 
6p22.1 PGBD1 chr6:28,310,000 - 28,333,000 3 
18q11.1 ROCK1 chr18:18,526,785 - 18,708,000 3 
2q22.3 ZEB2 chr2:145,092,000 - 145,180,000 3 
9p24.2 VLDLR chr9:2,230,000 - 2,480,000 3 
18q21.2 TCF4 chr18:52,889,552 - 53,332,028* 3 
2q22.1 CXCR4 chr2:136,860,000 - 136,886,000 2 
12q12 ARID2 chr12:46,110,000 - 46,301,833 2 
13q12.2 FLT3 chr13:28,577,401 - 28,674,739* 2 
13q14.11 DGKH chr13:42,614,162 - 42,830,726* 1 
19p13.3 TCF3 chr19:1,609,279 - 1,652,614* 1 
5q32 CSF1R chr5:149,432,844 - 149,492,945* 0 
1q25.2 ABL2 chr1:179,068,452 - 179,198,829* 0 
Xp22.3/Yp11.2 PAR1 chrX:1,321,616 - 1,397,693* 0 
5q32 PDGFRB chr5:149,493,390 - 149,535,445* 0 
9p24.1 JAK2 chr9:4,985,023 - 5,128,193* 0 
1q22 MEF2D chr1:156,433,503 - 156,470,644* 0 
Table 4.8. Targets for validation using SureSelect XT2 custom target enrichment kit. *Indicates 
whole gene covered. PAR1 refers to the pseudoautosomal region on Xp22.3/Yp11.2, in this case 




In total, 28 patient samples harbouring a combination of these abnormalities, were 
identified.  As detailed in section 4.3.4, 23 of these were successfully put through library 
prep and formed the NGS validation cohort (table 4.9). 
Patient Genetics Gene deletions for validation 
25267 B-other COL11A1 
26614 B-other RAG1, NF1 
28335 B-other N/A 
24890 B-other IKZF1, COL11A1 
25082 BCR-ABL1 NIPBL, CDC73, NF1, MBNL1, PTEN 
25208 BCR-ABL1 ABL1, IKZF1, LEMD3 
25247 BCR-ABL1 IKZF1, COL11A1 
28057 BCR-ABL1 PAX5, IKZF1, NF1, MBNL1 
28182 BCR-ABL1 PGBD1, NIPBL, MEF2C, IKZF1, NF1, MBNL1, PTEN 
28350 BCR-ABL1 ZEB2, VLDLR, RAG1, TCF4, MEF2C, CDC73, MBNL1, PTEN 
28670 BCR-ABL1 CXCR4, PAX5, IKZF1, MBNL1, LEMD3 
26660 BCR-ABL1 NIPBL, MEF2C, IKZF1, NF1, MBNL1, LEMD3, PTEN 
25967 Complex COL11A1 
25437 HoTr ETV6, KDM6A 
29407 HoTr KDM6A 
27833 IGH-BCL2 PAX5 
25130 IGH-CRLF2 CXCR4, RAG1, ETV6, PAX5, IKZF1, LEMD3 
25552 IGH@-r PGBD1, TCF4, ETV6, PAX5, IKZF1, LEMD3, COL11A1 
28581 KMT2A-AFF1 COL11A1 
25100 KMT2A-v PTEN 
27642 T-ALL KDM6A 
24813 Unknown ARID2, CDC73, PTEN 
25451 ZNF384-r COL11A1 
Table 4.9. NGS validation cohort. CNAs for validation in all patient samples successfully put 
through SureSelect XT2 library prep and targeted NGS.  
B-other: BCP-ALL with no primary chromosomal abnormality identified; Complex: 5 or more 
unrelated chromosomal abnormalities on karyotype; HoTr: low hypodiploidy/near triploidy; 




4.4.5 Targeted Next Generation Sequencing overview 
Quality control thresholds were passed for both sequencing runs with the percentage 
of bases ≥Q30 at 92.11% and 92.46% respectively. Sequencing depth of coverage for 
all samples can be found in supplementary table 5. 
An overview of the validation results is shown in figure 4.15. Translocations as well as 
the deletions, could be detected, and are discussed separately in section 4.4.8. 
 
Figure 4.15. Validation of gene deletions and rearrangements. As well as the individual patient 
relevant CNAs detailed in table 4.9, all cases were examined for structural variants in ABL1, 
CSF1R, ABL2, TCF3, PDGFRB and JAK2 as these are known recurrent primary abnormalities in 
ALL.  
PAR1*: Pseudoautosomal region on Xp22.3/Yp11.2; B-other: BCP-ALL with no primary 
chromosomal abnormality identified; HoTr: low hypodiploidy/near triploidy; KMT2A-v: KMT2A 
fusion with any partner; T-cell: T-cell ALL; SV: structural variant. 
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In total, 49% (34/69) deletions were validated. All deletions affecting LEMD3 (n=5), 
PAX5 (n=4), RAG1 (n=3), KDM6A (n=3), PGBD1 (n=2), CXCR4 (n=2) and ETV6 (n=3) 
and 8 of the 9 IKZF1 deletions were validated. In comparison, none of the suspected 
deletions in COL11A1 (n=7), PTEN (n=6), NIPBL (n=3), MEF2C (n=3), CDC73 (n=3), 
ZEB2 (n=1) and ARID2 (n=1) could be validated in this study. 
 
4.4.6 Validated focal deletions by NGS 
4.4.6.1 IKZF1 deletions 
In total, 9 cases included in the NGS validation had IKZF1 deletions by SNP array and 
MLPA (table 4.10).  




exons (NGS) Concordance 
25247 ex. 4-7 ex. 4-7 ex. 4-7 Complete 
24890 ex. 4-7 ex. 4-7 ex. 4-7 Complete 
25130 ex. 2-8 ex. 2-8 ex. 2-8 Complete 
25208 ex. 2-7 ex. 2-8 ex. 2-7 Minor discrp. 
28057 ex. 1-7 ex. 4-7 ex. 4-7 Minor discrp. 
28182 ex. 2-8 ex. 4-7 ex. 4-7 Minor discrp. 
25552 ex. 2-7 ex. 4-7 ex. 4-7 Minor discrp. 
26660 ex. 4-8 ex. 4-8 Not detected Major discrp. 
28670 ex. 2-7 ex. 2-7 Translocation Major discrp. 
Table 4.10. Details of IKZF1 deletions in nine patients assessed by SNP array, MLPA and NGS 
with level of concordance/discrepancy in deletion breakpoints.  
Minor discrp: minor discrepancy between SNP array, MLPA and NGS where deletion detected by 
all methods with some discrepancy in breakpoints; Major discrp: major discrepancy between 
SNP array, MLPA and NGS where deletion missed by one method or different event detected. 
 
In 3/9 cases complete concordance was seen between SNP array, MLPA and NGS.  
A further 3 cases showed minor discrepancies, where the SNP array derived deletion 
breakpoints differed slightly from the MLPA and NGS result (28057, 28182 and 25552). 
This could usually be explained by subtle discrepancies in SNP array segmentation 
either side of the highly repetitive region between exons 3 and 4. In one case (25208), 
there was a very minor discrepancy between the MLPA deletion compared with SNP 
array and NGS (single exon difference), although the reason for this was not clear.  
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In the remaining two cases (26660, 28670), more significant discrepancies were seen. 
One of these (26660) had an IKZF1 deletion identified by SNP array and MLPA, which 
could not be detected in IGV. This sample also had a BCR-ABL1 translocation which 
was not apparent in this NGS validation. Both SNP array and MLPA had yielded clear 
evidence of IKZF1 loss and the bone marrow blast percentage was 84% (data not 
shown), rendering the possibility of discrepancy from low VAF less likely. Other 
considerations include uneven amplification during WGA resulting in under-
representation of the relevant fragments or a sample mislabelling issue although the 
latter is less likely due to the successful confirmation of a LEMD3 deletion in this case 
(figure 4.15). The final case (28670) had a deletion detected by SNP array and MLPA. 
However, in IGV, this abnormality was found to be a more complex unbalanced 
translocation, which could only be detected by an NGS approach (discussed later, 
section 4.4.8.2). 
 
4.4.6.2 LEMD3 deletions 
Focal deletions in LEMD3 on 12q14.3 were discovered in 6% (5/83) of the SNP array 
cohort. After IKZF1, this deletion was the most prevalent CNA in the validation cohort 
and was confirmed in all relevant cases (n=5). Primary chromosomal abnormalities 
were known in 4 of the five patients (table 4.11). Patient 25552 had an IGH@ 
translocation but the partner had not been identified as fixed cells were not available. 
However, CRLF2 is the most common IGH@ rearrangement partner so it is plausible 
this case could also harbour IGH-CRLF2. Another observation was that all five cases 
had IKZF1 deletions. 
Patient ID Sex (M/F) Age (yrs) Genetic subgroup WCC at diagnosis (x109/L) 
25208 M 62 BCR-ABL1 205.4 
25130 F 62 IGH-CRLF2 33.6 
28670 F 61 BCR-ABL1 1.6 
26660 F 62 BCR-ABL1 18.2 
25552 M 61 IGH@ translocation 2.9 
Table 4.11. Clinical and demographic details of cases with LEMD3 deletions. Case 25552 did not 
have material for IGH@ partner testing.  
M: male; F: female; WCC: white cell count 
 
A typical example of a focal LEMD3 deletion is shown in figure 4.16. 
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Figure 4.16.: Example focal LEMD3 deletion as visualised in Nexus (patient 26660). Clear focal 
decrease in log2 ratio accompanied by loss of heterozygous AB alleles can be seen. 
 
The deletion breakpoints matched very closely between SNP array and NGS, when 




Figure 4.17. Example proximal deletion breakpoint in IGV (patient 25208) demonstrating reads 
with mate pairs mapping 21 kb away, consistent with ~21 kb deletion in LEMD3. 
 
Patient ID Deleted segment Size of deletion (bp) Deleted exons 
25208 chr12:65,579,942-65,602,114 22,172 None 
25130 chr12:65,579,942-65,597,922 17,980 None 
28670 chr12:65,579,942-65,591,462 11,520 None 
26660 chr12:65,579,942-65,608,678 28,736 ex. 2 
25552 chr12:65,579,801-65,611,980 32,179 ex. 2-3 
Table 4.12. Details of all LEMD3 deletions in SNP array cohort, demonstrating highly consistent 
proximal breakpoint within intron 2.  
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The LEMD3 deletions were focal intragenic events, ranging from 11-32 kb in size, and 
had highly consistent proximal breakpoints in intron 2. In three cases, the deletion was 
restricted to intron 2 and in the other two cases, at least one exon was also involved 
(table 4.12). Although the consequence of these particular intronic deletions cannot be 
predicted, copy number variation outside coding regions has been shown to impact 
splicing and gene expression (Rigau et al., 2019).  
 
4.4.6.3 RAG1 deletions 
Focal deletions affecting RAG1 on 11p12 were identified in 5% (4/83) of cases by SNP 
array. These were successfully validated in the three cases included in the NGS cohort 
(25130, 26614 and 28350).  
Affected patients had primary chromosomal abnormalities as detailed in table 4.13. No 
fixed cells were available for patient 26614 for screening of B-other gene 
rearrangements so these abnormalities could not be excluded.  
Patient ID Sex (M/F) Age (yrs) Genetic subgroup WCC at diagnosis (x109/L) 
25130 F 62 IGH-CRLF2 33.6 
26614 M 75 B-other 8 
27754 F 63 BCR-ABL1 93.1 
28350 F 62 BCR-ABL1 11.4 
Table 4.13. Demographic and clinical details of cases with focal RAG1 deletions.  
M: male; F: female; WCC: white cell count; B-other: BCP-ALL with no primary chromosomal 
abnormality detected. 
 
The focal RAG1 deletions ranged from 14-56 kb and always affected exon 2. Three of 
the deletions also included the entirety of RAG2 and the first 2 exons of C11orf74 




Figure 4.18. Approximate deletion breakpoints in RAG1 and neighbouring genes in all four cases 
containing RAG1 deletion by SNP array (25130, 26614, 27754 and 28350).  
 
Patient ID Deleted segment Size of deletion (bp) Genes affected 
25130 chr11:36,590,053-36,642,721 52,668 RAG1, RAG2, C11orf74 
26614 chr11:36,598,277-36,613,167 14,890 RAG1 
27754 chr11:36,598,795-36,642,721 43,926 RAG1, RAG2, C11orf74 
28350 chr11:36,599,564-36,656,180 56,616 RAG1, RAG2, C11orf74 
Table 4.14. Details of deleted segments affecting RAG1 and neighbouring genes. 
 
4.4.6.4 KDM6A deletions 
In total focal deletions involving KDM6A on Xp11.3 were discovered in 5% (4/83) of 
cases in the SNP array cohort. These were successfully validated in the three patients 
included in the NGS cohort (29407, 25437 and 27642). All events were focal intragenic 
deletions ranging from 56-316 kb in size.  
Patient ID Sex (M/F) Age (yrs) Genetic subgroup WCC at diagnosis (x109/L) 
28011 M 61 B-other 3.5 
29407 F 60 HoTr 2.9 
25437 F 64 HoTr 1.4 
27642 F 72 T-ALL Not known 
Table 4.15. Demographic and clinical details of cases with focal KDM6A deletions.  
M: male; F: female; WCC: white cell count; B-other: BCP-ALL with no primary chromosomal 
abnormality detected; HoTr: low hypodiploidy/near triploidy. 
 
Two of the four patients had underlying low hypodiploid/near triploid ALL, and the white 
cell counts at diagnosis were noted to be low, although this is associated with the HoTr 
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phenotype. Three of the four patients had deletions affecting either both or their only 
KDM6A alleles (table 4.16). 





28011 chrX:44,810,083-44,867,059 56,967 Hemizygous ex. 3-4 
29407 chrX:44,778,209-44,905,069 126,860 Homozygous ex. 3-8 
25437 chrX:44,775,342-44,885,557 110,215 Homozygous ex. 3-6 
27642 chrX:44,860,967-45,176,870 315,903 Heterozygous ex. 5-29 
Table 4.16. Details of deleted segments affecting KDM6A. SNP array from 29407 had 
heterozygous loss of chromosome X and focal homozygous deletion in KDM6A. SNP array from 
25437 had a nested biallelic deletion in KDM6A with retained disomic complement of X 
chromosomes.  
 
The affected male patient had a deletion affecting the only KDM6A allele as KDM6A is 
present on the X-chromosome. Interestingly, biallelic KDM6A deletions were seen in 
the two female patients with low hypodiploid ALL, albeit by two different mechanisms. 
By cytogenetics and SNP array, patient 29407’s leukaemic blasts had lost one copy of 
chromosome X. SNP array and NGS confirmed the remaining homologue had a focal 
deletion within KDM6A. In comparison, in patient 25437, both copies of chromosome 
X had focal but subtly distinct intragenic KDM6A microdeletions (figure 4.19).  
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Figure 4.19. Homozygous KDM6A deletion in case 25437, demonstrating two slightly distinct 
KDM6A deletions measuring 110kb and 87kb respectively and resulting in biallelic loss of exons 
3-6. Small gain noted following segment of homozygous deletion. Both deletions were validated 
by NGS in IGV. 
 
4.4.6.5 6p22.1 deletions 
Deletions encompassing three genes on 6p22.1 – PGBD1, ZSCAN31 and ZKSCAN3 
– were identified in 2% (2/83) of the SNP array cohort and were both validated by NGS. 
Further details of affected patients are shown in table 4.17.   
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Patient ID Sex (M/F) Age (yrs) Genetic subgroup WCC at diagnosis (x109/L) 
25552 M 61 IGH@-r 2.9 
28182 F 60 BCR-ABL1 118.3 
Table 4.17. Clinical and demographic details of cases with focal deletions on 6p22.1.  
M: male; F: female; WCC: white cell count; IGH@-r: IGH@ rearrangement. 
 
Interestingly, the deletions had identical breakpoints by SNP array (table 4.18). A 
common feature in both cases was also the presence of 1q gain. 
Patient 





25552 chr6:28,246,968-28,323,426 76,459 PGBD1, ZSCAN31, ZKSCAN3 
28182 chr6:28,246,968-28,323,426 76,459 PGBD1, ZSCAN31, ZKSCAN3 
Table 4.18. Details of deleted 6p22.1 segments and affected genes 
 
4.4.6.6 CXCR4 deletions 
Deletions affecting CXCR4 on 2q22.1 were seen in 2% (2/83) of the SNP array cohort 
and were confirmed by NGS in both patients. Further details of affected patients are 
shown in table 4.19.  
Patient ID Sex (M/F) Age (yrs) Genetic subgroup WCC at diagnosis (x109/L) 
28670 F 61 BCR-ABL1 1.6 
25130 F 62 IGH-CRLF2 33.6 
Table 4.19. Demographic and clinical details of cases with focal CXCR4 deletion.  
M: male; F: female; WCC: white cell count. 
 
Both deletions had very similar breakpoints (table 4.20), resulting in loss of exon 1 of 
the gene only, with no other neighbouring genes affected. 
Patient ID Deleted segment Size of deletion (bp) Deleted exons 
28670 chr2:136,874,225-137,067,525 193,301 ex. 1 
25130 chr2:136,874,992-137,067,525 192,534 ex. 1 
Table 4.20. Details of CXCR4 deletions from SNP array data, validated by NGS in IGV. 
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4.4.6.7 Deletions that were not validated 
None of the COL11A1 (n=7), PTEN (n=6), NIPBL (n=3), MEF2C (n=3), CDC73 (n=3), 
ZEB2 (n=1) or ARID2 (n=1) deletions were validated by the targeted NGS analysis. 
Although these genes were included in the validation experiment due to their biological 
significance in malignancy (e.g. PTEN) or their high frequency of suspected copy 
number change in the SNP array cohort (e.g. COL11A1), the deleted segments were 
ambiguous by standard visual analysis of the relevant SNP arrays. Similarly, 1/2 TCF4, 
1/5 NF1 and 1/6 MBNL1 deletions were confirmed by NGS. As with the other 
unvalidated CNAs, these were very equivocal findings on visual assessment of the 
relevant SNP arrays so were therefore likely to represent false positive calls.  
 
4.4.7 Complete cohort copy number profile 
The summary copy number profile of the complete cohort is outlined in figure 4.20. Any 
deletions included in the NGS experiment that could not be validated have been 





































































































































































































Paired end sequencing also permits the discovery of chromosomal translocations 
when reads cover at least one of the translocation breakpoints. Mate pairs would 
usually be expected to map to genomic regions as far apart as the insert size (~1 kb in 
this experiment). However, when they map to regions on different chromosomes, a 
chromosomal translocation is suspected, and can be confirmed when significant 
concordance is seen in multiple reads.  
 
4.4.8.1 ABL1 translocations 
Consistent with their primary genetic abnormality, clear breakpoints in ABL1 were 
identified in 7/8 of the BCR-ABL1+ cases. Mate pairs mapped to BCR thereby 
confirming the BCR-ABL1 translocation. However, translocation breakpoints could not 
be identified in either ABL1 or BCR in case 26660, although the reasons for this are 
not clear (discussed in section 4.4.6.1). Approximate breakpoints for all the other BCR-
ABL1 cases are shown in figure 4.21.  
 
Figure 4.21. Approximate ABL1 and BCR breakpoints in 7/8 BCR-ABL1+ cases. Each coloured 
line represents breakpoint in ABL1 and BCR for a specific case. Numbers represent individual 
exons.  
 
The BCR breakpoints were clustered in two regions, specifically intron 1 in four cases 
(25082, 28182, 28350, 28670) and intron 14 in three cases (25208, 25247, 28057). 
These are consistent with the minor (p190) and major (p210) breakpoint cluster regions 
respectively. ABL1 breakpoints were found between exons 1b and 1a (cases 25082, 
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25208, 28057, 28670) and 1a and 2 (25247, 28182, 28350), similar to previous studies 
(Score et al., 2010).  
 
4.4.8.2 IKZF1 translocation 
An unusual IKZF1 gene rearrangement was identified in the sample from patient 
28670. The SNP array demonstrated a deletion affecting the majority of IKZF1. 
However, the telomeric portion of the gene seemed to harbour a homozygous deletion 
whereas the centromeric portion showed a more typical pattern of heterozygous loss 
(figure 4.22A). When analysed in IGV, several breakpoints were seen in IKZF1 
suggestive of a more complex structural variant, involving a pericentromeric region on 




Figure 4.22. (A) SNP array demonstrating IKZF1 deletion, which appears homozygous in 
telomeric and heterozygous in centromeric portion of gene. (B) IKZF1 breakpoints identified in 
IGV, and mapping of mate pairs to pericentromeric region of chromosome 2 (red and green), 
together with additional breakpoints where mate pairs could not be mapped (blue). Findings are 
consistent with a complex rearrangement of IKZF1. 
 
4.4.8.3 Translocation t(5;9)(q21.3;p24.2) 
A translocation was also identified in patient 28350. Recurrent focal deletions had been 
noted between two genes on 9p24 – VLDLR and SMARCA2 (figure 4.23) – and the 
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common breakpoint region was therefore included in the custom-designed SureSelect 
XT2 kit.  
 
 
Figure 4.23. Deletion between SMARCA2 and VLDLR (case 28350). In total, focal deletions in this 
region were seen in 4/83 cases by SNP array. 
 
In the only case harbouring the event that could be included in the library prep (28350), 
the deletion was found to be part of an unbalanced translocation. However, no 
breakpoints were identified within genes so the consequences of this abnormality 
remain uncertain. SMARCA2 is a member of the SWI/SNF chromatin remodelling 
complex, which is deregulated in a number of sold organ malignancies. SMARCA2 
mutations have been identified in several cases of AML with monosomy 7 (Eisfeld et 
al., 2017) and a translocation involving SMARCA2, resulting in a fusion gene, has been 




Figure 4.24. Approximate breakpoints (red lines) and neighbouring genes of t(5;9)(q21.3;p24.2) 
translocation in patient 28350. Genes closest to breakpoints were SMARCA2 (~50kb from 9p24.2 
breakpoint) and PJA2 (~60kb from 5q21.3 breakpoint) on chromosomes 9 and 5 respectively. As 
the breakpoints were not in known genes or regulatory regions, the consequences of this 
abnormality could not be predicted. 
 
4.5 Discussion 
This study involved an in-depth copy number analysis of ALL genomes in 83 older 
adults, constituting one of the largest genomic analyses of ALL patients in this age 
group to date. Using carefully tailored SNP array segmentation settings in Nexus, 
consistent and biologically plausible results were seen across the cohort. A delicate 
balance needed to be achieved between the discovery of subtle and potentially novel 
abnormalities and minimising false positive calls. An initial validation between SNP 
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array and MLPA-derived CNAs in 8 genes confirmed the accuracy of the segmentation 
settings with 94% concordance between the two techniques. Discordant results were 
related to increased sensitivity of the customised SNP array segmentation to identify 
subclonal CNAs, suggesting that this achieved detection below 20% clonality, which is 
the limit of MLPA (Schwab et al., 2010). 
Based on the validated SNP array segmentation and using the filtering steps described 
to exclude germline variants and minimise false positives, a mean of 10.1 deletions 
(range 1-51) and 3.1 gain (range 0-29) were seen per patient sample. These findings 
are similar to other copy number studies in adult ALL (Ribera et al., 2017) and slightly 
higher than those from childhood ALL cohorts (mean 6-8 CNAs per patient), although 
many of the latter were performed using older, lower density arrays making such 
comparisons difficult (Mullighan et al., 2007, Mullighan et al., 2009b).  
CNAs were separated into arm/chromosome-level events and focal abnormalities. Of 
the former, deletions of 9p were the most frequent abnormality, seen in over 20% of 
cases. Monosomy 7, 7p deletion and 1q gain were also recurrent events, present in at 
least 10% of non-low hypodiploid cases. Focal abnormalities were considered 
separately, and analysis was focussed in identifying candidate “driver” genes. 
 
4.5.1 Deletions in established driver genes 
Recurrent deletions impacting known driver genes were identified affecting IKZF1 in 
52%, CDKN2A/B in 45%, PAX5 in 39%, RB1 in 22%, ETV6 in 21%, EBF1 in 19% and 
BTG1 in 12% of patient samples. No PAR1 deletions, resulting in P2RY8-CRLF2 
fusion were seen, despite one patient having the abnormality detected by FISH (patient 
25246). FISH testing had identified <25% rearranged cells in the sample, so this may 
have evaded detection by SNP array in this case. Overall, the frequency of deletions 
affecting many of these genes is higher than that observed in childhood and younger 
adult cohorts (table 4.21). It is noteworthy however, that ERG deletions were 
completely absent in this study. These are present in 3-4% of childhood BCP-ALL 
patients and are associated with an excellent prognosis, despite frequent co-existing 
IKZF1 deletions (Clappier et al., 2014). 
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Age group IKZF1 CDKN2A/CDKN2B PAX5 RB1 ETV6 EBF1 BTG1 PAR1 
Older adults1 52% 45% 39% 22% 21% 19% 12% 0% 
Young adults2 39% 37% 22% 7% 8% 3% 11% 1% 
Paediatric3 14% 28% 19% 6% 22% 2% 6% 4% 
Table 4.21. Comparison of specific deletions in established genes/regions in ALL patients in 3 
age cohorts. 1This study. 2Analysis of 653 adults <65 years (Moorman et al., 2019). 3Analysis of 
1427 children with BCP-ALL (Schwab et al., 2013). 
 
The high frequency of IKZF1 deletions in this study is partly explained by the high 
proportion of BCR-ABL1+ patients. However, even when these are excluded, IKZF1 
deletions were still seen in 40% (20/50) of cases. Additionally, when low hypodiploid 
cases (n=9), which all had IKZF1 deletions by default (due to monosomy 7), were also 
omitted, the findings still suggested double the IKZF1 deletion rate compared to 
childhood cohorts (27% vs 14%). 
IKZF1, CKDN2A, CDKN2B and PAX5 deletions were the most frequent events in this 
cohort of 83 older adults. These genes are of particular interest due to their role in 
informing prognosis, as defined by the IKZF1plus profile. This is based on the presence 
of IKZF1 deletion co-occurring with deletions in CKDN2A, CDKN2B, PAX5, or PAR1, 
in the absence of an ERG deletion, and has been associated with a reduced event free 
survival of just 53% in paediatric ALL (Stanulla et al., 2018). This high-risk copy number 
profile, validated in childhood ALL, was identified in 36% (29/81) of the BCP-ALL 
samples in this cohort, compared with just 6% of paediatric cases in the original study. 
The IKZF1plus profile correlated with primary cytogenetic abnormalities and was seen 
in BCR-ABL1+ (n=14), B-other (n=8) and low hypodiploid (n=7) patients. 
To facilitate the detection of potentially novel abnormalities, genes at the breakpoints 
of all focal deletion segments were specifically scrutinised. This was based on the 
observation that “driver” CNAs are usually as small as is required to produce the 
survival benefit or transformative properties to the leukaemic cells, with the important 
exclusion of arm-level or whole chromosomal events. Hence, CNA breakpoints are 
recurrently observed within “driver” genes. This method appropriately captured the 
most common focal abnormalities (IKZF1, CDKN2A/B, PAX5 deletions, etc), together 
with a number of potentially novel lesions, worthy of further investigation.  
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4.5.2 LEMD3 deletions 
LEMD3 deletions were recurrently observed, being present in 6% (5/83) of patient 
samples as a focal intragenic event, and subsequently validated by targeted NGS.  
LEMD3 is a protein coding gene located on 12q14.3, containing 13 exons and 
measuring 79 kb. The gene encodes a nuclear envelope protein that regulates the 
bone morphogenic protein (BMP) and transforming growth factor β (TGF-β) pathways. 
TGF beta superfamily ligands, including BMPs, activate Smad proteins. These enter 
the nucleus and regulate gene transcription (figure 4.25). Activation of TGF-β signalling 
can produce both oncogenic and tumour suppressor activity in different circumstances 
and the pathway is known to be deregulated in a number of malignancies (Ikushima 
and Miyazono, 2010). Although pathogenic LEMD3 mutations are the hallmark of 
Buschke-Ollendorff syndrome, a rare connective tissue disorder (Hellemans et al., 
2004), a significant role in cancer has, to date, not been reported. The significance of 
these deletions therefore remains uncertain, particularly as 3/5 events did not include 
exons. However, interestingly, infrequent LEMD3 mutations were identified in 
childhood BCP-ALL cases in a large pan-cancer analysis of paediatric tumours (Ma et 
al., 2018). A focal LEMD3 deletion, present at both diagnosis and relapse, was also 
identified in a single patient in a study of 61 paediatric patients with relapsed ALL 
(Mullighan et al., 2008b).   
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Figure 4.25. Role of LEMD3 (MAN1) in regulation of TGF-β and BMP signalling pathways. LEMD3 
is a nuclear envelope protein, that downregulates transcription of TGF-β and BMP target genes. 
TGF-β: transforming growth factor beta; BMP: bone morphogenic protein. 
 
In solid organ malignancies, opposing effects of increased TGF-β signalling are 
described depending on the stage of the disease. In early stages, TGF-β has a tumour 
suppressive effect by inhibiting cell cycle progression and proliferation, whereas in late 
stages, tumour promoting effects have been shown, by promoting tumour invasiveness 
and metastasis (Syed, 2016). TGF-β signalling also plays a role in normal 
haematopoiesis and haematological malignancies. Regulation of normal 
haematopoiesis is reliant of TGF-β signalling as an anti-proliferative and differentiation 
signal for haematopoietic progenitors, preventing cell cycle entry. Certain disease 
specific oncoproteins, such as RUNX1-ETO and PML-RARA in AML with t(8;21) and 
acute promyelocytic leukaemia (APL) respectively, produce anti-apoptotic effects and 
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cell cycle entry by repressing SMAD proteins and thereby reducing TGF-β signalling 
(Dong and Blobe, 2006). In these contexts, the TGF-β pathway appears to play a role 
in tumour suppressor function, with a disease-related reduction in TGF-β signalling 
producing the observed anti-apoptotic leukaemic properties. In comparison, loss of 
function genomic LEMD3 abnormalities would be predicted to induce TGF-β signalling 
as LEMD3 acts as a negative regulator of transcription of TGF-β target genes. 
Interestingly, certain haematological malignancies, specifically those associated with 
reactive bone marrow fibrosis (e.g. hairy cell leukaemia) have shown increased TGF-
β signalling, which is postulated to be the cause of the fibrotic reaction (Shehata et al., 
2004). At presentation, ALL may also be associated with reactive bone marrow fibrosis 
and although this could plausibly be induced by increased TGF-β signalling through 
LEMD3 loss of function aberrations, the frequency of reactive fibrosis in ALL (up to 
70% in childhood ALL) is far higher than the LEMD3 abnormalities described (Wallis 
and Reid, 1989). As TGF-β signalling has a complex role in malignancy, including both 
pro- and anti-apoptotic properties, further work will be required to determine the 
consequences, if any, of the focal LEMD3 deletions. 
 
4.5.3 KDM6A deletions 
KDM6A deletions were present in 5% (4/83) of the cohort and were biallelic events in 
50% of affected cases. KDM6A (also known as UTX) plays a key role in epigenetic 
regulation. In eukaryotic cells, DNA is organised into nucleosomes, each of which 
comprises 147bp of DNA wound around an octamer of histone proteins. The N-
terminal tails of the histone proteins can be subjected to post-translational modification, 
which then influences transcriptional regulation. This tightly regulated process can 
produce an effect on cell proliferation, survival and apoptosis. KDM6A encodes a 
histone H3 lysine 27 (H3K27) demethylase enzyme and a component of the mixed 
lineage leukaemia (MLL) 2/3 complexes that promote histone 3 lysine 4 (H3K4) 
methylation (Lee et al., 2007). H3K27 methylation correlates with genome silencing 
and repression of transcription, therefore, through H3K27 demethylation, KDM6A 
facilitates a transcription permissive chromatin state. H3K4 methylation is also a mark 
of open and actively transcribed chromatin (van Haaften et al., 2009, Ler et al., 2017). 
Through these functions, KDM6A antagonises EZH2/polycomb repressive complex-2 
(PRC2) activity, which acts as an H3K27 methyltransferase and represses 
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transcription of its target genes. Inactivating KDM6A mutations therefore result in 
increased EZH2/PRC2 activity, and a sustained repression of the EZH2/PRC2 
regulated genes. This aberrant EZH2 over-expression has been identified in a number 
of tumours and has been linked to increased tumour growth and metastatic potential 
(Gan et al., 2018).  
KDM6A is located on Xp11.3 and is one of only a few genes that escape X inactivation 
in females (Dunford et al., 2017). To preserve physiological gene dosage, female 
eukaryotic cells inactivate one copy of their X chromosomes. However, a small number 
of tumour suppressor genes, including KDM6A, escape this inactivation and have been 
termed “escape from X-inactivation tumour suppressors” (EXITS). Hence, KDM6A has 
been described as a gender-specific tumour suppressor gene, whereby males, being 
hemizygous for KDM6A, can experience complete loss of KDM6A tumour suppressor 
function through abnormalities affecting the only allele. In comparison, females are 
relatively protected as biallelic inactivation is required (Greif et al., 2018). Indeed, this 
observation has been made in T-ALL patients whereby KDM6A mutations were 
exclusively observed in male patients and postulated to partly explain the male 
prevalence of this subtype (Van der Meulen et al., 2015). 
KDM6A mutations have been identified in several tumour types, including up to 10% 
of myeloma cases (van Haaften et al., 2009). Inactivating KDM6A mutations have been 
reported, albeit infrequently in ALL (Li et al., 2018, Xiao et al., 2016, Mar et al., 2012). 
Additionally, these alterations appear to confer a survival advantage to leukaemic cells 
in AML, and have been specifically associated with mechanisms of cytarabine 
resistance (Greif et al., 2018, Stief et al., 2020), and a similar enrichment in relapsed 
disease has also been observed in ALL (Mar et al., 2014). To date, focal somatic 
CNAs, rather than sequence mutations, have only been described in very occasional 
ALL patients, specifically adults with relapsed disease (Ribera et al., 2017). In 
comparison, KDM6A is the second most frequently mutated gene in urothelial bladder 
cancer and studies have focussed on exploiting this therapeutically (Ler et al., 2017). 
As KDM6A inactivation produces uncontrolled EZH2 overexpression, inhibition of 
EZH2 has provided an indirect therapeutic target, which has been shown to reduce 
tumour size in KDM6A-mutated mouse and cell line models of urothelial bladder 
cancer. This could also provide a conceivable therapeutic avenue in KDM6A-deleted 
ALL patients and would be particularly valuable as half the affected cases had low 
hypodiploidy, representing a very high-risk subgroup with extremely poor prognosis. 
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4.5.4 RAG1 deletions 
RAG1 deletions were identified in 5% (4/83) of all cases, and were validated in all three 
cases included in the NGS cohort. 
RAG1 is located on 11p12 and encodes the catalytic component of the RAG1/2 
recombinase complex, which mediates DNA cleavage during immunoglobulin V(D)J 
recombination. The RAG complex preferentially binds to highly conserved 
recombination signal sequences (RSS), which lie adjacent to the V, D and J 
sequences, where RAG1 catalyses a double strand DNA break in the first stage of 
V(D)J recombination (Schatz and Ji, 2011). Specifically, RAG endonucleases bind 
DNA at RSS sites, which consist of a highly conserved heptamer (CACAGTG) followed 
by a 12bp or 23bp spacer sequence and a less well conserved nonamer 
(ACAAAAACC). Aberrant RAG activity has been identified as the key mechanism of 
focal deletions, including IKZF1,  in ETV6-RUNX1 ALL, whereby RSS-like sequences 
can be detected at deletion breakpoints (Papaemmanuil et al., 2014). RAG1/2 
deletions are described in BCP-ALL (Lilljebjörn et al., 2010, Mullighan et al., 2008b), 
and have been found to arise through this aberrant activity in the RAG endonucleases 
themselves (Papaemmanuil et al., 2014). Unlike other recurrent deletions, their 
consequences and prognostic impact are less well defined. Mouse models have shown 
that loss of both CDKN2A and RAG1 results in a higher rate of transformation to BCP-
ALL than when either gene is knocked down alone, indicating a potential 
leukaemogenic effect, although further data are lacking (Hauer et al., 2011).  
 
4.5.5 CXCR4 deletions 
CXCR4 is a small 3.8 kb gene located at 2q22.1 encoding a chemokine receptor that 
is expressed on the surface of haematopoietic stem cells. CXCR4 is specific for stromal 
cell-derived factor-1 (CXCL12/SDF-1), which is secreted by bone marrow stromal cells. 
This interaction retains the CXCR4 expressing cells in the bone marrow 
microenvironment. CXCR4 is also expressed to varying degrees on leukaemic blasts 
and high levels of CXCR4 expression have been shown to negatively impact treatment 
outcomes in both AML and ALL (Spoo et al., 2006, van den Berk et al., 2014) through 
a mechanism described as cell adhesion-mediated drug resistance (Damiano et al., 
1999). Conversely, mouse models pharmacologically blocking CXCR4 expression, 
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thereby releasing leukaemic cells from the bone marrow niche, have demonstrated 
increased mobilisation of ALL blasts into peripheral blood (Welschinger et al., 2013) 
and associated increased chemo-responsiveness (Randhawa et al., 2016).  
Germline mutations in CXCR4 are recognised and produce an immunodeficiency 
syndrome – warts, hypogammaglobulinaemia, infections and myelokathesis (WHIM) 
syndrome – resulting from truncating gain of function mutations, which retain 
neutrophils in the bone marrow (Hernandez et al., 2003). Similar activating somatic 
mutations are observed in 25% of patients with Waldenstrom’s macroglobulinaemia, a 
low grade lymphoproliferative disorder, and are associated with more aggressive 
disease (Treon et al., 2014).  
Interestingly, focal CXCR4 deletions are not described and hence represent a novel 
finding in ALL. Although most gene deletions result in reduced or absent protein 
functionality, the impact of these partial CXCR4 deletions remains uncertain, 
particularly in the context of numerous gain of function mutations from truncation of the 
CXCR4 C-terminal (Poulain et al., 2016). In this study, the CXCR4 deletions did not 
appear to have a consistent impact on the peripheral blood blast count at presentation 
(table 4.19), although the number of affected patients was very small (n=2). 
 
4.5.6 6p22.1 deletions 
Small 76kb deletions were identified in 2/83 patients, and encompassed 3 genes – 
PGBD1, ZSCAN31 and ZKSCAN3. PGBD1 is expressed in brain tissue although its 
function is not known. ZSCAN31 and ZKSCAN3 encode zinc finger transcription 
factors. ZKSCAN3 has been found to modulate Cyclin D2 expression in a myeloma 
cell line model (Yang et al., 2011). However, the gene was usually over-expressed 
through copy number gains rather than deleted. ZKSCAN3 had additionally been 
identified as a master regulator of autophagy (Chauhan et al., 2013). Autophagy is a 
cellular process, through which damaged or defective cellular components are 
eliminated or recycled by lysosomes (Saftig and Klumperman, 2009). ZKSCAN3 
encodes a protein that functions as a repressor of autophagy and lysosome biogenesis 
and silencing of the gene has been shown to induce these processes (Chauhan et al., 
2013). Overall, these three genes did not have a convincing biological role in ALL and 
were only present in a very small number of patients. 
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4.5.7 Conclusion 
Copy number abnormalities were highly prevalent in older adults with ALL. Deletions 
affecting established recurrent driver genes were more frequent in older adults than in 
both younger adult and paediatric patients, with the notable exception of ERG and 
ETV6 deletions, the latter being particularly strongly associated with ETV6-RUNX1 
fusion. Of the novel abnormalities, KDM6A deletions were the most biologically 
interesting and potentially therapeutically actionable discovery. Importantly, these 
were noted in patients with high risk disease, who are likely to derive the most benefit 
from novel treatment approaches and further screening and functional analysis of 
these lesions would be warranted. 
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Chapter 5. SNP array profiling of low 




In BCP-ALL, large non-random ploidy shifts define distinct primary genetic entities, 
such as high hyperdiploidy (51-67 chromosomes), near-haploidy (23-29 
chromosomes) and low hypodiploidy (30-39 chromosomes) of the leukemic cells. High 
hyperdiploid clones typically have trisomies of chromosomes 4, 6, 10, 14, 17, 18, X 
and tetrasomy 21 (Heerema et al., 2007, Paulsson and Johansson, 2009, Paulsson et 
al., 2010). In low hypodiploidy, chromosomes, 3, 7, 15, 16, 17 are usually lost with the 
sex chromosomes (X and Y) and chromosome 21 always retained (Harrison et al., 
2004). Low hypodiploid cells often additionally undergo chromosomal endo-
reduplication without subsequent cytokinesis creating leukemic blasts with a near 
triploid karyotype of 60-78 chromosomes (Charrin et al., 2004, Safavi and Paulsson, 
2017). This “doubling-up” phenomenon has been described in 40-65% of low 
hypodiploid patients and is also seen in 65% of near-haploid patients (Safavi and 
Paulsson, 2017, Charrin et al., 2004, Harrison et al., 2004, Pui et al., 2019). Low 
hypodiploidy is present in <1% childhood ALL and 3-4% of adult ALL overall; but 
increases in frequency with age and has been reported in >10% of patients over 60 
years (see chapter 3) (Safavi and Paulsson, 2017, Moorman et al., 2010). Patients 
with low hypodiploidy have a very poor outcome compared to their age-matched 
counterparts: 5-year overall survival 0-20% in adults (Moorman et al., 2007, Safavi and 
Paulsson, 2017) and 35-50% in children (Safavi and Paulsson, 2017, Nachman et al., 
2007, Pui et al., 2019). In comparison, high hyperdiploidy is the commonest genetic 
subtype of childhood BCP-ALL, seen in up to 35% of new diagnoses and was one of 
the first subgroups to be associated with a favourable prognosis (Lampert, 1967, 
Secker-Walker et al., 1978). With the use of modern protocols, childhood high 
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hyperdiploid ALL is now associated with an excellent 5 year overall survival >90% 
(Paulsson and Johansson, 2009). High hyperdiploidy is rarer in adults (5-10%) and 
while it appears to have a favourable outcome, the evidence is less robust with 5-year 
overall survival rates ranging from 33-88% (Brandwein et al., 2014, Pullarkat et al., 
2008, Issa et al., 2017, Chilton et al., 2013).  
Ninety percent of low hypodiploid ALL cases are additionally and very specifically 
associated with pathogenic TP53 mutations (Holmfeldt et al., 2013, Mühlbacher et al., 
2014). In childhood cohorts, almost half of such patients have also been shown to 
harbour these mutations in non-leukemic cells and childhood low hypodiploid ALL is 
therefore considered a manifestation of the Li Fraumeni Syndrome (Malkin, 2011). 
Adult patients with low hypodiploid ALL also exhibit a high frequency of TP53 
mutations, although these appear to be somatic in the majority of cases (Mühlbacher 
et al., 2014).  
The accurate and timely detection of low hypodiploidy at the diagnosis of ALL is critical 
for the optimal management of patients. However, the large-scale chromosomal loss 
and the “doubling up” phenomenon pose significant diagnostic challenges. Although 
the pattern of chromosomal loss is non-random, significant variation is observed 
between patients, and the working definition of low hypodiploidy, and indeed high 
hyperdiploidy, is based on modal chromosome number rather than the loss of specific 
chromosomes. Thus, genome-wide techniques, such as cytogenetics and single 
nucleotide polymorphism (SNP) arrays, are preferred to focal testing, such as 
fluorescence in situ hybridisation (FISH). In cases where the near-triploid sub-clone is 
larger than the low hypodiploid clone, cytogenetic analysis frequently only detects the 
near-triploid sub-clone, which is referred to as “masked low hypodiploidy”. Importantly, 
the near-triploid clone, which will have between 60 and 78 chromosomes, can be 
mistaken for a high hyperdiploid clone due to the overlap in modal chromosome 
numbers between the subgroups, potentially resulting in a drastic impact on risk 
stratification and treatment protocol allocation (Carroll et al., 2019, Charrin et al., 2004). 
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5.2 Aims and objectives 
Although the genetic subtypes of ALL characterised by large scale ploidy shifts are 
defined cytogenetically, in large part using the modal number of chromosomes in the 
leukaemic cells, SNP arrays provide complementary information, such as variation in 
copy number state and loss of heterozygosity, which help categorise ploidy subgroups. 
This chapter will focus on examining the use of SNP arrays in the accurate diagnosis 
of low hypodiploidy and high hyperdiploidy in ALL by addressing the following aims. 
1. Defining the cytogenetic abnormalities in a cohort of adults and children with 
low hypodiploidy (including masked cases), and high hyperdiploidy. 
2. Analysing SNP arrays on a large cohort of patients to identify discrepancies 
between the cytogenetics-derived and SNP-array derived subgroup. 
3. Using TP53 sequencing to resolve discrepant cases. 
4. Using hierarchical clustering and machine-learning techniques to develop a 
diagnostic classifier to accurately determine the ploidy subgroup using SNP 
array data in the absence of cytogenetics. 
 
5.3 Methods 
5.3.1 Patients and samples 
The Leukaemia Research Cytogenetics Group (LRCG) database was first searched 
for all adults over 60 years of age at diagnosis enrolled in the UKALL14 and UKALL60+ 
trials. All patients who had been assigned a genetic subgroup of low hypodiploidy/near 
triploidy (HoTr) were then identified and SNP arrays were performed on all those with 
available DNA from diagnostic bone marrow samples. To create a comparison cohort 
of high hyperdiploid ALL samples, younger adult and paediatric ALL samples were also 
included due to the rarity of this subtype in older patients. A small number of younger 
patients with HoTr were also entered to optimise the size of the cohort. 
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5.3.2 SNP array analysis 
Raw IDAT and CEL files were loaded onto Nexus as described previously (chapter 2 
sections 2.6.1.4 – 2.6.1.5). Visual SNP array analysis was limited to the documentation 
of patterns consistent with specific ploidy groups by focussing on whole chromosomes 
rather than more focal abnormalities. Identifying loss of heterozygosity in multiple 
chromosomes at the lower copy number state (i.e. the lower log2 ratio) (hereafter 
termed LOH-LCN pattern) was considered consistent with HoTr. This pattern arises 
through an initial step of chromosomal loss (producing LOH and reduced log2 ratio). 
Even if the chromosomal complement then undergoes endoreduplication, 
chromosomes exhibiting LOH still have a lower log2 ratio than those with preserved 
heterozygosity. In comparison, a pattern of retained heterozygous SNPs in 
chromosomes at the lower copy state, combined with additional maternal and/or 
paternal homologues in chromosomes at the higher copy number states (indicative of 
chromosomal gains) (hereafter termed HET-CNG pattern) was considered consistent 
with HeH. An overview of these patterns is shown in figure 5.1. 
 
Figure 5.1. Overview of characteristic HoTr and HeH chromosomal patterns on SNP array. A 
demonstrates features of typical disomic chromosome with preserved heterozygous AB alleles. 
B demonstrates pattern arising through chromosomal loss. Log2 ratio reduces relative to 
heterodisomy (A) and heterozygous AB alleles are lost (LOH-LCN). Importantly, the pattern is 
constant even in the event of endoreduplication whereby A becomes tetrasomic and B becomes 
disomic with LOH. C demonstrates pattern arising through single copy gain. Log2 ratio rises 
relative to heterodisomy and additional allelic pattern seen on B-allele frequency due to gain of 
a single maternal or paternal homologue (HET-CNG). 
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Importantly, although HeH can be associated with whole chromosomal LOH, this does 
not occur as a result of initial chromosomal loss so affected chromosomes will show a 
similar log2 ratio to preserved heterodisomies. Using this approach, all cases were re-
classified based on these SNP array patterns. Where neither pattern was apparent 
(including where the SNP array appeared largely normal), the case was classified as 
“inconclusive’.  
To derive chromosome-level numerical values, without assumption of the modal 
chromosome number or ploidy status of each case, whole chromosome segments 
were manually created in Nexus and their log2 ratios extracted for further analyses  
 
5.3.3 Creation of whole chromosome copy number segments in 
Nexus 
Nexus segmentation algorithms were kept to default settings. Subsequently, new 
segments were manually created across the entire length of individual chromosomes. 
These overrode any existing segments. The log2 ratios of these new whole 
chromosome segments were automatically computed by Nexus and were exported 
into a single table incorporating all cases. To account for sex-related disparity in the 
log2 ratios of X and Y chromosomes, these were removed from all further downstream 
analysis. 
The dataframe containing all whole chromosomal log2 ratios was then read into R (R 
Core Team, 2019) for subsequent clustering and classification analyses.  
 
5.3.4 Per-sample standardisation of log2 ratios 
The scale of positive and negative deflection in the log2 ratios of copy number 
segments is influenced by several factors. For example, CNAs in a pure sample will 
produce much greater positive or negative log2 ratio deflections than would be seen in 
a sample heavily contaminated with non-leukaemic DNA. Similarly, due to their 
different chemistries, Illumina and Affymetrix arrays produce different deflection in log2 
ratios. To account for these variations between samples, whole chromosomal log2 
ratios needed to be standardised to a consistent scale. Therefore, using R-package 
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BBmisc, the whole chromosomal log2 ratios within each sample were standardised to 
a mean of 0 and standard deviation of 1. These standardised whole chromosomal log2 
ratios were then used for all subsequent analyses.  
 
5.3.5 Principle components analysis (PCA) and unsupervised 
hierarchical clustering 
A principle components analysis (PCA) involves reducing the dimensionality of a 
dataset by creating new uncorrelated variables, based upon the primary variables, in 
this case whole chromosome log2 ratios (Jolliffe and Cadima, 2016). Using R-package 
prcomp, a PCA was performed using the standardised whole chromosomal log2 ratios 
as input variables and visualised using R-package factoextra. Unsupervised 
hierarchical clustering was similarly performed using R-package ComplexHeatmap 
(Gu et al., 2016b). Individual cases were labelled according to their reported 
cytogenetic subgroup, which highlighted any cases that clustered unexpectedly. The 
SNP array patterns based on the visual SNP array analysis were then used to ascertain 
whether such cases had been incorrectly classified by cytogenetic analyses. 
 
5.3.6 TP53 sequencing 
To add further confirmation where cases had a SNP array pattern of HoTr but had 
been cytogenetically classed as HeH, coding exons of TP53 were sequenced in 
selected samples. This was achieved by including all exons of TP53 in the custom-
designed SureSelect XT2 target enrichment kit (Agilent, Santa Clara, CA, USA) 
(chapter 2, section 2.7 and supplementary table 4).  
 
5.3.7 Classification and regression tree (CART) analysis 
CART analysis is a supervised machine learning technique, whereby a dataset 
consisting of different classes is partitioned according to a set of variables. The 
variables that produce the clearest separation of the different classes are chosen by 
the model in a sequential manner to eventually obtain nodes that give the best 
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separation of the input classes. This method can therefore be used effectively to 
produce an algorithm (decision tree) to classify a new case based on the same 
variables.  
To use whole chromosome log2 ratios to aid the accurate classification of ploidy status 
(HoTr, HeH or non-ploidy), a CART analysis was performed and a decision tree 
classifier was created. Initially, all HoTr and HeH cases in the cohort were re-classified 
based on the most probable genetic subgroup using all available data from 
cytogenetics, SNP arrays and TP53 status. Where the SNP profile showed the clear 
LOH-LCN pattern described above, the case was categorised as HoTr, even if this 
conflicted with the initial cytogenetic subgroup. Similarly, if the SNP array 
demonstrated the HET-CNG pattern consistent with chromosomal gains, the case was 
classified as HeH. To create a non-ploidy group for the CART analysis, all SNP arrays 
lacking a major ploidy shift from the CNA analysis of older adults detailed in chapter 4 
were added to this study. Whole chromosomal log2 ratios were created and 
standardised as detailed above.  
Following any re-classification of HoTr or HeH discrepancies, the CART analysis was 
performed using R-package rpart (see supplementary table 8 for input dataset), and a 
decision tree was created based on the standardised whole chromosomal log2 ratios.  
The performance of the CART model was then assessed using internal 10-fold cross-
validation in R-package caret. This involved internal random partitioning of the dataset 
into 10 subsets. Each subset was held out in turn and the remainder of the dataset 
was used to train the decision tree. The accuracy of the decision tree in classifying 
cases in the held out subset was then assessed. As each subset was held out in turn, 
this generated 10 independent validations and the mean accuracy of the model was 
reported. 
 
5.3.8 External validation of decision tree classifier 
A cohort of 29 Affymetrix Cytoscan HD arrays was provided by the Children’s Cancer 
Research Institute (CCRI) (Vienna, Austria) to perform external validation of the 
decision tree classifier. These comprised the following genetic subgroups: HeH (n=7), 
HoTr (n=7), near haploidy (n=8), ETV6-RUNX1 (n=2), TCF3-PBX1 (n=1), KMT2A-
AFF1 (n=1), B-other (n=3). Whole chromosomal log2 ratios were extracted by 
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collaborators at the CCRI and sent blinded to provide an external testing set for the 
classifier. The whole chromosomal log2 ratios were standardised using R-package 
BBmisc as detailed above and the resulting values were used to place each case in 
one of the decision tree’s nodes. The genetic subgroups for each case were then 
unblinded by the CCRI group and compared to the output from the classifier.  
 
5.4 Results 
5.4.1 Patient demographics and cytogenetic analyses 
The patient cohort comprised 88 patients with HoTr or HeH who were initially identified 
by cytogenetics (n=71) or SNP array (n=17). Cytogenetic results were available for 
95% (n=84) of patients. Patient characteristics and detailed cytogenetic data can be 
found in supplementary tables 6 and 7. Centralised review of karyotype data and 
assignment of cytogenetic subgroups had been undertaken at the LRCG as previously 
described (Harrison et al., 2001). At the start of the study, 40 patients had been 
assigned a genetic subgroup of HeH and 48 patients HoTr (figure 5.1). The median 
age of the patients was 51 years (range 7-87) for the HoTr subgroup and 7 years 
(range 1-58) for the HeH subgroup; reflecting the disparate age-specific frequencies of 







































































































































All patients with complete cytogenetic analyses were first examined to document the 
specific whole chromosomal gains and losses that had occurred from the baseline 
diploid state. The chromosomal gains and losses reflected distinct patterns which are 
characteristic of these genetic entities (figures 5.3 and 5.4). Near triploidy is thought to 
arise through endoreduplication of a low hypodiploid clone, which would be expected 
to generate disomies and tetrasomies. It is therefore noteworthy that frequent trisomic 
chromosomes were also present in the near triploid clones (figure 5.4), suggesting that 
the process of endoreduplication is imperfect and is likely to be more complex than 
pure doubling of the chromosomal complement.  
 
 
Figure 5.3. Summary of copy number state of individual chromosomes across 13 patients with 
high hyperdiploid ALL and a complete karyotype (3 cases with SNP arrays suggestive of masked 





Figure 5.4. Copy number status of individual chromosomes as reported in karyotypes containing 
near triploid (A) and low hypodiploid (B) clones. Cases with discrepant cytogenetic and SNP 
array findings are not shown (n=2). Near triploid clones demonstrate distinct pattern from high 
hyperdiploidy with gains of chromosomes 1, 2, 4, 5, 10, 11, 12, 18, 19, 21 and 22 predominating. 
Disomic chromosomes in near triploid clones (A) reflect monosomic chromosomes in low 
hypodiploid clones (B). 
 
5.4.2 SNP array analysis 
Initially, a standard visual analysis of the SNP array profiles was performed for all 88 
cases in Nexus by examining log2 ratio and B-allele frequency traces. In 32 cases the 
HET-CNG pattern was observed and cytogenetic analyses were consistent with the 
classic high hyperdiploidy profile previously described with trisomies of chromosomes 
4, 6, 10, 14, 17, 18 and tetrasomy of chromosome 21 dominating (figures 5.3 and 5.5).  
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Figure 5.5. Representative SNP array whole genome view of typical high hyperdiploid ALL case. 
Log2 ratio and B-allele frequency traces and table detailing whole chromosomal log2 ratios for 
each chromosome 1-22 and whether B-allele frequency indicates loss of heterozygosity (LOH) 
(Y/N). The case demonstrates classic pattern of high hyperdiploidy where chromosomes with 
the lowest log2 ratio possess a normal disomic component of SNPs on B-allele frequency (BB, 
AB and AA alleles) and chromosomes with higher log2 ratio possess a trisomic pattern of SNPs 
(BBB, ABB, AAB and AAA alleles) on B-allele frequency. 
 
The SNP profile of a further 35 cases exhibited the LOH-LCN pattern, characteristic of 
HoTr. Importantly, this pattern was seen regardless of whether the karyotype showed 
a low hypodiploid clone, near triploid clone or both (figures 5.4 and 5.6).  This was 
consistent with the LOH occurring as a result of primary chromosomal loss; typically 
affecting chromosomes 3, 7, 15, 16, 17 (figure 5.4). Among these 35 cases, 
cytogenetic analysis revealed a low hypodiploid, near-triploid or both clones in 9, 9 and 
8 cases respectively; or analysis had failed (n=9) (figure 5.2).  
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Figure 5.6. Whole genome view of SNP arrays and whole chromosome log2 ratios. (A) Example 
of a low hypodiploid case where only a low hypodiploid clone was detected on karyotype. 
Reduced log2 ratios are seen in chromosomes with complete loss of heterozygosity (LOH) on 
B-allele frequency trace and elevated log2 ratios in chromosomes with preserved disomic 
pattern of SNPs on B-allele frequency. (B) Example case where only near triploid clone was 
detected on karyotype. SNP array demonstrating complete LOH of chromosomes with reduced 
log2 ratios consistent with copy number neutral LOH (CNN-LOH). Some other chromosomes 
show a trisomic complement of SNPs suggestive of inexact doubling of a low hypodiploid clone.  
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Interpretation of the SNP profile for the remaining 21 cases led to a conclusion that 
contradicted cytogenetic analysis (n=4) or was inconclusive (n=17).  Three cases 
(29491, 27478, 26910) were identified that had initially been classified as HeH but 
whose SNP array profile was consistent with HoTr (figure 5.7A). Crucially all three of 
these cases had a modal chromosome number below the theoretical threshold of 60 
chromosomes for duplicated low hypodiploidy. In addition, a further case (27058) was 
initially classed as HoTr on the basis of the cytogenetic result but had a SNP array 
suggestive of HeH ALL (figure 5.7B). The inconclusive SNP array profiles (n=17) had 
a near-normal SNP array profile likely due to low leukemic DNA content and/or normal 




Figure 5.7. Two cases with discrepant cytogenetic and SNP array results.  
A. Patient 27478 cytogenetically classified as high hyperdiploidy (HeH). However, SNP array 
demonstrates widespread loss of heterozygosity at the lower copy number state (LOH-LCN), 
suggestive of low hypodiploidy/near triploidy (HoTr).  
B. Patient 27058 cytogenetically classified as HoTr. However, SNP array demonstrates preserved 
heterozygosity in chromosomes at lower copy number state, therefore excluding loss of 
chromosomes. Although the pattern of chromosome gains is not typical, features are otherwise 
consistent with HeH.  
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5.4.3 Clustering and classification of cases using SNP array data 
The whole chromosomal log2 ratios were extracted from Nexus and can be found in 
supplementary table 7. The values were then standardized using R-package BBmisc 
as previously described. 
PCA and unsupervised hierarchical clustering of standardised whole chromosomal 
log2 ratios demonstrated clear separation of HoTr and HeH cases (figure 5.8).  
However, four cases classified by cytogenetics as HeH clustered with HoTr cases. 
Reassuringly, three of these four cases (26910, 27478 and 29491) also exhibited the 
LOH-LCN pattern by standard visual SNP array analysis, demonstrating concordance 
between the unsupervised clustering analyses and the standard visual SNP analysis. 
The fourth case (24805) had an inconclusive SNP result following visual inspection 
with a largely normal profile, most likely due to low tumour DNA content in the 
diagnostic sample. Similarly, two cases cytogenetically classified as HoTr clustered 
with HeH samples. Of these, one (27058) demonstrated the HET-CNG pattern by SNP 
array analysis (figure 5.7B). Interestingly, the other case (28893) had an unusual 
karyotype, which was neither suggestive of HeH or HoTr, and an inconclusive SNP 
array. To investigate another primary genetic abnormality, FISH was performed for B-
other gene rearrangements as described previously (chapter 2, section 2.5) and an 
IGH-CRLF2 gene rearrangement was discovered. As this primary genetic abnormality 
is distinct from both HeH and HoTr, this finding is likely to explain the unusual karyotype 




Figure 5.8. Unsupervised clustering of cases by standardised whole chromosome log2 ratios. 
Principal component analysis (A) and unsupervised hierarchical clustering as a heatmap (B) 
demonstrate separation of high hyperdiploid (HeH) and low hypodiploid (HoTr) clusters with 
information contributed by each chromosome (information gain) displayed as a bar chart 
underneath (C). Cases within the incorrect cluster based on initial cytogenetic classification are 
detailed in table 5.1.  
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The six cases that clustered discordantly based on their cytogenetic classification were 
examined in further detail (table 5.1). As mentioned, the three patients cytogenetically 
classified as HeH with SNP array profiles and clustering results consistent with HoTr 
(26910, 27478 and 29491) all had fewer than 60 chromosomes by karyotypes, which 
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HoTr Inc HeH 
Table 5.1. Cytogenetic, SNP array and standardised whole chromosomal log2 ratio clustering 
results of all cases that clustered discordantly from their cytogenetic subgroup.  
Cyto: cytogenetics; HeH: high hyperdiploidy, HoTr: low hypodiploidy/near triploidy, Inc: 
inconclusive SNP array pattern. 
 
5.4.4 TP53 mutations 
For additional evidence that the three patients classified cytogenetically as high 
hyperdiploidy were in fact masked low hypodiploidy (26910, 27478 and 29491), coding 
regions of TP53 were sequenced by including the samples in the SureSelect XT2 
library prep described previously (chapter 2, section 2.7 and supplementary table 4). 
This confirmed that all three patient samples harboured pathogenic TP53 mutations 
(table 5.1). The TP53 variants identified are reported in the Catalogue of Somatic 
Mutations in Cancer (COSMIC) (Tate et al., 2018) and were missense mutations 
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affecting the DNA binding domain (TP53 p.P151S and TP53 p.R282W) and a 
nonsense mutation in the C-domain (TP53 p.K305*). Additionally, one of the two cases 
classified cytogenetically as duplicated low hypodiploidy that clustered with high 
hyperdiploid cases (28893) had a JAK2 mutation identified, and did not harbour any 
pathogenic TP53 variants. This finding was consistent with the discovery of the IGH-
CRLF2 rearrangement, which is strongly associated with JAK2 abnormalities, and 
confirms this case represented a separate genetic entity (Mullighan et al., 2009a).  
Demographic, clinical and outcome data as well as TP53 status of the six cases that 













26910 43 M 31.4 HeH HoTr TP53 p.P151S Died in CR1 within 1 yr 
27478 58 F 8.43 HeH HoTr TP53 p.R282W Relapsed and died within 2 yrs 
29491 51 M 9.5 HeH HoTr TP53 p.K305* CR1 (4 months) 
24805 46 F 58.34 HeH HoTr Not done Died in CR1 within 1 yr 
27058 7 F 121.9 HoTr HeH Not done CR1 (2 years) 
28893 27 M 31.7 HoTr HeH JAK2 p.T875N CR1 (1 year) 
Table 5.2. Clinical, demographic and outcome data of cases that clustered discrepantly from 
initial cytogenetic subgroup. Relevant mutations also shown. Case 28893 did not harbour a TP53 
mutation.  
M: male; F: female; WCC: white cell count; Cyto: cytogenetics; HeH: high hyperdiploidy; HoTr: 
low hypodiploidy/near triploidy; CR1: first complete remission 
 
5.4.5 Development of ploidy classifier using whole chromosome log2 
ratios 
The clustering analyses demonstrated that the distribution of whole chromosome log2 
ratios in the HeH and HoTr cohorts was non-random, reflecting the patterns of 
chromosomal gains and losses in the two subgroups (figure 5.7B). The contribution of 
each whole chromosome log2 ratio to the unsupervised hierarchical clustering analysis 
was also non-random with chromosome 1 being the most informative discriminator 
(figure 5.7C).  
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To explore whether whole chromosome log2 ratios could be used to develop a ploidy 
classifier, CART analysis was used to identify the most informative chromosomes for 
a decision tree. To maximise its diagnostic power, the decision tree was built using the 
88 low hypodiploid and high hyperdiploid cases, as well as an additional 72 cases 
broadly representative of adult ALL (supplementary table 6). Prior to running the CART 
analysis, four of the discrepant cases (26910, 27478, 29491 and 27058) were re-
classified according to the SNP array, clustering and TP53 results, as these provided 
overwhelming evidence that the cytogenetic-derived subgroup had been inaccurate. 
Similarly, the IGH-CRLF2 rearranged case (28893) was re-classified into the non-
ploidy subgroup as the underlying primary genetic lesion was clearly distinct from both 
HoTr and HeH. Thus, the final CART analysis cohort comprised 160 cases, specifically 
HoTr (n=50), HeH (n=41) (including three cases with BCR-ABL1 and high 
hyperdiploidy) and non-ploidy (n=69).  
Using the complete dataset (n=160), CART analysis identified a decision tree based 
on the standardised log2 ratios of chromosomes 1, 7 and 14 (figure 5.9). Using these 
variables, cases could be delineated into one of four terminal nodes: one each for HoTr 
and HeH and two for the non-ploidy cases. The majority of HoTr cases (47/50, 94%) 
were correctly placed into the HoTr group, while 3 cases were placed into non-ploidy 
groups. Similarly, the majority of HeH cases (33/41, 80%) were correctly assigned to 
the HeH node.  
The model was then validated internally using 10-fold cross validation and delivered 
an overall average accuracy of 79% (95% confidence interval 72%-85%) across all 
three ploidy classes. Positive predictive values were 91%, 68% and 77% for HoTr, HeH 
and non-ploidy cases respectively and negative predictive values were 94%, 92% and 
81% for HoTr, HeH and non-ploidy cases respectively. 
Overall, eleven cases called as HoTr or HeH by cytogenetics and/or SNP array were 
incorrectly assigned by the decision tree (figure 5.8). There was no overlap between 
these 11 misclassified cases and the 4 cases re-classified by the SNP array analysis 
described above (table 1). Review of the karyotypes revealed atypical chromosome 
gain/loss or complex structural rearrangements in the majority.  
Importantly, for clinical diagnostic practice, chromosome 1 was a very powerful 
discriminator between HoTr and HeH cases, and accurately segregated 97% (88/91) 
of cases with a ploidy shift.  Taken together these data show that if cytogenetic 
analysis, FISH or DNA index identifies a hyperdiploid clone, the standardised log2 ratio 
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of chromosome 1 (<> 0.28) can extremely reliably discriminate between high 
hyperdiploidy and duplicated low hypodiploidy.  
 
5.4.6 External validation of the decision tree classifier using Vienna 
cohort 
Using the external Vienna validation cohort, the classifier correctly placed 100% (7/7) 
of the HoTr cases in the HoTr node. Additionally, 86% (6/7) of the HeH cases were 
correctly classified. One HeH case was placed in a non-ploidy group due to the 
absence of a chromosome 14 gain. The near haploid cases were split amongst the 
HeH (n=5), and non-ploidy nodes (n=3). Such cases were not included in the primary 
cohort so did not have a dedicated node, and these data confirm that as expected they 
have a SNP array profile distinct from HoTr. Unblinded cytogenetic details of the 




Figure 5.9. Decision tree for assigning cases to a genetic ploidy subgroup using standardized 
whole chromosome log2 ratios of chromosome 1, 7 and 14. SNP arrays with standardized log2 
ratios for chromosome 1 ≥0.28 and chromosome 7 <-0.33 had a 94% probability of being HoTr 
cases. Cases with a standardized log2 ratios <0.28 for chromosome 1 and ≥0.37 for chromosome 
14 had 94% probability of being HeH. Cases where the log2 ratio was <0.28 for chromosome 1 
and <0.27 for chromosome 14, had an 87% probability of the absence of major ploidy shift. 
Importantly, these three scenarios accounted for 95% of the patients in the dataset. A total of 11 
cases called by cytogenetics and/or SNP array as having ploidy shifts were incorrectly assigned 
by the decision tree: (a) This patient had high hyperdiploidy and t(9;22)/BCR-ABL1, which is 
recognised to have a different pattern of chromosomal gains from primary high hyperdiploidy 
(Chilton et al., 2013) ; (b) Although this patient had a low hypodiploid karyotype with -7 there was 
unbalanced translocation between the long arms of chromosome 6 and 7; (c) 4/7 cases failed 
cytogenetics while none of the remaining 3 cases had a +14; (d) Karyotypes had been classed 
as HoTr by cytogenetics but SNP array analysis was inconclusive.  
Chr: chromosome; HoTr: low hypodiploidy/near triploidy; HeH: high hyperdiploidy; Hap: near 
haploidy; Non-ploidy: absence of primary large scale ploidy shift. 
 
5.5 Discussion 
As discussed in chapter 3, HoTr is one of the commonest subgroups in older adults 
with ALL, and has been poorly studied to date, largely due to its rarity in other age 
groups. Although younger patients were also included in this study to permit a more 
robust clustering analysis, there is no evidence that fundamental biological differences 
exist between older and younger patients with HoTr.  
The results of this study provide compelling evidence of the importance of SNP arrays 
in the detection of clinically relevant ploidy groups at diagnosis of BCP-ALL. The most 
important finding is that modal chromosome number alone should not be used to 
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distinguish between high hyperdiploidy and masked low hypodiploidy. These data 
demonstrate that duplicated low hypodiploidy can give rise to karyotypes with 
significantly fewer than the theoretical and working lower limit of 60 chromosomes 
(Charrin et al., 2004, Moorman et al., 2007). Three cases with 50-60 chromosomes 
have been identified that are consistent with masked low hypodiploid ALL based on 
SNP array features (figure 5.7A) and the presence of pathogenic TP53 mutations 
(table 5.1).  
It is important to note that these cases did not show direct cytogenetic evidence of a 
low hypodiploid clone and that CNN-LOH is well described in high hyperdiploidy 
(Paulsson et al., 2010), where it may occur as a result of chromosomal mis-segregation 
during mitosis (Makishima and Maciejewski, 2011). However, several features on the 
SNP arrays were highly reminiscent of the HoTr pattern in all three cases. Firstly, the 
LOH observed was much more extensive than reported in HeH cases and affected the 
typical chromosomes that are lost in low hypodiploid ALL. Additionally, LOH was 
consistently seen in chromosomes at the lower copy number state, and those with 
preserved heterozygosity always had higher log2 ratios, suggesting that affected 
chromosomes underwent an initial heterozygous deletion followed by subsequent 
duplication of the remaining homologue.  
Secondly, the hierarchical clustering was unsupervised and was independent of any 
observed loss of heterozygosity. Based solely on whole chromosomal log2 ratios, the 
three relevant cases clearly clustered with other HoTr samples, irrespective of the 
pattern and extent of the readily apparent LOH, thereby demonstrating that whole 
chromosomal log2 ratios alone provide a characteristic signature for low hypodiploid 
ALL.  
Cytogenetically, all three cases had trisomy of chromosome 1. In addition, CART 
analysis revealed that the standardised whole chromosome log2 ratio of chromosome 
1 was the most discriminating factor for distinguishing between the two ploidy groups. 
This strongly suggests that the presence of trisomy 1 in an otherwise high hyperdiploid 
karyotype should prompt further analysis with a SNP array and TP53 mutation analysis 
to exclude masked low hypodiploidy. Interestingly, these cases were all adults aged 
over 40 years at diagnosis and accounted for 3/14 (21%) of the cytogenetically defined 
high hyperdiploid adult patients in this cohort. This suggests that high hyperdiploidy 
may be even rarer than previously thought in this age group, and that misclassified 
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cases of masked low hypodiploidy may account for the poorly defined prognostic value 
of hyperdiploidy in adults.  
As SNP array analysis is performed on a fixed amount of DNA rather than a fixed 
number of cells, exact multiples of cellular DNA content all result in the same pattern 
on the microarray. For example, exact tetraploidy is indistinguishable from diploidy. 
Although some studies have developed methods for normalisation of aneuploid 
genomes, these are based on the assumption of a single aneuploid tumour population 
at a fairly constant ploidy level (Pounds et al., 2009, Van Loo et al., 2010). Resolving 
the copy number state of individual chromosomes in samples that potentially contain 
at least three different ploidy populations (low hypodiploid, near triploid and normal 
diploid DNA) is likely to be challenging. However, within each sample, relative over or 
under-representation of genomic loci can be inferred based on positive or negative 
deflections in the log2 ratio respectively. In this analysis, this principle has been used 
to manually derive log2 ratios for entire chromosomes. Although re-centering of log2 
ratios to presumed diploid regions is often performed in aneuploid samples (either 
manually or computationally within SNP array analysis software), the individual sample 
standardisation described (to mean whole chromosome log2 ratio = 0 and SD = 1) 
negates any assumption of copy number state and therefore permits an unbiased 
analysis with no prior knowledge of the sample ploidy status. Each individual 
chromosome’s copy number status is considered relative to the others in the sample 
rather than as an absolute value. Indeed, defining diploid regions is often flawed in 
samples with drastically disparate ploidy levels where the relative proportion of 
different clones is unknown.  
In many cases, a descriptive analysis of SNP array patterns is sufficient to distinguish 
HoTr from HeH with confidence. However, these data have highlighted that a 
significant proportion of samples (20% of cases with a major ploidy shift in this cohort) 
may yield an inconclusive result. It is not clear why DNA from these 17 samples did 
not produce clear SNP array profiles but in three cases the DNA had been extracted 
from fixed cell suspension and in a further nine cases samples had been stored for >2 
years prior to performing SNP arrays, potentially leading to noisy profiles. Alternatively, 
near normal SNP array patterns are often encountered when the leukaemic DNA 
content is low, although this did not seem to be the case with the majority of samples 
in the cohort (supplementary table 7). However, importantly, these “real-world” analysis 
issues did not hamper the reliability of the decision tree classifier, which was still able 
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to accurately delineate cases lacking a clear diagnostic SNP array profile by standard 
visual analysis as differences in whole chromosomal log2 ratios are present, even if 
not readily apparent by standard visual SNP array interpretation. Chromosome 1 is 
consistently relatively over-represented in HoTr compared with HeH samples and is 
the most discriminatory predictor to differentiate these ploidy groups. Moreover, in the 
absence of cytogenetics, log2 ratios of key chromosomes (1, 7 and 14) can offer 
valuable information to resolve the ploidy status of a sample, even when visual 
interpretation of the SNP array is inconclusive. Current SNP array visualisation 
software (e.g. Nexus copy number or Affymetrix Chromosome Analysis Suite among 
others) can be used to create whole chromosome segments and extract log2 ratios to 
support genetic risk stratification in diagnostic genetic laboratories.  
This analysis is limited by case selection only on the basis of the availability of DNA, 
meaning that the low hypodiploid subgroup is composed predominately of adult ALL 
cases whereas the high hyperdiploid subgroup comprises predominately childhood 
ALL. However, this is a true reflection of the underlying epidemiology of these ploidy 
subgroups and the large number of low hypodiploid cases compiled for this study 
permitted a very robust clustering analysis.  
In conclusion, cytogenetics alone cannot always be used to accurately distinguish 
between HoTr and HeH. Approximately half of all HoTr cases are masked and present 
with a near-triploid karyotype. Using modal chromosome number to define a lower limit 
is flawed, as demonstrated by cases with as few 54 chromosomes, well within the 
typical range for HeH. Using SNP arrays helps to detect both low hypodiploidy and 
high hyperdiploidy in cases with normal or failed karyotypes and can usually distinguish 
between these two ploidy groups. In addition, the ploidy classifier uses the log2 ratios 
of whole chromosomes to assist SNP array interpretation, and is of particular value in 
situations where low blast percentage and contaminating non-leukemic DNA may 
hamper clear SNP array evaluation. Virtually all childhood and most adult ALL 
treatment protocols will assign patients with HoTr and HeH ALL to very different 
treatment schedules. Hence the accurate detection of these two ploidy groups is vital 
to optimal patients’ management.   
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Chapter 6. Mutational landscape of ALL 
in older adults 
 
6.1 Introduction 
Mutations are the hallmark of cancer development. In ALL, initiating abnormalities 
often involve novel fusion genes or large-scale ploidy shifts, but these events alone 
are usually insufficient to generate leukaemia. Secondary abnormalities include copy 
number abnormalities or somatic mutations, and these drive transformation of a 
preleukaemic clone into clinically overt disease.  
Mutations refer to small changes in the genetic sequence and take different forms, with 
different functional consequences. The most common type of mutation involves a 
single nucleotide variant (SNV), which occurs when a single base in the genome is 
substituted with a different base. Due to redundancy in codon to amino acid mapping, 
many SNVs do not alter the relevant amino acid (synonymous variants). However, 
when a base substitution results in a changed amino acid, this disrupts the protein 
structure (missense mutation) or can code a premature stop codon (nonsense 
mutation), resulting in a truncated protein. Mutations may also involve small insertions 
or deletions of up to 50 bp, termed indels. These events have the potential to produce 
very significant disruption to the protein when they produce a shift in the reading frame 
(frameshift mutations). 
During oncogenesis, cells acquire certain mutations that confer survival or growth 
advantage by Darwinian natural selection (driver mutations). In contrast, passenger 
mutations are neutral events which occur through mutagenic exposure or genome 
instability, and although these can also be passed along subsequent generations, they 
do not confer a specific survival advantage to the neoplastic clone (Greenman et al., 
2007). 
In ALL, the leukaemic genome generally harbours fewer mutations than most non-
haematological tumours (Greenman et al., 2007). Indeed, a study incorporating NGS 
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(predominantly exome sequencing) of 203 ALL patients identified a median of 11 
(range 0-88) and 9 (range 0-45) non-silent mutations in adult and paediatric cases 
respectively  (Liu et al., 2016). On average, ALL genomes have one of the lowest 
mutation rates, of all cancers, shown to be 0.57 mutations per Mb of DNA in one study, 
compared to 18.54 mutations per Mb of DNA in melanoma (Greenman et al., 2007). 
Despite their low mutation rate, certain pathways are recurrently disrupted in ALL 
genomes. The RAS signalling pathway consists of a number of functionally related 
RAS proteins that bind to and activate RAF proteins (Downward, 2003). In turn, RAF 
phosphorylates ERK1/2, which then activate transcription factors permitting cell cycle 
progression through the G1 phase. Activating point mutation in RAS proteins have 
been recognised for many years and are one of the most frequent targets of somatic 
mutation in oncogenesis, present in around 20% of human tumours (Bos, 1989, 
Downward, 2003). These increase cell proliferation, contributing to the malignant 
phenotype, and constitute some of the most frequent mutations in childhood ALL 
samples (Case et al., 2008, Irving et al., 2014). Indeed these aberrations are 
particularly prevalent in certain subgroups, and have been identified in the majority of 
ALL patients with either high hyperdiploidy (Paulsson et al., 2015) or intrachromosomal 
amplification of chromosome 21 (Ryan et al., 2016), as well as being enriched in the 
relapse setting (Ding et al., 2017, Irving et al., 2014). As with the vast majority of 
translational research into ALL, published analyses of ALL genomes are heavily biased 
towards paediatric patients. To date, very few such studies have included adult 
patients, let alone older adults (Roberts and Mullighan, 2015). One large NGS study 
included 92 adults, analysed predominantly by exome sequencing (Liu et al., 2016). 
The authors reported a similar pattern of mutations to the childhood cohort with RAS 
pathway genes predominating, and also noted a very slight increase in the number of 
mutations with advancing age. Mutations in epigenetic modifiers were also seen more 
frequently in adult patients. As discussed in chapter 5, perhaps the closest interaction 
between a genetic subtype of ALL and a pathogenic mutation is that seen between low 
hypodiploidy and TP53 variants (Holmfeldt et al., 2013, Mühlbacher et al., 2014). This 
genetic entity is seen more frequently with advancing age, and is therefore of particular 
relevance in the genomic landscape of ALL in older adults. 
The pattern of somatic mutations in cancer is non-random and detailed genomic 
analysis of large datasets has identified specific mutational signatures. These differ 
due to the distinct mutational processes underlying oncogenesis in different tumours. 
Mutational signatures are characterised both by the pattern of base substitutions seen 
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in a sample and the genomic sequence context within which these arise. As such, the 
six possible substitutions – C>A, C>G, C>T, T>A, T>C, T>G (referred to by the 
pyrimidine of the mutated base pair) – can arise in the context of any of the four 
possible bases immediately 5’ and 3’ to the mutated base pair. This generates 96 
possible mutation types, which take into account both the base substitution and the 
bases immediately adjacent. Mutational signatures are characterised by prominence 
or absence of these specific mutation types, reflecting an underlying biological 
process. Using these, 30 COSMIC mutational signatures (version 2) have been 
described and validated (Tate et al., 2019). For example, signature 1 is characterised 
by a prominence of C>T substitutions at NpCpG trinucleotide sites, which occurs as a 
result of spontaneous deamination of 5-methylcytosine. This process is particularly 
associated with ageing and is positively correlated with increasing patient age at 
cancer diagnosis. In comparison, signature 2 arises through C>T and C>G mutations 
at TpCpN trinucleotides, a process which results from over-activity of the APOBEC-
family of cytidine deaminases (Alexandrov et al., 2013). 
 
6.2 Aims 
To date, most studies have focussed on elucidating the genomic landscape of 
paediatric ALL. As the frequency of the specific primary genetic abnormalities is very 
different in younger and older patients, it is likely that the co-operating mutational profile 
will also be distinct. This chapter will focus on examining the smaller genomic 
aberrations in a cohort of older adults with ALL with the following aims. 
1. Identifying mutations in coding regions of the ALL genome using exome 
sequencing in a small cohort of older adults with ALL. 
2. Identifying the predominant mutational signatures underpinning ALL in older 
adults. 
3. Unravelling the spectrum of mutations in known leukaemia genes and their co-
operation with the primary genetic subtypes of older adults with ALL using 
targeted sequencing. 
4. Screening for background clonal haematopoiesis mutations in ALL in older 
adults. 
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5. Selecting and tracking variants identified at diagnosis in follow up samples to 
evaluate clonal persistence and evolution in older adults on treatment 
 
6.3 Methods 
6.3.1 Serial bone marrow sampling cohort 
A cohort of six locally recruited patients were consented for biobanking of excess bone 
marrow tissue taken at routine time points during treatment. To maximise patient 
numbers, patients aged 50 years and over were approached for sample donation. A 









subgroup Treatment type 
29779 87 M Not done Palliative (vincristine + dexamethasone)  
29780 55 F B-other UKALL14 (chemo only, no allo SCT) 
29854 75 F BCR-ABL1 UKALL60+ (Ph +ve arm) 
30142 66 F B-other UKALL60+ (intensive → non-intensive arm) 
30643 52 M IGH-CRLF2 UKALL14 (chemo only, no allo SCT) 
31044 63 F HoTr UKALL60+ (intensive → non-intensive arm) 
Table 6.1. Demographic, genetic characteristics and treatment details of the six patients 
recruited for sample biobanking. Patients 30142 and 31044 were initially treated on the intensive 
arm of the UKALL60+ protocol but were de-escalated to non-intensive treatment after induction 
phase 1 due to treatment related toxicity. No patients underwent allogeneic stem cell 
transplantation.  
M: male; F: female; B-other: BCP-ALL with no primary chromosomal identified; HoTr: low 
hypodiploidy/near triploidy; allo SCT: allogeneic stem cell transplant. 
 
Serial samples were collected at several time points for each recruited patient (figure 
6.1). All sample time points were dictated by routine clinical care, when the patient 
underwent bone marrow aspiration according to standard of care assessments or due 




Figure 6.1. Patient progress through treatment and sample time points. Arrows indicate 
timepoints of sample collection (red = diagnosis/relapse, green = morphological remission). 
Patient 29779 had peripheral blood taken at all time points. All other patients underwent bone 
marrow aspiration at all time points. In addition to these samples, all patients had constitutional 
DNA isolated using a buccal swab.  
 
6.3.2 Patient samples and sequencing 
6.3.2.1 Exome sequencing cohort 
After bone marrow or peripheral blood sample collection in the patients outlined above 
(table 6.1 and figure 6.1), mononuclear cells were isolated on the same day using a 
Lymphoprep density gradient medium (chapter 2, section 2.4.1). Viable mononuclear 
cells were then stored at -150°C for DNA extraction at a later date (chapter 2, section 
2.4.2). Buccal swabs were obtained from each patient and constitutional DNA was 
extracted for use as a germline control (chapter 2, section 2.4.3). Details of all samples 
selected for exome sequencing are shown in table 6.2. 
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29779 Diagnosis 15 211.6 226.2 1.87 180x 
29779 Germline 30 ND 48.4 1.80 90x 
29779 Relapse 20 ND 238.5 1.88 180x 
29780 Diagnosis 15 136.6 154.4 1.85 180x 
29780 Germline 40 52.4 83.2 1.85 90x 
29854 Diagnosis 15 66.4 103.8 1.80 180x 
29854 Germline 40 ND 40.0 1.95 90x 
30142 Diagnosis 15 197.2 256.7 1.90 180x 
30142 Germline 45 ND 38.1 1.84 90x 
30643 Diagnosis 30 ND 46.3 1.67 180x 
30643 Germline 15 ND 40.3 1.96 90x 
31044 Diagnosis 40 ND 43.7 2.16 180x 
31044 Germline 20 ND 38.7 1.82 90x 
Table 6.2. Details of samples submitted for exome sequencing. For patients 29779, 29780, 29854 
and 30142, buccal samples yielded insufficient high quality DNA to meet the requirements for 
exome library prep so remission samples were used as matched germline alternatives. For 
patients 30643 and 31044, buccal swabs yielded sufficient high quality DNA to proceed to exome 
library prep.  
dsDNA conc: double stranded DNA concentration; Nanodrop conc: Nanodrop concentration; 
ND: not done. 
 
Each sample was sent to the Core Genomics Facility (International Centre for Life, 
Newcastle University) for exome sequencing on the NovoSeq instrument. Each tumour 
sample (diagnosis or relapse, where applicable) was put through library prep twice and 
therefore sequenced as two separate samples to generate double the standard read 
depth of 90x to facilitate detection of lower variant allele frequency (VAF) clones. 
Sequencing data were returned in the form of FASTQ files and initial bioinformatic 
analysis of raw reads was performed by Dr Matthew Bashton using the GATK Mutect 
somatic variant caller (patients 29779, 29780, 29854, 30142 and 30643) and the 
Bioinformatic Support Unit (Newcastle University) using the GATK Mutect 2 variant 
caller (all patients). 
 
6.3.2.2 Targeted sequencing cohort 
Separately, a targeted NGS sequencing cohort was created from the patient samples 
included in the SureSelect XT2 library prep sequenced on the NextSeq instrument 
(chapter 4, section 4.4.4). Together with the deletion breakpoints used for the 
validation experiment, a number of leukaemia-associated genes were included in the 
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capture library, and thus constituted a targeted sequencing panel that could be applied 
to the discovery of pathogenic mutations in these samples (table 6.3 and 
supplementary tables 3 and 4).  
Gene Region captured Gene Region captured 
ABL1 whole gene DNMT3A all exons 
ABL2 whole gene FOXO1 all exons 
ARID2 whole gene IKZF2 all exons 
CSF1R whole gene IKZF3 all exons 
DGKH whole gene IL7R all exons 
ETV6 whole gene JAK1 all exons 
FLT3 whole gene JAK3 all exons 
IKZF1 whole gene KMT2C all exons 
JAK2 whole gene KRAS all exons 
KDM6A whole gene NOTCH1 all exons 
MEF2C whole gene NR3C1 all exons 
MEF2D whole gene NRAS all exons 
NF1 whole gene NT5C2 all exons 
PAX5 whole gene PTPN11 all exons 
PTEN whole gene RB1 all exons 
PDGFRB whole gene RUNX1 all exons 
RAG1 whole gene TET2 all exons 
TCF3 whole gene TOX all exons 
TCF4 whole gene SH2B3 all exons 
ASXL1 all exons TFDP3 all exons 
ATM all exons TP53 all exons 
CREBBP all exons ZFHX3 all exons 
Table 6.3. Custom 44 gene panel included in SureSelect XT2 capture library (chapter 4). Only 
known cancer/leukaemia genes shown. Full capture library shown in supplementary tables 3 and 
4. 
 
In total 30 patient samples were included in the targeted sequencing cohort, and 
consisted of the samples from the deletion validation experiment (n=23) and additional 
samples with ploidy abnormalities (n=7). 
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6.3.3 Exome sequencing variant calling 
Mutect, a variant caller developed by the Broad Institute, was specifically developed to 
identify somatic point mutations in tumours, and has been extensively validated in this 
capacity (Cibulskis et al., 2013). The method identifies sites in the genome where an 
allele differs from the reference. These are compared to the matched germline sample 
and are flagged if variation is identified. Pre and post processing corrections are 
performed whereby low quality reads are excluded and noise corrections are 
implemented according to baseline somatic mutation rates. 
Mutect2 is a more recently developed somatic variant caller, able to identify both SNVs 
and indels in tumour DNA (Benjamin et al., 2019). The method uses a system whereby 
active sites of possible somatic variation are identified through haplotypes that vary 
from the reference. Variation that is also present in the matched germline sample is 
discarded at an early stage, and after various stages of probabilistic scoring, candidate 
somatic variants are selected. 
The variant call file (VCF) output from Mutect or Mutect 2 was then annotated using 
Ensembl Variant Effect Predictor (VEP) (McLaren et al., 2016). Where available, this 
gathered existing information on each variant, including population frequencies, 
pathogenic scoring and known associations with cancer. In silico functional predictions 
of variants was obtained through the SIFT (Sim et al., 2012) and Polyphen2 (Adzhubei 
et al., 2010) databases. 
 
6.3.4 Filtering pipeline 
A customised filtering pipeline was then designed and executed in R to extract 
candidate pathogenic variants from the VEP output (figure 6.2). Briefly, likely benign 
variants present in at least 1% of the general population, obtained from either the 
gnomAD (Karczewski et al., 2020) or ExAC (Karczewski et al., 2017) databases, were 
first excluded. Annotation from SIFT and Polyphen2 was then used to filter out variants 
that were predicted to be both tolerated and benign. The final filtering step then 
involved removing intronic variants, upstream or downstream gene variants, or those 
in the 5’ or 3’ untranslated regions (UTRs). Finally, the file was converted into a 
mutational annotation format (MAF), a similar tab-delimited text file to VEP output with 
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specific column headings, and containing all samples from a project in a single file. 
Variant allele frequency (VAF) data for each call was also incorporated into the final 
MAF file from the VCF output of Mutect. Bioconductor packages maftools (Mayakonda 
et al., 2018) and ensembldb (Rainer et al., 2019) were used in R to visualise the data 
and conduct further analyses.   
 
Figure 6.2. Overview of filtering pipeline to extract candidate pathogenic variants, coded and 
executed in R.  
 
6.3.5 Generating mutational signatures 
The Mutect output was then used to identify specific mutational signatures that were 
enriched in the patient cohort. The pre-filtered output was used to maximise the 
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number of mutational events to generate the mutational signature. As synonymous and 
intronic variants are as relevant as pathogenic coding variants in mutational signatures, 
the raw VEP output was directly converted into MAF format. Next, a trinucleotide matrix 
of all mutations was created by obtaining the 5’ and 3’ base immediately adjacent to 
each variant using R-packages maftools and BSgenome.Hsapiens.UCSC.hg19 as the 
reference genome. Once this trinucleotide sequence was available for each mutation, 
samples were compared to the validated COSMIC mutational signatures using the 
extractSignatures function in R-package maftools. 
 
6.3.6 Targeted sequencing variant calling 
The targeted sequencing cohort patient samples did not have matched germline 
material so variant calling using Mutect and Mutect2 was not appropriate. Instead, raw 
sequencing reads were processed by the Bioinformatic Support Unit using the GATK 
HaplotypeCaller (Poplin et al., 2017). This is a germline variant caller that uses a similar 
method of generating calls as Mutect2 and is able to identify both SNVs and indels. 
Regions of variation from the reference are first flagged as “active regions”. Based on 
statistical modelling, the most probable haplotypes in the region of variation are then 
identified, and the likely genotype at each variant site is then defined. Because the 
software is intended for the detection of germline variation, each case only requires a 
single sample. If tumour DNA is used, germline variation in the sample cannot be 
excluded directly. However, using a targeted panel of 44 leukaemia-related genes, the 
potential for germline variants was already more limited. The same filtering pipeline 
described in figure 6.2 was executed in R to extract potential pathogenic variants from 
the VEP output. Additionally, all variants with existing dbSNP identifiers were 
scrutinised in the dbSNP database (Sherry et al., 2001) and were dismissed as 
potential germline variants if no clinical significance was reported. All remaining 
mutations were classed as candidate pathogenic variants, although without germline 
DNA analysis, their somatic nature could not be confirmed.  
VEP outputs for SNVs and indels were processed in the same way. Additional filtering 
was then applied through visualisation of all post-processing calls in IGV. During this 
variant calling process, it was noted that frequent deletions were called by 
HaplotypeCaller in ABL2. However, when all the deduplicated and re-aligned BAM files 
were inspected in IGV, this region showed numerous mismatched bases in all samples 
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and was therefore likely to represent an artefact. A decision was made to exclude these 
ABL2 calls from the downstream analysis. 
 
6.4 Results 
6.4.1 Exome sequencing Mutect results 
Patients 29779, 29780, 29854, 30142 and 30643 were included in the Mutect analysis, 
which was performed before patient 31044 was recruited. 
From these five patients, six VEP files were processed (patient 29779 had both 
diagnosis and relapse samples). Across these six patient samples, 966 variants had 
been called through Mutect. Following the post processing filtering outlined in figure 
6.2, 116 candidate pathogenic mutations were flagged, equating to a median of 17 
(range 9-37) pathogenic SNVs per sample (figure 6.3).  
 
Figure 6.3. Summary of SNVs from Mutect output and downstream filtering from 6 patient 
samples.  
SNV/SNP: single nucleotide variant; D: diagnostic sample; R: relapse sample; Miss: missense 
mutation; Non: nonsense mutation; Splice: splice site mutation. 
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The vast majority of SNVs were missense variants and C>T transitions accounted for 
41% of events (figure 6.3). There was no association between the number of variants 
and age at diagnosis and only 6 genes were recurrently mutated. Two separate KRAS 
mutations were identified, both in the same sample (30643). Mutations in COL4A6, 
ALPK2 and ABCA1 were present in both diagnostic and relapse samples from patient 
29779. Identical TFDP3 mutations were present in diagnostic samples from patients 
29779 and 30643. ROBO2 was affected by missense and nonsense mutations in 
patients 30142 and 29854 respectively. 
Two of the 6 samples had pathogenic variants in genes known to be recurrently 
mutated in ALL (figure 6.4).  
 
Figure 6.4. Mutations identified in known ALL-related genes (red) following Mutect variant caller 
and downstream filtering.  
D: diagnostic sample; R: relapse sample; VAF: variant allele frequency. 
 
6.4.2 Exome sequencing Mutect2 results 
Mutect2 was run on all seven tumour-germline pairs (including one relapse-germline 
pair) by the Bioinformatic Support Unit (Newcastle University), and as with Mutect 
variant calling, an annotated VEP file was produced for downstream filtering and 
variant interpretation. A similar filtering pipeline as shown previously (figure 6.2) was 
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used to identify candidate pathogenic mutations in each sample and R-package 
maftools was used for subsequent analysis. 
Across these seven patient samples, 5,115 variants were called by Mutect2 consisting 
of 2,403 SNVs, 1,083 insertions, 962 deletions, 667 substitutions. The high rate of 
insertions and deletions from the Mutect2 output was unusual. When visualised directly 
in IGV, many of these were thought to be artefact rather than genuine abnormalities. 
Most had very few supporting reads and were seen towards the ends of the sequencing 
reads. Furthermore, significant batch effect was noted. Almost all indels were detected 
in samples 29779 (diagnosis), 29780 (diagnosis), 30142 (diagnosis) and 30643 
(diagnosis), which were all part of the first sequencing batch. Very few were seen in 
29779 (relapse) and 31044 (diagnosis), which were sequenced on different runs at a 
later date. As such, a decision was made to exclude all the indels from downstream 
analysis. In comparison, the SNV calls appeared genuine in IGV and importantly, this 
still allowed comparison between Mutect and Mutect2 derived data. Following the 
subsequent filtering process outlined above (figure 6.2), 262 candidate pathogenic 
mutations were selected, equating to a median of 39 (range 12-79) variants per sample 
(figure 6.5).  
 
Figure 6.5. Summary of variants from Mutect2 output and downstream filtering from 7 patient 
samples  
SNV/SNP: single nucleotide variant; DNP: dinucleotide variant, TNP: trinucleotide variant; Miss: 
missense mutation; Non: nonsense mutation, Splice: splice site mutation; D: diagnostic sample; 
R: relapse sample; Miss: missense mutation; Non: nonsense mutation; Splice: splice site 
mutation. 
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As with the Mutect data, missense variants predominated and C>T transitions 
accounted for 38% (70/182) of base substitutions. Mutations in known ALL related 
genes were also identified through Mutect2 (figure 6.6). In patient 30643’s diagnostic 
sample, the same ETV6, KRAS and NT5C2 variants were identified by both variant 
callers, but a JAK2 variant was only identified through Mutect. In comparison, patient 
30142 had variants in PTPN11 and FOXO1 identified by both variant callers and a 
PDGFRB variant identified only by Mutect2. Exomes from patient 31044 were only 
processed through Mutect2. Here, a pathogenic TP53 mutation was detected, 
consistent with the underlying primary genetic abnormality of low hypodiploidy 
(Holmfeldt et al., 2013), as well as an NRAS mutation. 
 
Figure 6.6. Mutations identified in known ALL-related genes (red) following Mutect2 variant caller 
and downstream filtering. Variant allele frequency (VAF) data was not available from the Mutect2 
output.  
D: diagnostic sample; R: relapse sample. 
 
6.4.3 Mutect vs Mutect2 concordance 
To determine the concordance in variant calling between Mutect and Mutect2, SNVs 
were examined in isolation. All indels, dinucleotide and trinucleotide substitution calls 
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by Mutect2 and variants in patient sample 31044 (only analysed by Mutect2) were 
excluded to permit a direct comparison. Following variant calling and post-processing 
filtering as outlined above, SNV calls by Mutect (n=116) and Mutect2 (n=171) were 
examined. In total, 77 concordant SNVs were identified by both variant callers, leaving 
39 calls unique to Mutect and 94 calls unique to Mutect2. As noted above (figures 6.4 
and 6.6), the majority of SNVs in known leukaemia driver genes were identified by both 
methods.  
 
6.4.4 Mutational signatures 
Mutational signatures were successfully extracted from the unfiltered Mutect output 
using R-package maftools. The two most prominent mutational signatures across the 
exome cohort were identified as COSMIC signatures 1 and 25 (figure 6.7). 
 
Figure 6.7. Predominant COSMIC mutational signatures in exome cohort analysed using Mutect. 
Mutational signatures extracted using extractSignatures function in R-package maftools.  
 
COSMIC signature 1 is one of the signatures characterised by a prominence of C>T 
transitions. These occur specifically at NpCpG trinucleotide sites due to spontaneous 
deamination of 5-methylcytosine, which generates thymine. This leads to T-G 
mismatches, which may then fail to be repaired before DNA replication. This process 
is correlated with the age at cancer diagnosis, and is consistent with the observation 
that many of the observed mutations will have occurred prior to the onset of 
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malignancy, at a constant rate during post-natal development (Alexandrov et al., 2015).  
In comparison, COSMIC signature 25 has unknown aetiology and has been described 
in Hodgkin’s lymphoma cell lines, rather than primary patient material (Tate et al., 2019, 
Alexandrov et al., 2015). Other mutational signatures present most prominently 
alongside signature 25 included COSMIC signature 5 (cosine similarity 0.60), which is 
found in all cancer samples and has unknown aetiology and COSMIC signature 3 
(cosine similarity 0.59), which is associated with defective double stranded DNA repair 
by homologous recombination (Tate et al., 2019). 
 
6.4.5 Targeted sequencing results 
The targeted NGS results were analysed separately using HaplotypeCaller variant 
calling in the 30 patient targeted sequencing cohort. Following post-processing filtering 
of VEP files using the R pipeline outlined in figure 6.2, 61 SNVs and 17 indels were 
identified across the 30 patient samples. Apart from the artefactual ABL2 variants 
described in section 6.3.6, all other calls were confirmed visually in IGV. Specific 
variants in 14 of the genes were filtered out due to dbsnp identifiers that were not 
associated with any clinical significance. The final candidate pathogenic mutations 
discovered in the targeted sequencing cohort consisted of 34 SNVs and 14 indels and 
are shown in figure 6.8 along with the primary genetic abnormalities in relevant 
patients. Detailed mutational data can be found in supplementary table 11. In total, at 





Figure 6.8. Oncoplot of all mutations identified by targeted sequencing in 22/30 patient samples 
using GATK HaplotypeCaller and customised filtering pipeline (created using R-package 
maftools). 8/30 cases (not shown) had no pathogenic mutations in any of the 44 genes covered 
by the targeted panel.  
Multi-hit: single nucleotide variant (SNV) and indel in same gene; B-other: BCP-ALL with no 
identified primary chromosomal abnormality.  
 
6.4.6 Combined exome and targeted NGS cohort 
The combined NGS cohort (table 6.4) comprised a total of 36 patients, with diagnostic 




Patient ID Age (yrs) Sex (M/F) Genetic subgroup Sequencing technique 
29854 75 F BCR-ABL1 Exome 
25082 62 F BCR-ABL1 Targeted 
25208 62 M BCR-ABL1 Targeted 
25247 64 M BCR-ABL1 Targeted 
28057 64 F BCR-ABL1 Targeted 
28182 60 F BCR-ABL1 Targeted 
28350 62 F BCR-ABL1 Targeted 
28670 61 F BCR-ABL1 Targeted 
26660 62 F BCR-ABL1 Targeted 
31044 63 F HoTr Exome 
25437 64 F HoTr Targeted 
29407 60 F HoTr Targeted 
24401 54 F HoTr Targeted 
27400 46 F HoTr Targeted 
29491 51 M HoTr Targeted 
26910 43 M HoTr Targeted 
27478 58 F HoTr Targeted 
28581 65 F KMT2A-AFF1 Targeted 
25100 63 F KMT2A-v Targeted 
27642 72 F T-ALL Targeted 
30643 52 M IGH-CRLF2 Exome 
25130 62 F IGH-CRLF2 Targeted 
28893 27 M IGH-CRLF2 Targeted 
27833 73 F IGH-BCL2 Targeted 
27181 65 M IGH-CEBPE Targeted 
25552 61 M IGH-other Targeted 
25451 63 M EP300-ZNF384 Targeted 
25967 60 M Complex Targeted 
29780 55 F B-other Exome 
30142 66 F B-other Exome 
25267 63 F B-other Targeted 
26614 75 M B-other Targeted 
28335 63 M B-other Targeted 
24890 65 M B-other Targeted 
29779 87 M Unknown Exome 
24813 62 F Unknown Targeted 
Table 6.4. Combined cohort of patients with diagnostic samples analysed by NGS techniques. 
M: male; F: female; HoTr: low hypodiploidy/near triploidy; KMT2A-v: KMT2A fusion with non-
AFF1 partner; Complex: 5 or more unrelated chromosomal abnormality on karyotype; B-other: 
BCP-ALL with no identified primary chromosomal abnormality. 
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Median age at diagnosis for the combined cohort was 62 years (range 27-87) and 61% 
(n=22) of patients were female. The majority of patients (78%, n=28) were older adults 
aged 60 years and over at diagnosis. In total, eight younger adults were also included. 
Most of these (5/8) were over 50 years old, and had been included to optimise patient 
numbers and produce a more robust analysis. Additionally, three younger patients 
aged <50 years at diagnosis were also included due to unusual karyotypes which were 
suspicious for masked low hypodiploidy, with the aim of screening for TP53 variants 
(chapter 5, section 5.4.4). The combined cohort consisted of patients with BCR-ABL1 
(n=9), low hypodiploidy (n=8), KMT2A fusions (n=2), T-ALL (n=1), unknown (n=2). 
Additionally, fourteen B-other patients were included; IGH-CRLF2 (n=3), other IGH@ 
translocations (n=3), EP300-ZNF384 (n=1), complex karyotype (n=1), and B-other 
unspecified (n=6). 
 
6.4.6.1 TP53 mutations 
TP53 was the most commonly mutated gene in this cohort with variants detected in 
14% (5/36) of patients from the targeted NGS analysis (n=4) and exome sequencing 
analysis (n=1). These were all in low hypodiploid cases, which were relatively over-
represented in the patient cohort (8/36 patients). All TP53 variants were recognised 
pathogenic mutations, reported in the COSMIC database (Tate et al., 2019), and 
affected the DNA binding domain (TP53 p.P151S, p.Y220C and p.R282W) and the C-
domain (TP53 p.K305*) (figure 6.9). All affected cases had additionally lost one copy 




Figure 6.9. Protein domain and alteration plot detailing all TP53 mutations from targeted (n=4) 
and exome (n=1) sequencing (created using R-packages ensembldb and maftools). TP53 
p.P151S, p.Y220C and p.K305* were seen in single patients and TP53 p.R282W was present in 
two cases. 
 
6.4.6.2 RAS pathway mutations 
Several components of the RAS pathway were recurrently mutated in the cohort (figure 
6.10). KRAS was the most frequently affected member of the RAS pathway, with four 
mutations identified in 8% (3/36) of cases. Two distinct variants were seen in the 
diagnostic sample from patient 30643. These were not present on the same 
sequencing reads when examined in IGV, implying they most likely affected either 
different alleles or separate subclones. Overall, the KRAS mutations were present in 
two B-other patients (EP300-ZNF384 and IGH-CRLF2) and one 
t(4;11)(q21;q23)/KMT2A-AFF1 patient. NRAS was also mutated in 3/36 patients (one 
HoTr, one B-other (complex karyotype) and one unknown). Two identical FLT3 
variants were also found, both in HoTr patients. Apart from patient 30643, all RAS 
pathway mutations were in different patients. 
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Figure 6.10. Protein domain and alteration plots of RAS pathway genes mutated more than once 
across all 36 patients (created using R-packages ensembldb and maftools).  
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Two additional mutations in RAS pathway genes were also discovered; PTPN11 
p.A72V and NF1 p.R1375H, both in B-other ALL patients (30142 and 28893).  
In total, 11 RAS pathway mutations were identified in the cohort of 36 patients. All 
KRAS, NRAS, PTPN11 and FLT3 variants were confirmed somatic mutations in 
COSMIC, apart from KRAS p.R68W, which was a novel variant. The other KRAS, 
NRAS and PTPN11 mutations are well curated pathogenic mutations from multiple 
cancer types (Tate et al., 2019). In comparison, FLT3 p.V194M has been shown to be 
a tolerated passenger mutation in AML (Fröhling et al., 2007) and NF1 p.R1375H is a 
variant of unknown significance in the ClinVar database (Landrum et al., 2014).  
 
6.4.6.3 JAK2 mutations 
JAK2 mutations were discovered in 11% (4/36) patients (figure 6.11). The variants 
were exclusively seen in B-other patients, specifically three cases with IGH-CRLF2 
rearrangements (30643, 28893, 25130) and one where a primary chromosomal 
abnormality was not identified (24890). Unfortunately, CRLF2 break apart FISH could 
not be performed in this case as no fixed cells were available. JAK2 mutations are well 
described in BCP-ALL and are associated with the BCR-ABL1-like profile (Mullighan 
et al., 2009c), specifically patients with CRLF2 overexpression (Harvey et al., 2010). 
The p.R683 amino acid residue is the most frequent site of mutation in affected cases 
and is located in the pseudokinase (JH2) domain. Such mutations disrupt the negative 
auto-regulation of JAK2 activity, leading to constitutive activation, and increased JAK-




Figure 6.11. Protein domain plot detailing JAK2 mutations in four patients (created using R-
packages ensembldb and maftools). 
 
The JAK2 p.R683T and p.T875N are both reported pathogenic mutations in the 
COSMIC database and have been confirmed in BCP-ALL cohorts, whereas JAK2 
p.R769M and p.875I are novel somatic variants. 
 
6.4.6.4 PAX5 mutations 
The PAX5 variants (figure 6.12) were identified in 3/36 patients – two B-other and one 
BCR-ABL1+ patient.  
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Figure 6.12. Protein domain plot detailing PAX5 mutations in three patients (created using R-
packages ensembldb and maftools). 
 
PAX5 p.R38C is confirmed as a pathogenic somatic mutation in the COSMIC 
database. Both the PAX5 p.R38C and p.R140L variants have been previously 
identified in a large transcriptional analysis of BCP-ALL (Li et al., 2018). In comparison 
PAX5 p.A322T is present in the dbSNP database (Sherry et al., 2001) and although 
reported in ClinVar (Landrum et al., 2014), no conclusive evidence of pathogenicity or 
lack thereof is provided. 
 
6.4.6.5 Insertions and deletions 
Patient 25130 was found to harbour a 1bp insertion in ETV6 (NM_001987.5 c.1243-
1244insT) as well as a 4bp insertion in IKZF1 (NM_006060.6 c.185-186insTTCC). Both 
these events were seen in the vast majority of reads in IGV. By SNP array, this case 
had both IKZF1 and ETV6 deletions present, confirming that the small frameshift 
insertions identified affected the only remaining allele, most likely resulting in profound 
loss of function.  
Several frameshift insertions in NF1 were also discovered, specifically a 7bp insertion 
in patient 25437 (NM_001042492.3 c.7989-7990ins GGATAAG), a 1bp insertion in 
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patient 27478 (NM_001042492.3 c.7292-7293insG) and an 8bp insertion 
(NM_001042492.3 c.1977-1978ins GTCTCCGT) in patient 29407. All three patients 
had low hypodiploid ALL, where one copy of chromosome 17 had been deleted. As 
such these mutations affected the remaining NF1 allele, as is observed with TP53 
mutations in this subtype. A further patient (26910), also with low hypodiploid ALL, had 
a 1bp frameshift insertion in IKZF3 (NM_012481.5 c.266-267insT), which is also 
located on chromosome 17, and therefore resulted in biallelic inactivation. 
 
6.4.6.6 Mutations associated with clonal haematopoiesis 
DNMT3A, TET2 and ASXL1 are the most frequently mutated variants in clonal 
haematopoiesis and were therefore included in the targeted sequencing panel. In total, 
mutations in these genes were only detected in 8% (3/36) of patients (figure 6.8). 
Missense mutations in DNMT3A (DNMT3A p.L653V) and TET2 (TET2 p.R1572W) 
were identified as well as a 1bp insertion in ASXL1 (NM_015338.6 c.1926-1927insG). 
The TET2 variant was present in COSMIC and has previously been reported in chronic 
myelomonocytic leukaemia (Kohlmann et al., 2010). 
 
6.4.6.7 Genes associated with BCR-ABL1-like ALL 
Two pathogenic CSF1R variants were identified (CSF1R p.G413S and p.V32G in 
KMT2A rearranged and IGH@ rearranged patients respectively). Both mutations are 
reported in the COSMIC database and have previously been identified in myelofibrosis 
and/or myeloma, but not in ALL. Interestingly, an ABL1 mutation (ABL1 p.P829L) was 
identified in an IGH-CRLF2 +ve patients. This variant is also present in the COSMIC 
database, although has only been reported in a small number of non-haematopoietic 
tumours. Finally, a PDGFRB mutation (PDGFRB p.R439W) was identified in the 
Mutect2 analysis of a B-other ALL case. The variant was predicted to be deleterious 
and possibly damaging in the SIFT and PolyPhen databases but has not been reported 
in the literature. 
 
6.4.6.8 Other mutations 
In total, four ETV6 variants were discovered (3 indels and 1 SNV). The SNV (ETV6 
p.R418G) was identified in an IGH-CRLF2+ patient (figures 6.4 and 6.6), and is a 
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known germline variant associated with inherited thrombocytopenia and a 
predisposition to ALL (Noetzli et al., 2015). Interestingly, this mutation was identified in 
both the Mutect and Mutect2 analyses, supporting a somatic rather than germline 
event in patient 30643. The same patient also displayed an NT5C2 p.Y348D variant, 
potentially conferring resistance to purine analogues (Tzoneva et al., 2013). 
KDM6A mutations were discovered in two BCR-ABL1+ patients in the targeted NGS 
cohort (figure 6.8). The KDM6A p.Y215H and p.K987Q variants are not reported in the 
literature but the SIFT and Polyphen in silico prediction tools described deleterious and 
probably damaging consequences respectively.    
A somatic FOXO1 p.R21C mutation was identified in patient 30142 in the exome 
sequencing cohort. This patient did not have a primary genetic abnormality identified 
using standard genetic analyses, and interestingly FOXO1 variants, including p.R21C, 
are recurrent events in diffuse large B-cell lymphoma, where they are postulated to 
play a critical role in pathogenesis. FOXO1 p.R21C affects the N-terminal domain of 
the protein resulting in loss of phosphorylation with associated nuclear retention and 
increased transcriptional activity (Trinh et al., 2013). 
 
6.4.7 Clonal tracking of variants through ALL treatment 
Diagnostic (n=6), follow up (n=15) and relapse (n=1) samples (figure 6.1) were 
obtained for the six patients in the exome sequencing and clonal tracking work 
package. Based on findings from the exome sequencing analysis, the mutations 
detailed in table 6.5 were selected to design the SureSelect XT HS2 capture library. In 
addition to these regions, all exons of TP53, exons 2 and 3 of NRAS and KRAS and 
exons 3, 8 and 13 of PTPN11 were also included due to their prevalence in driving 
relapse (Irving et al., 2014). Indeed, it is conceivable that such events could be present 
in subclones at very low allele frequencies in diagnostic samples, evading detection by 
exome sequencing, but identifiable using this highly sensitive technique with molecular 
barcoding. Also, due their role in clonal haematopoiesis, all exons of DNMT3A and 
TET2 together with exons 11 and 12 of ASXL1 were included in the capture library 
(supplementary table 10). 
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Sample Gene Location Consequence Amino acid change 
29779 ABCA1 chr9:107582289 Missense variant V/M 
29779 ALPK2 chr18:56247149 Missense variant D/Y 
29779 NFKBID chr19:36380898 Missense variant E/G 
29779 COL4A6 chrX:107417755 Missense variant P/R 
29779 TFDP3 chrX:132351898 Missense variant C/W 
29779_rel HDAC1 chr1:32790095 Missense variant D/G 
29779_rel EXT1 chr8:119122811 Missense variant D/N 
29779_rel ABCA1 chr9:107582289 Missense variant V/M 
29779_rel ALPK2 chr18:56247149 Missense variant D/Y 
29779_rel NAA10 chrX:153199405 Missense variant L/Q 
29780 HMCN1 chr1:186114957 Missense variant R/Q 
29780 ACTN2 chr1:236908040 Missense variant R/H 
29780 COL5A2 chr2:189916926 Missense variant A/V 
29780 PTPRD chr9:8436635 Missense variant R/T 
29780 PTCH1 chr9:98238416 Missense variant R/H 
29854 USH2A chr1:216062120 Missense variant P/L 
29854 ROBO2 chr3:77526570 Stop gained R/* 
29854 DYNC1I1 chr7:95665015 Missense variant V/M 
29854 KMT2C chr7:151848600 Missense variant C/Y 
29854 PIEZO1 chr16:88786335 Stop gained W/* 
30142 RIT1 chr1:155874263 Missense variant M/V 
30142 DNAH7 chr2:196729067 Missense variant R/C 
30142 ROBO2 chr3:77626709 Missense variant V/F 
30142 PTPN11 chr12:112888199 Missense variant A/V 
30142 FOXO1 chr13:41240289 Missense variant R/C 
30643 JAK2 chr9:5089726 Missense variant T/I 
30643 NT5C2 chr10:104853013 Missense variant Y/D 
30643 ETV6 chr12:12038959 Missense variant R/G 
30643 KRAS chr12:25398262 Missense variant L/F 
30643 KRAS chr12:25398284 Missense variant G/D 
30643 TFDP3 chrX:132351898 Missense variant C/W 
31044 NRAS chr1:115258748 Missense variant G/S 
31044 TP53 chr17:7578190 Missense variant Y/C 
Table 6.5. Mutations identified from exome sequencing selected for clonal tracking capture 
library. Unless stated otherwise events were detected in diagnostic patient samples.  




Unfortunately, prior to commencing the SureSelect XT HS2 library prep, the COVID-
19 pandemic resulted in the suspension of all laboratory activity so this experiment 
could not be completed in the required timeframe.  
 
6.5 Discussion 
In total, 36 patient samples had NGS analyses performed, including targeted panel 
sequencing (n=30) and exome sequencing (n=6). A customised filtering pipeline was 
designed to screen the annotated VEP files generated by the GATK Mutect, Mutect2 
and HaplotypeCaller variant callers.  
Mutect and Mutect2 variant calling produced biologically plausible SNVs that could be 
readily confirmed in IGV. Unfortunately, indels generated by Mutect2 frequently 
appeared artefactual when visualised so were excluded from further analysis. The 
exact reason for the indel anomalies could not be elucidated in this study, although a 
very strong batch effect was noted, whereby almost all were detected in 4/6 samples, 
which were all sequenced on the same run. Indel artefact has been noted previously 
with Mutect2 in The Cancer Genome Atlas (TCGA) database, although chiefly on 
whole genome amplified samples (Buckley et al., 2017).  
Of the SNVs detected by Mutect, 66% (77/116) were also detected by Mutect2 and of 
the SNVs detected by Mutect2, 45% (77/171) were also detected by Mutect. Mutect2 
has the potential to detect variants at lower VAFs than most other comparable variant 
callers (Xu, 2018, Wang et al., 2019), which may in part explain the discrepancy and 
larger number of calls generated.  
The most common mutations were C>T transitions, which accounted for around 40% 
of base substitutions in candidate driver genes. Based on the trinucleotide context of 
all identified mutations, the two predominant mutational signatures were COSMIC 
signature 1, associated with ageing, and COSMIC signature 25, of unknown aetiology. 
The cosine similarity index was around 0.6 for both signatures, indicating some 
similarities, but not a strong match. Relatedly, exome, unlike whole genome 
sequencing, does restrict the number of events that can be used for mutational 
signature profiling so these data only permitted a limited analysis of mutational 
signatures.  
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The targeted analysis confirmed SNVs (n=34) were more common than indels (n=14)  
in leukaemia-related genes. Two cases were affected by both an SNV and indel in the 
same gene (“Multi-hit”) (figure 6.8 and supplementary table 11). The affected genes 
were IL7R (case 24890) and CREBBP (case 27833). The CREBBP variants were seen 
in the same sequencing reads and were therefore present on the same allele. The 
IL7R variants were too far apart to verify whether they were present on different alleles. 
The combined exome and targeted sequencing cohort consisted of 36 patients, which 
represented the major genetic subgroups of adult ALL, permitting a relatively 
comprehensive analysis of the genomic landscape of ALL in older adults. TP53 and 
NF1 were the most frequently mutated genes, and were almost exclusively seen in low 
hypodiploid cases. Interestingly, NF1 seemed particularly susceptible to indel 
mutations in this subtype. A single additional NF1 variant was identified in an IGH-
CRLF2 patient, although the diagnostic karyotype also showed large scale ploidy shift. 
Both genes are tumour suppressors and are present on chromosome 17, which almost 
always becomes monosomic in low hypodiploidy, so these events will very likely have 
produced a profound impact on protein function. Given that these mutations occur 
specifically in HoTr ALL and that this entity was slightly over-represented in this NGS 
cohort (19% vs 14% of cases in the unselected clinical trial population of older adults 
in chapter 3), it is difficult to be certain of the true incidence of TP53 and NF1 mutations 
in older adults with ALL. 
Pathogenic mutations in components of the RAS signalling pathway were present in 
31% (11/36) of patients and affected NF1 (n=4), KRAS (n=3), NRAS (n=3) and 
PTPN11 (n=1). The variants were identified in patients with a range of primary 
abnormalities, specifically low hypodiploidy (n=4), IGH-CRLF2 (n=2), EP300-ZNF384 
(n=1), KMT2A-AFF1 (n=1), B-other (n=1) and unknown (n=1). Interestingly, RAS 
pathway mutations were not seen in BCR-ABL1+ patients. The majority of the variants 
detected are known to activate RAS signalling (Vatansever et al., 2019, Wang et al., 
2013, Niihori et al., 2005), which leads to uncontrolled cellular proliferation and 
malignant transformation (Downward, 2003).  
JAK2 mutations were very strongly associated with IGH-CRLF2 and were seen in all 
three patients with this gene rearrangement, as well as one additional patient without 
an identified primary chromosomal abnormality. The co-occurrence of CRLF2 
overexpression and activating JAK2 mutations is known to result in constitutive JAK-
STAT signalling, which is a feature of this genetic subtype (Mullighan et al., 2009a).  
 195 
The only gene recurrently mutated in BCR-ABL1+ patients in this cohort was KDM6A, 
which was disrupted in two cases (28670 and 25082). Interestingly, both cases had 
multiple additional chromosomal abnormalities visible on karyotype. No BCR-ABL1 
kinase domain mutations were identified, which are known to confer resistance to 
imatinib (Soverini et al., 2006). 
Interestingly, a mutation in NT5C2 was seen at a high VAF in the diagnostic sample 
for patient 30643 (figure 6.4). This gene is commonly implicated in the relapse setting, 
whereby mutations confer resistance to thiopurines, which play a major role in the 
management of ALL in all age groups, throughout the treatment schedule. Unlike many 
other relapse-founder mutations, these events are not reported at diagnosis, purely 
emerging through therapy following exposure to thiopurines (Dieck and Ferrando, 
2019). The clinical significance of identifying pathogenic NT5C2 mutations in 
diagnostic samples is not clear but could conceivably signpost the need for increased 
monitoring for the emergency of treatment resistant clones. The variant identified 
(NT5C2 p.Y348D) is not reported in the literature, although is predicted as deleterious 
and probably damaging to protein function in the SIFT and PolyPhen databases 
respectively.  
Overall, the mutational profile of older adults with ALL correlated with the primary 
chromosomal abnormalities and largely mirrored the aberrations seen in younger 
patients. As the exome sequencing cohort was small and the targeted panel was based 
on known leukaemia genes, the potential for discovery of new lesions was fairly limited. 
Interestingly, the three genes most commonly mutated in clonal haematopoiesis 
(DNMT3A, TET2 and ASXL1) were only mutated in 8% of patients, which is very similar 
to the background rate in age-matched controls (Jaiswal et al., 2014). This suggests 
that clonal haematopoiesis is unlikely to play a significant role in the pathogenesis of 
ALL in older adults.  
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Chapter 7. Discussion 
 
ALL in older adults is an area of unmet clinical need with very poor prognosis and high 
treatment related morbidity. To date, the genetic and genomic characterisation of these 
patients has been very limited, mainly focussing on the frequency of BCR-ABL1 
positive disease. This study provides the largest genetic characterisation to date of 
older adults with ALL. Median patient age was 64 years, and a quarter of patients were 
over 70 years old.  
 
7.1 Genetic and genomic landscape of ALL in older adults 
The landscape of primary chromosomal lesions and secondary copy number 
abnormalities is clearly distinct from that observed in children and younger adults. The 
incidence of T-ALL peaks at 20-29 years of age and then rapidly drops thereafter 
(Marks et al., 2009). This effect seems to continue in later life, with a reported T-cell 
disease frequency of 14% in ALL patients aged 55-65 years (Sive et al., 2012), 
dropping further to only 5% in this study.  
Overall, 26% of patients in this study were BCR-ABL1 positive. There was no evidence 
of increasing frequency of Philadelphia positivity with advancing age over the age of 
60 years, which supports the findings from the large German study where this was 
seen to plateau after 45 years of age (Burmeister et al., 2008). In comparison, this 
study is the first to demonstrate that low hypodiploidy/near triploidy becomes more 
frequent with advancing age, whereby it is encountered in <2% of childhood patients, 
4-9% of adults aged 25-60 (Safavi and Paulsson, 2017, Moorman et al., 2019) rising 
to around 15% of adults aged 60 years and over (chapter 3). Other high risk 
cytogenetic subgroups, specifically KMT2A fusions and complex karyotypes were 
present in 6% and 3% of patients respectively, indicating a frequency very similar to 
that seen in younger adults (Moorman et al., 2019, Moorman et al., 2007). High 
hyperdiploidy was very rare in this patient cohort (<1%) and ETV6-RUNX1 remains 
unreported in older patients. The cytogenetically cryptic primary chromosomal 
 197 
abnormalities CRLF2, ZNF384 and MEF2D rearrangements were identified in 5%, 2% 
and <1% of the complete patient cohort respectively.  
Copy number abnormalities in key genes recurrently disrupted in ALL were discovered 
in the majority of patients. IKZF1 loss was present in over half of all cases tested by 
SNP array, affecting 70% of BCR-ABL1 positive and 40% of BCR-ABL1 negative 
patients. The high rate of IKZF1 loss in BCR-ABL1+ ALL is consistent with much of the 
published literature (Mullighan et al., 2008a, Fedullo et al., 2019). However, the 
frequency of IKZF1 deletion in Philadelphia negative patients was double that reported 
in younger adults (Moorman et al., 2012). This discrepancy is at least in part driven by 
the increased frequency of low hypodiploidy in older adults. Deletions in other key 
driver genes in BCP-ALL (CDKN2A/B, PAX5, RB1, ETV6 and EBF1) were also 
encountered more frequently than in younger adults (Moorman et al., 2019). 
Interestingly, KDM6A deletions were discovered in 5% (4/83) of patients who 
underwent SNP array analysis, specifically low hypodiploid (n=2), B-other (n=1) and 
T-ALL (n=1) patients (chapter 4). Inactivating KDM6A mutations were also seen in 6% 
(2/36) of patients who had NGS analyses, exclusively in BCR-ABL1 positive patients 
(chapter 6). KDM6A is well recognised as a tumour suppressor gene, involved in 
epigenetic regulation through repression of PRC2/EZH2 activity. For the first time, 
KDM6A disruption has been demonstrated in a significant proportion of ALL patients 
(~10% of screened patients combining SNP array and NGS analyses). Overall, this 
therefore represents a proportion of patients who may respond to EZH2 inhibition, 
particularly if KDM6A inactivation is a truncal event in leukaemogenesis of affected 
cases. 
RAS pathway activating mutations are recurrent abnormalities in many malignancies. 
These have been found to be prevalent in paediatric BCP-ALL and are particularly 
enriched in certain subgroups such as high hyperdiploidy (Jerchel et al., 2018, 
Paulsson et al., 2015). In this study, of the 36 patient samples analysed by NGS 
techniques, RAS pathway mutations were identified in one third (11/36). Childhood 
ALL studies have reported frequencies of RAS pathway mutations ranging 30-45% 
(Case et al., 2008, Irving et al., 2014, Jerchel et al., 2018). In such cohorts, the 
frequency of RAS mutations is partly driven by the prevalence of high hyperdiploidy, 
which is particularly strongly associated with these abnormalities (Paulsson et al., 
2015). To date, comparable genomic studies in adult ALL are lacking. However, this 
study (chapter 6) has demonstrated that the high rate of RAS pathway mutations 
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continues in older adults with ALL, where they were identified in a range of genetic 
subgroups with the notable exception of BCR-ABL1 positive disease.  
 
7.2 Prognostic biomarkers and druggable lesions 
Chromosomal abnormalities associated with a poor prognosis are over-represented in 
older adults and this is accompanied by a steep decrease in those associated with a 
favourable outcome. The most important prognostic and predictive biomarker in older 
adults is the presence of BCR-ABL1 translocation. Although BCR-ABL1 positivity is 
usually associated with high risk disease, and considered an indication for allografting 
in first complete remission, Philadelphia positive older adults fare better than their 
Philadelphia negative counterparts (Gökbuget, 2013, Ribera et al., 2016). The advent 
of TKIs has permitted these patients to achieve complete remission with a significantly 
reduced burden of cytotoxic chemotherapy and its associated toxicity (Ottmann et al., 
2007, Rousselot et al., 2016). Indeed, recent combinations of TKI with immunotherapy-
based treatment have yielded promising chemotherapy-free options for such patients 
(Foà et al., 2020), thereby further reducing the treatment related morbidity and 
mortality, which needs to be at the forefront of all advances in the management of older 
adults with ALL. Although such approaches produce excellent rates of complete and 
even molecular remissions, the rate of sustained disease-free survival in the absence 
of allogeneic stem cell transplantation is still not clear. Philadelphia positive ALL may 
retain its high eventual relapse rate, although this needs to be viewed in the context of 
remaining life-years and death from other causes. 
The copy number status of 8 key genes/regions provides another prognostic 
biomarker, which is well validated in paediatric BCP-ALL. The high risk IKZF1plus copy 
number profile was identified in over a third of patients in this study (chapter 4), 
although its prognostic impact in older adults still needs to be elucidated. Moreover, no 
focal ERG deletions were identified. The latter are associated with favourable outcome 
(Clappier et al., 2014) and specifically co-occur with DUX4 rearrangements, which 
represent a more recently identified primary genetic abnormality (Zhang et al., 2016). 
Overall, these data confirm that all genetic biomarkers typically associated with a 
favourable outcome, namely ETV6-RUNX1 fusion, high hyperdiploidy and ERG 
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deletions are exceedingly rare in older adults with ALL, contributing to the challenges 
of treating this patient population. Additionally, as outcome data from older adult ALL 
trials mature, it may be that the important genetic biomarkers are distinct from those 
applied to younger patient groups. As mentioned previously, the presence of BCR-
ABL1 fusion improves outcome in older adults. The prognosis of older adults may 
therefore be primarily driven by whether or not a targetable genetic lesion is present, 
rather than underlying chemoresponsiveness and early attainment of MRD negativity. 
Over the last few years, the advent of bispecific antibodies and immunoconjugates has 
further improved the tolerability and effects of treatments. Currently, these are 
principally used in the relapse setting but, as with TKIs, there is good evidence that 
use of such therapies permits dramatic reduction in the burden of cytotoxic 
chemotherapy whilst retaining effective responses. A study of the anti-CD22 
immunoconjugate inotuzumab in combination with low intensity chemotherapy in older 
adults with ALL resulted in a 2-year progression free survival of 59% (Kantarjian et al., 
2018) and a ‘chemotherapy-free’ schedule of dasatinib and blinatumomab has shown 
particular promise in Philadelphia positive disease (Foà et al., 2020), paving the way 
for antibody-small molecule inhibitor combinations in ALL. 
Discovering gene rearrangements in genetically uncharacterised patients has the 
potential of identifying targetable lesions, as well as improving prognostication. CRLF2 
overexpression usually co-occurs with JAK2 mutations and leads to JAK-STAT 
pathway activation. The JAK inhibitor ruxolitinib has shown activity in patients with 
deregulated JAK-STAT signalling (Ding et al., 2018, Jain et al., 2017a) and a phase 2 
clinical trial of ruxolitinib is in progress for children with CRLF2 rearranged or JAK 
pathway mutated ALL (INCB-18424-269). JAK inhibition may therefore provide a 
therapeutic avenue for older patient with these abnormalities. 
The finding of focal biallelic KDM6A deletions provides another potential druggable 
target, although was only seen in a small number of cases. Importantly, as a 
transcriptional regulator, loss of KDM6A function results in EZH2 overactivity, which is 
important in the pathogenesis of several cancers. As such, the EZH2 inhibitor 
tazemetostat is being investigated for the treatment of advanced urothelial cancer with 
KDM6A loss of function (Ler et al., 2017), and is already FDA approved for relapsed-
refractory follicular lymphoma with activating EZH2 mutations. Future work is needed 
to identify whether such compounds are effective in the treatment of ALL with KDM6A 
abnormalities.  
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Several groups have demonstrated that leukaemic cells bearing clonal RAS mutations 
are sensitive to MEK inhibitors such as selumetinib (Ryan et al., 2016, Jerchel et al., 
2018), thereby providing a further avenue for non-chemotherapeutic targeted 
treatment options in frailer patients. Given that RAS mutations were identified in high 
risk subgroups, often considered incurable without stem cell transplantation, such as 
low hypodiploidy and KMT2A-rearranged ALL, MEK inhibitors may be an attractive 
option in older patients with these abnormalities. Relatedly, a high degree of synergism 
has been identified between selumetinib and glucocorticoids (Matheson et al., 2019). 
In turn, this has led to a phase I/II clinical trial investigating the combination of 
selumetinib and dexamethasone in children and adults with relapsed ALL and RAS 
pathway mutations (SeluDex, ISRCTN92323261). 
Even though certain cryptic gene rearrangements were identified in B-other ALL 
samples, an even greater number of patients remain genetically uncharacterised, 
posing an ongoing challenge for accurate prognostication and management. 
Techniques such as whole genome and transcriptome sequencing will likely be crucial 
for future discovery of novel gene rearrangements, although do require suitable 
material (often including matched germline samples) for their successful use. As such 
methods become more widely available and routinely integrated into clinical trials, 
more comprehensive characterisation of the genetic drivers of leukaemogenesis will 
become possible. Indeed, a large study combining genetic, genomic and 
transcriptomic analyses of BCP-ALL samples has identified 24 subtypes (Gu et al., 
2019). Nine of these were defined by integration of gene expression profile, karyotype 
and/or mutations, highlighting that any single technique is not sufficient to identify all 
subgroups. Such novel subgroups may account for the B-other patients in chapter 3 
that remain genetically uncharacterised using karyotype and FISH analyses.  
 
7.3 Novel approach to the diagnosis of low hypodiploidy 
Low hypodiploidy is one of the genetic entities associated with the poorest overall 
survival in all age groups (Pui et al., 1987, Charrin et al., 2004), and is the second most 
prevalent chromosomal abnormality in older adults (chapter 3). With the aim of 
shedding further light on this genetic entity, and specifically its distinction from high 
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hyperdiploidy, SNP arrays were performed on a large cohort of samples with ploidy 
shift. Unexpectedly, this revealed that low hypodiploid ALL is even more common than 
currently appreciated. A number of patients classified as high hyperdiploidy actually 
had masked low hypodiploidy, confirming that modal chromosome number alone is an 
inaccurate segregator of the two ploidy groups. The rate of misclassification was 
particularly high in older adults, and crucially highlight that low hypodiploidy may be 
even more prevalent than is currently reported in the ALL cytogenetic literature. 
Importantly, characteristic fluctuations in log2 ratios on a chromosomal level have 
facilitated the development of a diagnostic classifier (chapter 5), which could aid future 
accurate classification of such cases. This analysis has been based on the largest SNP 
array cohort of low hypodiploid/near triploid samples reported to date, and is 
particularly relevant to future prognostication of adult ALL patients. Such diagnostic 
issues can produce a significant impact on therapeutic decisions and these findings 
should in particular prompt caution with the categorisation of high hyperdiploidy in adult 
patients.  
This analysis also raised interesting biological observations into the relationship 
between low hypodiploidy and near triploidy. Masked low hypodiploidy is thought to 
arise through duplication of a low hypodiploid clone, producing cells with a near triploid 
karyotype. Such karyotypes would typically be expected to harbour disomies and 
tetrasomies, having arisen through chromosomal doubling. Interestingly, a number of 
otherwise characteristic masked low hypodiploid cases by SNP array had widespread 
trisomies. Although this calls into question the underlying mechanism through which 
near triploidy occurs, the presence of pathogenic TP53 mutations and the 
unsupervised clustering results support low hypodiploid and near triploid cases being 
biologically related. Matched germline samples were not available so the origin of the 
TP53 mutations could not confirmed, although previous studies suggest these are 
somatic in adults with low hypodiploid ALL (Mühlbacher et al., 2014). As well as TP53 
variants, other mutations were discovered in low hypodiploid samples. Affected genes 
were frequently also located on chromosome 17, namely NF1 (n=4) and IKZF3 (n=1), 
supporting the hypothesis that chromosomal loss unmasks recessive alleles (Safavi 




As a project performed entirely on primary patient material, experiments were highly 
dependent on the availability of suitable samples. FISH analyses required fixed cell 
samples that had been obtained from diagnostic cytogenetic laboratories throughout 
the UK. In a number of cases, such samples were either not available or had 
insufficient material to perform all required FISH tests.  
Similarly, SNP arrays were limited by availability of DNA extracted from the bone 
marrow aspirate at ALL diagnosis. A number of these samples had already been used 
for standard-of-care procedures such as MRD marker identification, and were often 
already depleted. As such, not all potential novel CNAs could be included in the 
subsequent SureSelect XT2 validation cohort. 
SNP arrays were performed on two different platforms, with significant differences in 
probe density. Although they were analysed using the same software, platform-specific 
adjustments of segmentation settings had to be made to try to minimise bias. Despite 
this, there was still a small difference between the average number of calls generated 
through Affymetrix and Illumina arrays that is unlikely to be biologically driven. Indeed, 
the Affymetrix arrays had poorer quality scores and may have produced a higher rate 
of false positive calls. It is therefore possible that the Affymetrix array performed less 
well with poorer quality material, although operator and protocol familiarity issues could 
have also played a part. For greater consistency, the study would have ideally been 
performed using a single SNP array platform. 
Next generation sequencing techniques that cover large amounts of the human 
genome such as exome or whole genome sequencing, are reliant on the provision of 
matched germline samples to exclude benign constitutional variants. In this project, 
germline DNA was extracted from buccal cells. Unfortunately, the quality of this DNA 
was highly variable. Despite repeated buccal sampling, a sufficient amount of suitable 
quality germline DNA was only obtained in two out of six patients in the exome cohort. 
Fortunately, remission bone marrow DNA was available to provide an acceptable 
matched germline alternative in the other patients. Given the depth of coverage (90x) 
used for sequencing these remission samples, it is unlikely that low level leukaemic 
clones will have been detected, and therefore incorrectly flagged as constitutional 
variants. However, it is possible that other somatic mutations (e.g. variants associated 
 203 
with clonal haematopoiesis) could have been filtered out if they were detected both in 
remission and diagnostic DNA. Indeed, clonal haematopoiesis is known to frequently 
persist in remission in patients treated for AML (Tanaka et al., 2019).  
Throughout the majority of this project, older adults have been defined as those aged 
60 years and over at diagnosis of ALL, matching cut-offs used regularly in clinical trials 
and the majority of the existing literature (Gökbuget, 2013, Thomas et al., 2001). All 
patients included in chapters 3 and 4 were therefore selected specifically from this age 
group. However, chapter 6 required prospective collection of diagnostic and matched 
germline samples from locally recruited patients. To maximise enrolment for 
biobanking, patients aged 50 years and over were approached. In total, two out of the 
six patients in the exome sequencing cohort were therefore aged 50-60 years, with the 
remaining four patients aged over 60 years at diagnosis. Similarly, chapter 5 detailed 
SNP array-based signatures of genetic ploidy groups, with the primary objective of 
accurately identifying masked low hypodiploid cases, which is particularly important in 
older adults due to its prevalence. To obtain sufficient cases for a robust analysis, 
younger adults and children were also included, principally to create the high 
hyperdiploid comparison cohort, which would not have been possible with older adults 
alone. 
 
7.5 COVID-19 impact on this project 
The COVID-19 pandemic had a large impact on the work detailed in chapter 6 of this 
thesis. The aims of this work package had centred around using NGS techniques to 
track leukaemia-associated mutations through treatment. Patient recruitment and 
biobanking of samples had commenced in 2017 and a total of 22 samples had been 
obtained (6 diagnostic, 16 follow up). Following analysis of somatic mutations from 
exome sequencing, a customised sequencing panel using molecular barcoding was 
designed and manufactured to track and quantify these events in the remission 
samples. Unfortunately, immediately prior to commencing the library prep workflow, all 
laboratory work was suspended due to the COVID-19 pandemic. 
Chapter 6 was therefore modified to focus on the mutational landscape of ALL in older 
adults. Together with the exome samples, the patient samples used in the NGS 
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validation of CNAs from chapter 4 had mutational analyses performed by virtue of the 
technique used. Due to the small number of RNA baits needed to cover exons alone, 
a number of genes could be included in this experiment, together with the larger 
regions required for validation of copy number breakpoints. The resulting gene panel 
covered most of the recurrently mutated genes in ALL (supplementary tables 3 and 4) 
and therefore permitted a broader mutational characterisation of ALL in older adults 
than had originally been intended, as an alternative to the planned clonal tracking 
experiment.  
 
7.6 Future work 
Overall, 37% (68/184) of older adults with BCP-ALL in the UKALL14 and UKALL60+ 
clinical trial cohort remain uncharacterised in terms of primary genetic abnormalities. 
Such cases are likely to benefit from the use of non-targeted techniques for the 
discovery of fusion genes or initiating mutations such as whole genome or whole 
transcriptome sequencing.  
Several novel focal gene deletions were discovered and validated. In particular, the 
KDM6A deletions provide a plausible driver abnormality meriting further investigation. 
In the first instance, this would need to be functionally assessed, for example, by 
performing gene knockdown experiments in a cell line model, including evaluation of 
EZH2 expression. The therapeutic effects of EZH2 inhibitors could then also be 
assessed. 
With outcome data, it will be important to correlate genetic subgroups and CNAs with 
prognosis. In particular, the prognostic value of BCR-ABL1 positivity compared to other 
subgroups, in patients who are frequently unsuitable for intensive treatments, will 
provide valuable insight into the benefit of targeted disease-modifying therapies in 
older patients. However, as the patients were treated in two separate trials, one of 
which (UKALL60+) offered four separate arms with different treatment intensities, a 
number of additional confounders will need to be taken into account to produce 
accurate subgroup-specific survival analyses.  
The SNP array characterisation of low hypodiploid ALL identified masked cases with 
unexpectedly low modal chromosome numbers that had been incorrectly classified as 
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high hyperdiploidy. This raises interesting uncertainties around the presumed 
duplication process and the formation of such near triploid karyotypes, particularly 
where trisomies rather than tetrasomies predominate. Addressing these issues would 
likely benefit from single cell genomic analyses. Specific comparisons will need to be 
made between the three main phenotypes of the low hypodiploid subgroup, namely 
patients presenting with a low hypodiploid clone alone, those with both low hypodiploid 
and near triploid clones and those with only a near triploid clone. 
Part of this work has already been presented in abstract format at the 61st ASH Annual 
Meeting (Creasey et al., 2019a, Creasey et al., 2019b), and granted an ASH Abstract 
Achievement Award. The work detailed in chapter 5 is also currently under 
consideration for publication. 
 
7.7 Final conclusion 
With an ageing population, the prevalence of older adults with ALL will increase. 
Optimising treatment for these patients poses a unique set of challenges, which are 
less regularly encountered in other age groups, namely that the existing approaches 
and aims of treatment, are often unsuitable for older individuals. Shifting the focus from 
traditional disease eradication through high intensity therapy to disease control through 
targeted therapy is of particular importance in these patients, and has already greatly 
benefited BCR-ABL1 positive patients. Pursuing other targets for personalised therapy 
based on the genetic and genomic aberrations encountered, will ultimately lead to a 
reduction in treatment-related morbidity and mortality and prolong survival. To this end, 
a greater understanding of the mechanisms of ALL leukaemogenesis in older adults 
will be required. Age-related clonal haematopoiesis does not appear to feature strongly 
in the pre-leukaemic background and the pre-natal lesions of childhood ALL are 
implausible initiating abnormalities. There is a clear association between specific high-
risk genetic features and advancing age at diagnosis, and molecular characterisation 
will have the potential to transform front-line treatment in a group of patients likely to 
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Supplementary table 1  
Patient demographics and details of genetic/genomic analyses conducted for all older 
adults included in chapters 3, 4 and 6. ‘Extended FISH’ refers to FISH experiments 




























































24309 63 Male UKALL14 B-other ✓ ✓ ✓ ✓   
24813 62 Female UKALL14 No data   ✓ ✓ ✓  
24890 65 Male UKALL14 B-other ✓  ✓ ✓ ✓  
24919 64 Female UKALL14 BCR-ABL1 ✓  ✓ ✓   
24983 60 Female UKALL14 BCR-ABL1 ✓      
25082 62 Female UKALL14 BCR-ABL1 ✓  ✓ ✓ ✓  
25100 63 Female UKALL14 KMT2A-r ✓  ✓  ✓  
25101 63 Female UKALL14 B-other ✓ ✓     
25102 63 Female UKALL14 HoTr ✓      
25123 60 Male UKALL14 HoTr ✓      
25130 62 Female UKALL14 CRLF2-r ✓ ✓ ✓ ✓ ✓  
25208 62 Male UKALL14 BCR-ABL1 ✓  ✓ ✓ ✓  
25235 63 Male UKALL14 ZNF384-r ✓ ✓     
25237 63 Female UKALL14 No data    ✓   
25246 64 Male UKALL14 CRLF2-r ✓ ✓ ✓ ✓   
25247 64 Male UKALL14 BCR-ABL1 ✓  ✓ ✓ ✓  
25267 63 Female UKALL14 MEF2D-r ✓ ✓ ✓ ✓ ✓  
25293 63 Male UKALL14 B-other ✓      
25344 61 Female UKALL14 B-other ✓ ✓ ✓ ✓   
25346 64 Male UKALL14 BCR-ABL1 ✓  ✓ ✓ ✓  
25371 60 Female UKALL14 CRLF2-r ✓ ✓ ✓ ✓   
25373 65 Male UKALL14 B-other ✓  ✓ ✓   
25415 64 Female UKALL14 B-other ✓ ✓     
25426 64 Female UKALL14 B-other ✓ ✓     
25437 64 Female UKALL14 HoTr ✓  ✓  ✓  





























































25491 63 Male UKALL14 BCR-ABL1 ✓      
25548 60 Female UKALL14 BCR-ABL1 ✓  ✓ ✓   
25552 61 Male UKALL14 IGH@-r ✓  ✓ ✓ ✓  
25685 62 Male UKALL14 No data       
25688 62 Male UKALL14 T-cell ✓      
25694 60 Male UKALL14 KMT2A-r ✓      
25695 63 Male UKALL14 HoTr ✓      
25709 62 Female UKALL14 KMT2A-r ✓   ✓   
25793 67 Female UKALL60 BCR-ABL1 ✓  ✓  ✓  
25794 65 Female UKALL60 HoTr ✓      
25842 64 Male UKALL14 HoTr ✓      
25893 78 Female UKALL60 BCR-ABL1 ✓  ✓ ✓   
25894 63 Male UKALL60 IGH@-r ✓      
25895 67 Male UKALL60 B-other ✓ ✓     
25907 70 Male UKALL60 IGH@-r ✓ ✓     
25925 61 Female UKALL14 BCR-ABL1 ✓      
25949 61 Female UKALL14 B-other ✓      
25953 71 Female UKALL60 BCR-ABL1 ✓  ✓ ✓   
25967 60 Male UKALL14 B-other ✓ ✓ ✓ ✓ ✓  
26062 61 Male UKALL14 BCR-ABL1 ✓  ✓ ✓   
26609 83 Male UKALL60 BCR-ABL1 ✓  ✓ ✓   
26610 65 Male UKALL60 BCR-ABL1 ✓  ✓ ✓   
26611 68 Male UKALL60 B-other ✓ ✓  ✓   
26612 66 Male UKALL60 B-other ✓ ✓     
26613 66 Male UKALL60 B-other ✓      
26614 75 Male UKALL60 B-other ✓  ✓ ✓ ✓  
26621 69 Female UKALL60 T-cell ✓  ✓ ✓   
26659 60 Male UKALL14 HoTr ✓  ✓    
26660 62 Female UKALL14 BCR-ABL1 ✓  ✓ ✓ ✓  
26682 63 Female UKALL60 BCR-ABL1 ✓  ✓ ✓   
26706 60 Male UKALL14 HoTr ✓  ✓    
26726 66 Male UKALL60 B-other ✓  ✓ ✓   
26732 64 Female UKALL14 BCR-ABL1 ✓      
26768 70 Female UKALL60 B-other ✓      
26971 67 Male UKALL60 B-other ✓ ✓ ✓ ✓   
26990 63 Female UKALL60 B-other ✓ ✓     
26995 70 Male UKALL60 B-other ✓ ✓ ✓ ✓   





























































27033 72 Male UKALL60 B-other ✓ ✓     
27043 65 Female UKALL14 BCR-ABL1 ✓  ✓ ✓   
27071 60 Female UKALL14 B-other ✓ ✓ ✓ ✓   
27085 63 Female UKALL60 BCR-ABL1 ✓  ✓    
27121 64 Female UKALL60 HoTr ✓   ✓   
27147 69 Female UKALL60 BCR-ABL1 ✓      
27181 65 Male UKALL14 IGH@-r ✓ ✓ ✓ ✓ ✓  
27219 65 Female UKALL60 B-other ✓ ✓     
27298 66 Male UKALL60 B-other ✓ ✓ ✓ ✓   
27333 63 Female UKALL14 BCR-ABL1 ✓  ✓ ✓   
27389 73 Female UKALL60 KMT2A-r ✓  ✓  ✓  
27391 65 Male UKALL60 B-other ✓  ✓ ✓   
27392 73 Female UKALL60 HoTr ✓  ✓ ✓   
27395 60 Male UKALL14 T-cell ✓      
27407 69 Female UKALL60 HoTr ✓      
27408 70 Male UKALL60 T-cell ✓      
27409 74 Male UKALL60 B-other ✓      
27441 61 Female UKALL14 No data   ✓ ✓   
27452 62 Male UKALL14 B-other ✓ ✓     
27490 64 Male UKALL60 B-other ✓ ✓ ✓    
27508 61 Male UKALL14 HoTr ✓      
27509 69 Male UKALL60 BCR-ABL1 ✓  ✓ ✓   
27537 67 Female UKALL60 HoTr ✓  ✓ ✓   
27554 78 Female UKALL60 B-other ✓ ✓ ✓ ✓   
27555 64 Male UKALL60 HoTr ✓  ✓ ✓   
27556 75 Female UKALL60 B-other ✓ ✓     
27557 61 Male UKALL14 T-cell ✓      
27579 60 Female UKALL60 BCR-ABL1 ✓      
27583 61 Female UKALL60 BCR-ABL1 ✓  ✓ ✓   
27584 76 Female UKALL60 BCR-ABL1 ✓  ✓ ✓   
27585 66 Female UKALL60 BCR-ABL1 ✓  ✓ ✓   
27596 62 Male UKALL60 HoTr ✓  ✓ ✓   
27640 67 Male UKALL60 B-other ✓ ✓     
27642 72 Female UKALL60 T-cell ✓  ✓ ✓ ✓  
27668 68 Male UKALL60 BCR-ABL1 ✓      
27752 73 Female UKALL60 B-other ✓ ✓ ✓ ✓   
27754 63 Female UKALL14 BCR-ABL1 ✓  ✓ ✓   





























































27811 64 Male UKALL14 HeH ✓      
27812 65 Male UKALL14 TCF3-PBX1 ✓  ✓ ✓   
27819 65 Female UKALL60 B-other ✓ ✓ ✓ ✓   
27833 73 Female UKALL60 IGH@-r ✓ ✓ ✓ ✓ ✓  
27836 63 Male UKALL14 BCR-ABL1 ✓  ✓ ✓   
27887 68 Female UKALL60 BCR-ABL1 ✓      
27919 82 Female UKALL60 B-other ✓      
27930 60 Male UKALL60 B-other ✓      
27978 66 Male UKALL60 No data ✓      
28011 61 Male UKALL14 B-other ✓ ✓ ✓ ✓   
28032 69 Female UKALL60 T-cell ✓      
28033 63 Female UKALL60 KMT2A-r ✓      
28034 74 Male UKALL60 No data       
28039 76 Male UKALL60 CRLF2-r ✓ ✓  ✓   
28050 66 Male UKALL60 B-other ✓ ✓     
28051 66 Male UKALL60 BCR-ABL1 ✓      
28057 64 Female UKALL14 BCR-ABL1 ✓  ✓ ✓ ✓  
28076 63 Male UKALL60 B-other ✓      
28091 64 Female UKALL14 T-cell ✓      
28092 71 Female UKALL60 HoTr ✓      
28093 72 Male UKALL60 B-other ✓      
28104 64 Female UKALL60 TCF3-PBX1 ✓      
28105 78 Female UKALL60 B-other ✓      
28135 79 Female UKALL60 BCR-ABL1 ✓      
28149 64 Female UKALL14 B-other ✓  ✓ ✓   
28150 65 Male UKALL60 BCR-ABL1 ✓      
28168 65 Male UKALL14 B-other ✓ ✓ ✓ ✓   
28182 60 Female UKALL14 BCR-ABL1 ✓  ✓ ✓ ✓  
28194 66 Male UKALL60 B-other ✓ ✓     
28196 61 Male UKALL14 BCR-ABL1 ✓  ✓ ✓   
28235 65 Female UKALL60 CRLF2-r ✓ ✓     
28310 66 Female UKALL60 B-other ✓ ✓     
28312 67 Female UKALL60 BCR-ABL1 ✓      
28317 80 Male UKALL60 B-other ✓ ✓     
28334 64 Male UKALL14 HoTr ✓      
28335 63 Male UKALL14 B-other ✓  ✓ ✓ ✓  
28350 62 Female UKALL60 BCR-ABL1 ✓  ✓ ✓ ✓  





























































28370 81 Male UKALL60 KMT2A-r ✓      
28403 71 Male UKALL60 KMT2A-r ✓      
28404 63 Female UKALL60 HoTr ✓      
28406 74 Male UKALL60 HoTr ✓      
28456 62 Male UKALL14 B-other ✓      
28581 65 Female UKALL14 KMT2A-r ✓  ✓ ✓ ✓  
28620 60 Male UKALL14 BCR-ABL1 ✓      
28644 64 Female UKALL14 HoTr ✓  ✓    
28670 61 Female UKALL14 BCR-ABL1 ✓  ✓ ✓ ✓  
28905 60 Male UKALL14 B-other ✓ ✓     
28934 60 Female UKALL14 KMT2A-r ✓  ✓ ✓   
28945 64 Female UKALL14 B-other ✓ ✓     
29089 60 Female UKALL14 BCR-ABL1 ✓  ✓ ✓   
29202 61 Male UKALL14 B-other ✓      
29407 60 Female UKALL14 HoTr ✓  ✓  ✓  
29453 63 Male UKALL14 T-cell ✓      
29454 65 Female UKALL14 B-other ✓      
29481 69 Female UKALL60 B-other ✓      
29517 65 Male UKALL14 BCR-ABL1 ✓      
29519 61 Female UKALL14 B-other ✓      
29589 61 Male UKALL14 BCR-ABL1 ✓  ✓ ✓   
29655 65 Female UKALL60 BCR-ABL1 ✓      
29710 67 Male UKALL60 B-other ✓ ✓     
29741 77 Male UKALL60 BCR-ABL1 ✓      
29779 87 Male Non-trial B-other ✓ ✓    ✓ 
29780 55 Female Non-trial B-other ✓ ✓    ✓ 
29808 66 Male UKALL60 IGH@-r ✓      
29809 63 Male UKALL60 BCR-ABL1 ✓      
29848 68 Female UKALL60 B-other ✓      
29849 70 Female UKALL60 HoTr ✓      
29854 75 Female Non-trial BCR-ABL1 ✓     ✓ 
29881 63 Male UKALL60 BCR-ABL1 ✓      
29882 71 Female UKALL60 HoTr ✓      
29908 62 Female UKALL14 KMT2A-r ✓  ✓  ✓  
29958 79 Male UKALL60 BCR-ABL1 ✓      
30031 73 Female UKALL60 BCR-ABL1 ✓      
30032 - Male Non-trial BCR-ABL1 ✓  ✓    





























































30034 - Female Non-trial B-other ✓  ✓    
30035 - Male Non-trial BCR-ABL1 ✓  ✓    
30036 70 Male Non-trial B-other ✓  ✓    
30063 69 Male UKALL60 No data       
30066 63 Male UKALL14 HeH ✓      
30085 67 Male UKALL60 ZNF384-r ✓ ✓     
30086 69 Female UKALL60 B-other ✓ ✓     
30102 67 Female UKALL60 CRLF2-r ✓ ✓     
30103 64 Female UKALL14 BCR-ABL1 ✓      
30142 66 Female Non-trial B-other ✓ ✓    ✓ 
30175 63 Female UKALL14 B-other ✓      
30236 73 Male UKALL60 T-cell ✓      
30237 74 Female UKALL60 B-other ✓      
30297 64 Female UKALL60 CRLF2-r ✓ ✓     
30298 69 Female UKALL60 B-other ✓      
30299 74 Female UKALL60 CRLF2-r ✓ ✓     
30300 74 Female UKALL60 KMT2A-r ✓      
30315 69 Female UKALL60 HoTr ✓      
30331 77 Female UKALL60 HoTr ✓      
30334 60 Male UKALL14 B-other ✓      
30347 70 Male UKALL60 B-other ✓      
30378 71 Male UKALL60 B-other ✓ ✓     
30389 83 Female UKALL60 B-other ✓      
30390 73 Male UKALL60 HoTr ✓      
30402 62 Female UKALL60 TCF3-PBX1 ✓      
30403 71 Male UKALL60 B-other ✓      
30419 64 Female UKALL60 B-other ✓      
30426 72 Male UKALL60 B-other ✓      
30428 61 Female UKALL14 HoTr ✓      
30438 81 Male UKALL60 B-other ✓ ✓     
30476 71 Male UKALL60 B-other ✓      
30487 60 Male UKALL14 IGH@-r ✓      
30521 66 Male UKALL60 BCR-ABL1 ✓      
30556 75 Male UKALL60 B-other ✓      
30557 78 Female UKALL60 BCR-ABL1 ✓      
30623 64 Male UKALL14 KMT2A-r ✓      
30641 62 Male UKALL60 B-other ✓      





























































30721 61 Female UKALL14 No data       
31044 63 Female Non-trial HoTr   ✓   ✓ 
31085 62 Female UKALL14 No data       
31095 64 Male UKALL14 T-cell ✓      
31145 62 Male UKALL14 BCR-ABL1 ✓      
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Supplementary table 2 
Nexus segmentation settings used for SNP array patient cohort. 
Patient SNP array Systematic correction 
Significance 
threshold Gain Loss 
Min 
probes 
24309 Illumina Sequential Loess  1.00E-14 0.06 -0.06 6 
24813 Illumina Sequential Loess  1.00E-18 0.1 -0.1 6 
24890 Illumina Sequential Loess  1.00E-12 0.08 -0.08 6 
24919 Illumina Sequential Loess  1.00E-12 0.08 -0.08 6 
25082 Illumina Sequential Loess  1.00E-13 0.06 -0.06 6 
25100 Illumina Sequential Loess  1.00E-12 0.08 -0.08 6 
25130 Illumina Sequential Loess  1.00E-12 0.08 -0.08 6 
25208 Illumina Sequential Loess  1.00E-12 0.08 -0.08 6 
25246 Illumina Sequential Loess  1.00E-14 0.04 -0.04 6 
25247 Illumina Sequential Loess  1.00E-12 0.08 -0.08 6 
25267 Illumina Sequential Loess  1.00E-12 0.08 -0.08 6 
25344 Illumina Sequential Loess  1.00E-12 0.08 -0.08 6 
25346 Illumina Sequential Loess  1.00E-12 0.08 -0.08 6 
25371 Illumina Sequential Loess  1.00E-12 0.08 -0.08 6 
25373 Illumina Sequential Loess  1.00E-12 0.08 -0.08 6 
25437 Illumina Sequential Loess  1.00E-15 0.09 -0.09 6 
25451 Illumina Sequential Loess  1.00E-12 0.08 -0.08 6 
25548 Illumina Sequential Loess  1.00E-12 0.1 -0.1 6 
25552 Illumina Sequential Loess  1.00E-15 0.05 -0.05 6 
25793 Illumina Sequential Loess  1.00E-25 0.05 -0.05 6 
25893 Affymetrix Quadratic  1.00E-20 0.15 -0.15 10 
25953 Affymetrix Quadratic  1.00E-20 0.15 -0.15 10 
25967 Illumina Sequential Loess  1.00E-12 0.08 -0.08 6 
26062 Illumina Sequential Loess  1.00E-12 0.08 -0.08 6 
26609 Affymetrix Quadratic  1.00E-20 0.15 -0.15 10 
26610 Affymetrix Quadratic  1.00E-20 0.15 -0.15 10 
26614 Affymetrix Quadratic  1.00E-15 0.15 -0.15 10 
26621 Affymetrix Quadratic  1.00E-18 0.15 -0.15 10 
26659 Illumina Sequential Loess  1.00E-25 0.06 -0.06 6 
26660 Illumina Sequential Loess  1.00E-12 0.08 -0.08 6 
26682 Affymetrix Quadratic  1.00E-18 0.15 -0.15 10 
26706 Illumina Sequential Loess  1.00E-35 0.08 -0.08 6 
26726 Affymetrix Quadratic  1.00E-20 0.15 -0.15 10 
26971 Affymetrix Quadratic  1.00E-18 0.07 -0.07 10 
26995 Affymetrix Quadratic  1.00E-15 0.15 -0.15 10 
27026 Illumina Sequential Loess  1.00E-25 0.04 -0.05 6 
27043 Illumina Sequential Loess  1.00E-12 0.08 -0.08 6 
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Patient SNP array Systematic correction 
Significance 
threshold Gain Loss 
Min 
probes 
27071 Illumina Sequential Loess  1.00E-12 0.08 -0.08 6 
27085 Affymetrix Quadratic  1.00E-22 0.15 -0.15 10 
27181 Illumina Sequential Loess  1.00E-12 0.08 -0.08 6 
27298 Affymetrix Quadratic  1.00E-30 0.1 -0.1 10 
27333 Illumina Sequential Loess  1.00E-18 0.05 -0.05 6 
27389 Illumina Sequential Loess  1.00E-12 0.08 -0.08 6 
27391 Affymetrix Quadratic  1.00E-30 0.15 -0.15 10 
27392 Affymetrix Quadratic  1.00E-25 0.15 -0.15 10 
27441 Illumina Sequential Loess  1.00E-12 0.08 -0.08 6 
27490 Affymetrix Quadratic  1.00E-30 0.15 -0.15 10 
27509 Affymetrix Quadratic  1.00E-30 0.05 -0.05 10 
27537 Affymetrix Quadratic  1.00E-30 0.05 -0.05 10 
27554 Affymetrix Quadratic  1.00E-28 0.08 -0.08 10 
27555 Illumina Sequential Loess  1.00E-32 0.02 -0.02 6 
27583 Affymetrix Quadratic  1.00E-25 0.08 -0.08 10 
27584 Affymetrix Quadratic  1.00E-20 0.15 -0.15 10 
27585 Affymetrix Quadratic  1.00E-28 0.08 -0.08 10 
27596 Affymetrix Quadratic  1.00E-18 0.15 -0.15 10 
27642 Affymetrix Quadratic  1.00E-25 0.15 -0.15 10 
27752 Affymetrix Quadratic  1.00E-18 0.15 -0.15 10 
27754 Illumina Sequential Loess  1.00E-12 0.08 -0.08 6 
27812 Illumina Sequential Loess  1.00E-12 0.08 -0.08 6 
27819 Affymetrix Quadratic  1.00E-25 0.15 -0.15 10 
27833 Affymetrix Quadratic  1.00E-22 0.15 -0.15 10 
27836 Illumina Sequential Loess  1.00E-15 0.06 -0.06 6 
28011 Illumina Sequential Loess  1.00E-12 0.08 -0.08 6 
28057 Illumina Sequential Loess  1.00E-12 0.08 -0.08 6 
28149 Illumina Sequential Loess  1.00E-10 0.08 -0.08 6 
28168 Illumina Sequential Loess  1.00E-13 0.15 -0.15 6 
28182 Illumina Sequential Loess  1.00E-16 0.07 -0.07 6 
28196 Illumina Sequential Loess  1.00E-12 0.08 -0.08 6 
28335 Illumina Sequential Loess  1.00E-12 0.08 -0.08 6 
28350 Illumina Sequential Loess  1.00E-20 0.05 -0.05 6 
28581 Illumina Sequential Loess  1.00E-20 0.15 -0.15 6 
28644 Illumina Sequential Loess  1.00E-20 0.05 -0.05 6 
28670 Illumina Sequential Loess  1.00E-12 0.08 -0.08 6 
28934 Illumina Sequential Loess  1.00E-12 0.08 -0.08 6 
29089 Illumina Sequential Loess  1.00E-12 0.08 -0.08 6 
29407 Illumina Sequential Loess  1.00E-16 0.05 -0.05 6 
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Patient SNP array Systematic correction 
Significance 
threshold Gain Loss 
Min 
probes 
29589 Illumina Sequential Loess  1.00E-16 0.05 -0.05 6 
29908 Illumina Sequential Loess  1.00E-12 0.1 -0.1 6 
30032 Affymetrix Quadratic  1.00E-20 0.15 -0.15 10 
30033 Affymetrix Quadratic  1.00E-22 0.15 -0.15 10 
30034 Affymetrix Quadratic  1.00E-22 0.15 -0.15 10 
30035 Affymetrix Quadratic  1.00E-22 0.15 -0.15 10 
30036 Affymetrix Quadratic  1.00E-22 0.15 -0.15 10 
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Supplementary table 3 
Genomic targets for full regions included in SureSelect XT2 capture library design. 
Gene Interval Size Coverage (%) 
Total RNA 
probes 
KDM6A chrX:44732411-44971867 239,457 69.8 1,202 
COL11A1 chr1:103342013-103574062 232,050 82.2 1,422 
PTEN chr10:89622860-89731697 108,838 77.8 636 
LEMD3 chr12:65569801-65589942 20,142 90.0 134 
MBNL1 chr3:151880890-151998320 117,431 82.1 720 
NF1 chr17:29421935-29709144 287,210 73.9 1,562 
CDC73 chr1:193071243-193132293 61,051 77.8 361 
IKZF1 chr7:50343669-50472809 129,141 66.1 683 
PAX5 chr9:36833262-37034486 201,225 88.5 1,424 
FLT3 chr13:28577401-28674739 97,339 60.3 402 
MEF2C chr5:88013965-88199932 185,968 88.9 1,244 
ETV6 chr12:11802778-12048346 245,569 90.1 1,688 
JAK2 chr9:4985023-5128193 143,171 69.8 785 
TCF4 chr18:52889552-53332028 442,477 90.5 3,063 
ARID2 chr12:46110000-46301833 191,834 72.4 1,009 
RAG1 chr11:36532249-36614716 82,468 63.1 394 
NIPBL chr5:36876851-37066525 189,675 79.8 1,143 
VLDLR chr9:2230000-2480000 250,001 71.0 1,337 
ZEB2 chr2:145092000-145180000 88,001 91.3 612 
MEF2D chr1:156433503-156470644 37,142 91.3 286 
ABL1 chr9:133589258-133763072 173,815 70.5 881 
PDGFRB chr5:149493390-149535445 42,056 95.0 337 
TCF3 chr19:1609279-1652614 43,336 86.2 389 
PAR1 chrx:1321616-1397693 76,078 34.7 174 
DGKH chr13:42614162-42830726 216,565 83.7 1,359 
ABL2 chr1:179068452-179198829 130,378 66.9 619 
CSF1R chr5:149432844-149492945 60,102 75.5 343 
CXCR4 chr2:136860000-136886000 26,001 90.4 179 
ROCK1 chr18:18526785-18708000 181,216 71.5 956 
6p22.1 chr6:28310000-28333000 23,001 84.7 151 
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Supplementary table 4 
Genomic targets for coding regions only (exons) included in SureSelect XT2 capture 
library design. 
Gene Interval Regions Size Coverage (%) 
ASXL1 chr20:30946569-31025151 17 5,060 99.5 
ATM chr11:108098342-108236245 62 10,411 100 
CREBBP chr16:3777709-3929927 31 7,988 100 
DNMT3A chr2:25457138-25536863 25 3,388 100 
FOXO1 chr13:41133650-41240359 2 2,008 100 
IKZF2 chr2:213872074-214014917 12 2,065 100 
IKZF3 chr17:37922033-38020389 9 1,793 100 
IL7R chr5:35857070-35876598 8 1,716 100 
JAK1 chr1:65300235-65351957 24 3,945 100 
JAK3 chr19:17937542-17955236 23 3,913 100 
KMT2C chr7:151833907-152132881 60 16,122 100 
KRAS chr12:25362719-25398328 6 828 100 
NOTCH1 chr9:139390513-139440248 34 8,348 100 
NR3C1 chr5:142658919-142780414 9 2,573 100 
NRAS chr1:115251146-115258791 4 650 100 
NT5C2 chr10:104849419-104934725 22 2,373 100 
PTPN11 chr12:112856906-112942578 16 2,142 97.4 
RB1 chr13:48878039-49054217 27 3,327 100 
RUNX1 chr21:36164422-36421206 11 1,804 100 
SH2B3 chr12:111855940-111886116 9 2,144 100 
TET2 chr4:106111617-106197686 10 6,365 100 
TFDP3 chrX:132351060-132352297 1 1,238 100 
TOX chr8:59720296-60031556 9 1,761 100 
TP53 chr17:7565247-7579922 14 1,658 94.2 
ZFHX3 chr16:72821053-72994054 9 11,292 100 
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Supplementary table 5 
Sequencing depth of coverage of samples included in SureSelect XT2 library prep 
calculated as follows: (average read length X number of reads) / genome length 


































Supplementary table 6 
Cytogenetic data for all cases included in the CART analysis of ploidy status in ALL. 
Genetic subgroups based on cytogenetics and SNP array are also shown as well as 
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HeH HeH 46,XX[20] 
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Supplementary table 7 
Demographic and clinical details of all cases included in the CART analysis of ploidy 
status in ALL. 
Patient ID Sex Age % BM Blasts 
4949 Female 20 99 
4950 Male 51 98 
24401 Female 54 54 
26076 Male 46 60 
26082 Female 48 80 
26706 Male 60 89 
27069 Female 46 96 
27121 Female 64 Not known 
27596 Male 62 64 
29588 Male 52 66 
923 Male 15 74 
11669 Male 16 100 
21894 Male 12 50 
25296 Male 28 94 
26624 Male 50 39 
26902 Female 43 60 
28336 Female 58 Not known 
28430 Female 42 37 
28508 Female 59 57 
28644 Female 64 95 
29407 Female 60 94 
22435 Female 12 100 
1142 Female 20 96 
5954 Male 50 95 
25437 Female 64 88 
25614 Female 56 75 
25950 Female 40 73 
27400 Female 46 89 
27537 Female 67 87 
27555 Male 64 Not known 
27873 Male 39 85 
28056 Female 55 90 
28885 Male 59 27 
28890 Female 49 Not known 
28893 Male 27 95 
29434 Female 49 97 
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Patient ID Sex Age % BM Blasts 
3071 Male 15 Not known 
27058 Female 7 Not known 
25434 Male 54 27 
27392 Female 73 72 
26659 Male 60 0 
28486 Female 55 59 
31044 Female 63 Not known 
M18/1850 Male 87 Not known 
M18/3283 Female 78 Not known 
M18/3510 Male 77 Not known 
M18/3469 Male 31 Not known 
M18/3777 Female 8 Not known 
24805 Female 46 39 
25852 Male 40 95 
26081 Female 28 85 
26910 Male 43 68 
27478 Female 58 88 
27599 Male 29 82 
27921 Male 48 18 
28195 Male 30 89 
28233 Male 58 56 
28894 Male 41 100 
29491 Male 51 90 
27847 Female 3 Not known 
M17/2484 Male 4 Not known 
M18/3960 Female 2 Not known 
M18/766 Male 3 Not known 
M18/968 Male 6 Not known 
M19/525 Male 8 Not known 
26726 Male 66 88 
27044 Female 54 95 
27212 Male 33 97 
25654 Male 8 Not known 
26690 Female 3 Not known 
27194 Female 5 Not known 
27214 Female 2 Not known 
27971 Female 4 Not known 
28003 Female 2 Not known 
28472 Male 12 Not known 
28668 Male 7 Not known 
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Patient ID Sex Age % BM Blasts 
28983 Male 3 Not known 
M18/1246 Female 7 Not known 
M18/1732 Female 3 Not known 
M18/3111 Male 3 Not known 
M19/1212 Male 7 Not known 
M19/1483 Female 3 Not known 
M19/1512 Male 1 Not known 
M19/1519 Female 4 Not known 
M19/1636 Male 16 Not known 
M19/185 Female 3 Not known 
M19/526 Female 2 Not known 
M19/548 Male 2 Not known 
28011 Male 61 Not known 
30036 Male 70 Not known 
27752 Female 73 48 
28149 Female 64 80 
25373 Male 65 32 
27181 Male 65 40 
25451 Male 63 88 
25130 Female 62 100 
25246 Male 64 42 
24890 Male 65 100 
27833 Female 73 98 
28168 Male 65 Not known 
27071 Female 60 90 
26614 Male 75 98 
27819 Female 65 90 
28335 Male 63 Not known 
27391 Male 65 Not known 
27554 Female 78 75 
25967 Male 60 95 
25552 Male 61 80 
30033 Female   Not known 
26621 Female 69 90 
27490 Male 64 40 
25344 Female 61 80 
25371 Female 60 50 
25267 Female 63 1 
26971 Male 67 50 
24309 Male 63 80 
 271 
Patient ID Sex Age % BM Blasts 
26995 Male 70 Not known 
27298 Male 66 90 
26611 Male 68 Not know 
28934 Female 60 9 
25100 Female 63 79 
29908 Female 62 Not known 
27389 Female 73 Not known 
28581 Female 65 88 
27584 Female 76 90 
26682 Female 63 35 
25548 Female 60 16 
27509 Male 69 60 
24919 Female 64 95 
27043 Female 65 90 
26610 Male 65 63 
25953 Female 71 90 
25208 Male 62 66 
27333 Female 63 73 
30035 Male Not known Not known 
27836 Male 63 61 
29589 Male 61 82 
28196 Male 61 99 
26660 Female 62 84 
25247 Male 64 95 
28182 Female 60 90 
27754 Female 63 Not known 
28670 Female 61 94 
27026 Female 63 Not known 
28057 Female 64 Not known 
28350 Female 62 72 
25082 Female 62 95 
26609 Male 83 50 
26062 Male 61 84 
25346 Male 64 40 
25793 Female 67 100 
27085 Female 63 92 
27583 Female 61 95 
30032 Male Not known Not known 
25893 Female 78 92 
27585 Female 66 62 
 272 
Patient ID Sex Age % BM Blasts 
29089 Female 60 90 
27812 Male 65 99 
30034 Female Not known Not known 
27642 Female 72 90 
  
 273 
Supplementary table 8 
Standardised whole chromosomal log2 ratios of all cases including in CART analysis 
of ploidy status (values in table rounded to 2 decimal places). HeH: High hyperdiploidy, 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary table 9 
Genetic details of Vienna validation cohort and output from decision tree classifier. 
Patient Classifier output Genetic classification Vienna 
1 Non-ploidy diploid/t(1;19)/TCF3-PBX1 
2 Non-ploidy diploid/t(12;21)/ETV6-RUNX1 
3 HoTr diploid/t(12;21)/ETV6-RUNX1 
4 Non-ploidy diploid/B-other/DUX4 
5 Non-ploidy diploid//KMT2A-AFF1 
6 Non-ploidy diploid/B-other/IKZF1plus 
7 Non-ploidy diploid/B-other/IKZF1plus 
8 Non-ploidy high hyperdiploid 
9 HeH high hyperdiploid 
10 HeH high hyperdiploid 
11 HeH high hyperdiploid 
12 HeH high hyperdiploid 
13 HeH high hyperdiploid 
14 HeH high hyperdiploid 
15 Non-ploidy masked near-haploid with genome-wide LOH 
16 HeH masked near-haploid with genome-wide LOH 
17 Non-ploidy masked near-haploid with genome-wide LOH 
18 Non-ploidy masked near-haploid with genome-wide LOH 
19 HeH masked near-haploid with genome-wide LOH 
20 HeH near-haploid/low hyperdiploid mosaic 
21 HeH near-haploid/low hyperdiploid mosaic 
22 HeH masked near-haploid with genome-wide LOH 
23 HoTr low hypodiploid 
24 HoTr low hypodiploid 
25 HoTr low hypodiploid 
26 HoTr low hypodiploid 
27 HoTr low hypodiploid 
28 HoTr low hypodiploid 
29 HoTr low hypodiploid 
  
 289 
Supplementary table 10 
Coding regions included in SureSelect XT HS2 capture library design due to 
prevalence in clonal haematopoiesis (DNMT3A, TET2, ASXL1) or relapsed ALL (TP53, 
KRAS, NRAS, PTPN11). 
Gene Genomic co-ordinates Exons 
NRAS chr1:115256299-115258874 2, 3 
DNMT3A chr2:25457138-25536863 all 
TET2 chr4:106111617-106197686 all 
PTPN11 chr12:112887835-112927579 3, 8, 13 
KRAS chr12:25380027-25398352 2, 3 
TP53 chr17:7565247-7579922 all 
ASXL1 chr20:31020911-31027928 11, 12 
  
 290 
Supplementary table 11 
Detailed mutational data of the SNVs (n=32) and indels (n=14) identified using the 
targeted NGS panel (library prep performed with SureSelect XT2 target enrichment kit) 
in 30 patients. 





TP53 chr17:7577094 G A SNV COSM1636702 27478 
TP53 chr17:7577094 G A SNV COSM1636702 29407 
TP53 chr17:7577025 T A SNV COSM 99951 29491 
TP53 chr17:7578479 G A SNV COSM3378358 26910 
NF1 chr17:29585375 G A SNV  28893 
NF1 chr17:29685516-29685517 T GGATAAG Ins  25437 
NF1 chr17:29676240-29676241 T G Ins  27478 
NF1 chr17:29552243-29552244 G TA Ins  29407 
NF1 chr17:29552244-29552245 G GTCTCCGT Ins  29407 
JAK2 chr9:5078361 G C SNV COSM 29637 25130 
JAK2 chr9:5080555 G T SNV  24890 
JAK2 chr9:5089726 C A SNV COSM 23940 28893 
PAX5 chr9:37006526 C A SNV  26614 
PAX5 chr9:36882049 C T SNV  28670 
PAX5 chr9:37020733 G A SNV  28893 
ETV6 chr12:12038950-12038951 C T Ins  25130 
ETV6 chr12:11905474-11905477 CAGGA - Del  26660 
ETV6 chr12:11905492-11905493 GAT - Del  26660 
CREBBP chr16:3786037 C A SNV  27833 
CREBBP chr16:3786715 A T SNV COSM 220497 27833 
CREBBP chr16:3786036-3786037 C TT Ins  27833 
ATM chr11:108175544 C T SNV  25437 
 291 
ATM chr11:108098576 C G SNV  29491 
CSF1R chr5:149449827 C T SNV COSM 956 25100 
CSF1R chr5:149460542 A C SNV COSM 51393 25552 
IKZF1 chr7:50450373 A G SNV  25451 
IKZF1 chr7:50444255-50444256 A TTCC Ins  25130 
FLT3 chr13:28626716 C T SNV COSM 28039 25437 
FLT3 chr13:28626716 C T SNV COSM 28039 29407 
KRAS chr12:25380256 T A SNV  25451 
KRAS chr12:25398284 C T SNV COSM1135366 28581 
NRAS chr1:115258748 C T SNV COSM 563 25967 
NRAS chr1:115258747 C T SNV COSM 564 24813 
IL7R chr5:35876251 A C SNV  24890 
IL7R chr5:35874574-35874575 A TG Ins  24890 
KDM6A chrX:44896923 T C SNV  25082 
KDM6A chrX:44938411 A C SNV  28670 
ABL1 chr9:133760106 C T SNV  25130 
ARID2 chr12:46246611 G A SNV  25967 
ASXL1 chr20:31022441-31022442 A G Ins  27833 
CXCR4 chr2:136872466-136872467 A GGGGGCC Ins  25437 
DNMT3A chr2:25464556 A C SNV  29407 
IKZF3 chr17:37949083-37949084 A T Ins  26910 
JAK3 chr19:17937610 T C SNV  27400 
KMT2C chr7:151859899 G A SNV COSM1581234 25100 
RAG2 chr11:36614521 C G SNV  27642 
RUNX1 chr21:36206783-36206784 T G Ins  28182 
TET2 chr4:106196381 C T SNV COSM 211627 25100 
 292 
 
